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ABSTRACT 
 Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease 
characterized by a pathognomonic distribution of hyperphosphorylated tau accumulations 
in neurons, astrocytes, and cell processes, situated around vessels at the depths of cortical 
sulci. Case reports of CTE pathology exhibit a common exposure to repetitive head 
impacts (RHI), suggesting that RHI are a necessary factor in the disease’s etiology. 
Currently, it is only possible to definitively diagnose CTE after death using 
histopathological techniques and consensus-based neuropathological diagnostic criteria 
recently established by the National Institute of Health and National Institute of 
Neurological Disorders and Stroke. Though considerable progress has been made in 
characterizing the neuropathology of CTE, less is known about the clinical aspects of the 
 ix 
disease. Specifically, additional research is needed to identify disease-specific clinical 
manifestations, clinicopathological correlations, and a means of diagnosis during life, all 
of which are critical to developing future epidemiological studies, preventative measures, 
and treatment trials. Moreover, it is not yet known which specific aspects of RHI 
exposure (type, frequency, duration) are causally linked to developing clinically 
meaningful neurological impairments or CTE neuropathology, nor have studies identified 
risk-modifying factors, such as genotype (e.g. APOE).  
The objective of this dissertation’s published works was to systematically address 
these gaps in knowledge. First, to define a common clinical presentation of CTE, we 
conducted a retrospective analysis of medical records and semi-structured next-of-kin 
reports of 36 former athletes with autopsy-confirmed CTE without comorbid 
neurodegenerative disease. We then published clinical diagnostic criteria for CTE based 
on a systematic review of clinical features exhibited in 202 former athlete cases and a 
pooled analysis of 83 neuropathologically confirmed CTE cases. In subsequent analyses, 
we operationalized clinical criteria to investigate specific clinicopathological associations 
between tau, amyloid beta, age, APOE genotype, and clinical outcomes and utilized the 
clinical criteria to explore potential risk-factors related to RHI from boxing and football. 
Lastly, we developed a metric to quantify cumulative RHI exposure in retired, living, 
football players. Using this metric, our study was the first to indicate a causal relationship 
between cumulative RHI exposure and risk of later life cognitive, mood, and behavioral 
impairment. These studies are preliminary, and our results require replication and 
validation in larger, longitudinal prospective studies. 
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Introduction and General Overview 
 
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that is 
most often reported in postmortem autopsies of individuals exposed to repetitive head 
impacts, such as former boxers and American football players.  The neuropathology of 
CTE is characterized by accumulations of hyperphosphorylated tau in a pattern that is 
distinct from other forms neurodegenerative tauopathy, including Alzheimer’s disease 
(see Figure 1). In the past decade, considerable progress has been made in the 
postmortem neuropathological characterization of CTE. In February of 2015, an expert 
panel convened by the National Institutes of Health (NIH) and the National Institute of 
Neurological Disorders and Stroke (NINDS) met at Boston University and successfully 
published the first set of consensus-based neuropathological diagnostic criteria for CTE 
[2]. The primary criteria for diagnosis involves “p-tau aggregates in neurons, astrocytes, 
and cell processes around small vessels in an irregular pattern [1].” Additional supportive 
features related to p-tau include: 1.) neurofibrillary tangles (NFTs) preferentially 
affecting superficial cortical layers II–III, 2.) NFTs and dendritic swellings preferentially 
affecting the CA2/CA4 of the hippocampus and p-tau immunoreactive lesions, 3.) 
neuronal and astrocytic aggregates in subcortical nuclei, 4.) thorny astrocytes in the glial 
limitans, subpial, and periventricular regions, and 5.) grain- and dot-like structures. Gross 
findings that were supportive of a diagnosis consisted of disproportionate dilatation of the 
third ventricle, septal abnormalities (e.g., cavum), mammillary body atrophy, and signs of 
previous traumatic injuries. These criteria represent an important development in the 
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study of long-term outcomes related to brain trauma [3]. Notably, published case reports 
of CTE pathology that meet these criteria all share a common history of exposure to 
repetitive head impacts (RHI).   
 3 
 
Figure 1. Comparison of hyperphosphorylated tau progression in CTE and AD. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The characteristic neuropathological findings of chronic traumatic 
encephalopathy including p-tau neurofibrillary tangle accumulations involving (a) 
superficial cortical layers that are commonly situated at the depths of the (b) cerebral 
sulci and in (c) perivascular spaces. (d) The microscopic p-tau pathology is often found in 
the relative absence of amyloid neuritic plaques. Comparatively, the cortical laminar 
distribution of p-tau pathology in AD typically involves the (e) deeper layers and is found 
neither (f) in the depths of the cerebral sulci nor (g) perivascularly. Additionally, AD 
pathology involves (h) neuritic amyloid plaques with concomitant p-tau neurofibrillary 
tangles. Figure previously published in Annual Reviews of Clinical Psychology 2015 [1]. 
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Despite considerable progress in characterizing CTE’s neuropathology, little is 
known about its clinical aspects and etiology during life [4]. There has been a lack of 
quantitative evidence associating the neuropathological features of CTE to clinical 
impairments before death [5]. Moreover, while RHI exposure is necessary for CTE 
neuropathology, it is not yet known what specific aspects of exposure (type, frequency, 
duration) are causally linked to the development of neurological impairment and CTE. 
Further research is needed to identify disease-specific clinical presentations, 
clinicopathological associations, and risk-factors. To address these important issues, a 
critical next step involves defining clinically practical measurements of RHI exposure 
and devising criteria to diagnose neurological impairment from RHI and CTE in vivo. 
Having clinical criteria that can accurately identify CTE in a living person will be 
necessary to conduct future treatment and prevention trials, as well as perform 
epidemiological research to determine incidence and prevalence [6].  
The main objective of the dissertation’s published works was to systematically address 
these gaps in knowledge.  
The first chapter [7] focused on identifying the clinical presentation specific to 
CTE using semi-structured questionnaires with next-of-kin informants and medical 
record review of 36 neuropathologically confirmed cases of CTE without comorbid 
neurodegenerative disease. A triad of symptoms from three clinical domains – behavior,  
mood, and cognition – were identified in more than 70% of cases [7]. In chapter two [8] 
we propose clinical diagnostic criteria for CTE based on a systematic review of clinical 
features exhibited in 202 former athlete cases and a pooled analysis of clinical features 
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reported in 83 neuropathologically confirmed CTE cases [8]. Like many other 
neurodegenerative diseases (e.g. Alzheimer’s disease, amyotrophic lateral sclerosis 
frontotemporal dementia, multiple sclerosis, etc), the clinical symptoms in our CTE 
sample clustered into distinct recurring phenotypes (i.e., clinical subtypes) [8]. Of the 84 
pooled CTE cases, the initial symptoms and presentation at disease onset were reported in 
54. Analysis of the initial presenting symptoms in the remaining 54 cases confirmed and 
extended the observations made in chapter one [7] having also demonstrated the presence 
of subtypes, including: a subtype group with behavioral/mood symptom onset at an 
earlier age (32%), a subtype group with cognitive symptom onset at a later age (28%), 
and a mixed symptom onset subtype group (40%) [8].  
With clinical diagnostic criteria operationalized in our sample, we performed 
quantitative analyses of the clinical features associated with CTE neuropathology in both 
chapters three [9] and four [10]. In chapter three [9], specific clinicopathological 
associations were assessed between tau, amyloid beta, age, APOE status, and the clinical 
outcomes designated by our clinical presentation and diagnostic criteria [7,8]. We 
hypothesized that subject specific modifiers, like ApoE4 genotype, would increase the 
risk of manifesting one clinical subtype over another [9]. We also hypothesized that the 
presence of co-morbid neuropathological lesion, such as amyloid beta plaques or Lewy 
bodies, would significantly alter the severity and progression of CTE tauopathy [9]. In 
chapter four, we tested the hypothesis that neuropathologically confirmed CTE cases with 
histories of cumulative exposure to RHI from different contact sports, such as boxing and 
American football, would have significant differences in the frequency of certain clinical 
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manifestations and regional severity CTE tauopathy [10].  
In the final chapter [11] we develop a metric to quantify cumulative repetitive 
head impact exposure from amateur football, which we term the cumulative head impact 
index (CHII). We used this index to examine the relationship between cumulative 
exposure to RHI and the risk of later-life depression, apathy, behavioral dysregulation, 
executive dysfunction, and cognitive impairment among former high school and college 
football players [11]. We found a strong, threshold dose-response relationship between 
estimated exposure and risk of impairment. Moreover, this new single index of 
cumulative head impact exposure was shown to be a better and stronger predictor of later 
life risk of impairment than previously studied measures, including: total years or seasons 
played, age at first exposure, and number of reported concussions. Using an instrumental 
variable analysis, we provide the first statistical evidence of a causal relationship between  
RHI and later-life impairment [11].  
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Chapter 1 
Clinical Presentation of Chronic Traumatic Encephalopathy 
 
Copyright © 2013, American Academy of Neurology 
 
Introduction 
 Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease marked 
by widespread accumulation of hyperphosphorylated tau (p-tau) [1,2]. To date, CTE has 
been documented in amateur and professional athletes involved in contact sports, military 
personnel exposed to explosive blast, and others subjected to repetitive brain trauma 
(RBT), including concussive and subconcussive injuries [1-5].  All reported neuro-
pathologically confirmed cases of CTE have had exposure to RBT.  However, not all 
individuals with histories of RBT develop CTE, indicating that additional risk factors, 
including genetics, likely play a role in the neuropathogenesis of this disease. For 
example, it has been suggested that the apolipoprotein E (ApoE) ε4 allele may increase 
susceptibility for CTE [6].  
Previously published descriptions of the clinical presentation of CTE vary. Case 
reports of presumptive CTE (formerly termed dementia pugilistica or “punch-drunk” 
when thought limited to boxers [4]) indicated a constellation of clinical features, 
including impairments in cognition, behavior, and mood, and in some cases, chronic 
headache and motor and cerebellar dysfunction. Several case reports of boxers suggested 
two forms of presentation: (1) younger onset, with initial behavioral and mood 
 10 
 
disturbance, but with minimal cognitive and motor features; and (2) older onset, with 
greater cognitive impairment, and, often, motor disturbance [4,7-10]. In advanced cases, 
CTE is associated with dementia, although it is unclear whether the clinical presentation 
of CTE dementia is different from that associated with Alzheimer’s disease (AD) or other 
age-related neurodegenerative disorders [11-13]. Herein, we describe the clinical 
presentation, course, and ApoE genotype of a sample of 36 athletes with 
neuropathologically confirmed CTE.  
 
Methods 
Subjects. The brains of 81 subjects in the Boston University Center for the Study 
of Traumatic Encephalopathy (CSTE) brain bank met recently published criteria for the 
neuropathologic diagnosis of CTE [1]. For the current study, 45 cases were excluded due 
to: (1) primary exposure to RBT from non-athletic activities; (2) inability to contact next-
of-kin to conduct an interview; and (3) presence of comorbid motor neuron disease [14], 
neurodegenerative disease, or other significant neuropathology. Seven were military 
veterans with unknown or no athletic history, 10 had no next-of-kin contact, and 28 had 
comorbid neuropathologic disease. Of the 36 remaining subjects, 28 were included in a 
previous report1 and 8 were new cases.   
 
CTE Neuropathological Staging. The cases were categorized into the four-stage 
rating scale of CTE (I=least severe, IV=most severe) based on the severity of p-tau 
pathology, as previously reported [1]. Diagnosis and staging were conducted blind with 
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respect to medical history, ApoE genotype, and informant interview. 
 
Interview and Medical Record Review. History and clinical presentation were 
obtained through postmortem telephone interviews with next-of-kin by a 
neuropsychologist (RAS) blinded to neuropathological findings and ApoE genotype 
status.  Medical records were available and reviewed for 23 cases.  The semi-structured 
interview was based on previous studies of postmortem dementia diagnosis made by 
interviews with family members [15,16].  Information queried during the interview 
included: demographics; cause of death; and athletic, military, medical, neuropsychiatric, 
and social/occupational histories.  The interview included specific questions regarding 
dementia, depression, changes in cognition, behavior, mood, and motor functioning, as 
well as instrumental activities of daily living. Responses were qualitatively summarized 
into an overall assessment of the subject’s presentation and course of symptoms and 
functioning.  The number of informants interviewed per case ranged from 1-7 
(median=2), with each interview lasting approximately 60 minutes.  Interviews were 
conducted at a median time of 4 months following time of death. 
 
ApoE Genotyping. DNA was extracted from brain tissue samples using a Qiagen 
QIAamp DNA extraction kit (Quiagen, Valencia, CA). Two single-nucleotide 
polymorphisms (SNPs; NCBI SNPs rs429358 and rs7412) were examined using TaqMan 
assays (Applied Biosystems, Foster City, CA).  Allelic discrimination was automated 
using the manufacturer’s software.  Positive controls, consisting of DNA of each of the 
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six possible APOE genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, ε4/ε4), were included on 
each plate and genotyped with restriction isotyping. 
 
Statistical Analyses.  Between-group differences were examined by independent 
sample T-tests.  Chi-square analyses were used for between group comparisons for 
categorical data.  ApoE genotype analyses comparing CTE cases with population norms 
[17] were conducted with the Chi-square goodness of fit test.  A probability level of 
p=.05 was used throughout. All statistical analyses were conducted with IBM SPSS 
Statistics, version 19.0 (IBM Corp., Armonk, NY). 
 
Standard Protocol Approvals, Registrations, and Patient Consents. Approvals 
for brain donation, post-mortem clinical record review, interviews with family members, 
and neuropathological evaluation, were provided by the Institutional Review Boards of 
Boston University Medical Center and the Bedford VA Hospital. 
 
Results 
Table 1 summarizes the demographics, cause of death, athletic history, 
neuropathological stage, and ApoE genotypes of the sample. All subjects were male 
athletes, with 6 (17%) African American and 1 (3%) of Hispanic origin.  There were 29 
football players (22 who played professionally, 4 who only played through college, and 3 
who only played through high school), 3 professional hockey players, 1 professional 
wrestler, and 3 boxers (1 professional, 2 amateur). Of the football players, the most 
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common position played was lineman (48%), followed by running back (21%), 
linebacker (10%), and smaller numbers of other positions.  There were no quarterbacks or 
kickers. Of the 36 subjects, 3 (8%) were asymptomatic. Tables 2 and 3 describe the 
clinical features and course of the remaining 33 subjects.   
  
 14 
 
Table 1.1 Description of Sample by Initial Clinical Presentation 
Variable 
All 
Subjects 
(N=36) 
Behavior/Mood 
Group 
(N=22)a 
Cognition 
Group 
(N=11)a 
Age at Death  
(M+SD, range) 
56.8+21.9  
(17-98) 
51.4 +18.5  
(21-84)* 
69.2+21.8  
(34-98)* 
Cause of Death,% 
Systemic Illness = 
41.8 
 
Accidental OD = 
13.9 
 
Dementia-Related = 
13.9 
 
Suicide =  
16.7 
 
Injury =  
8.4 
Systemic Illness = 
49.8 
 
Accidental OD = 
18.2 
 
Dementia-Related = 
9.1 
 
Suicide =  
18.2 
 
Injury =  
4.5 
Systemic Illness = 
27.3 
 
Accidental OD = 
9.1 
 
Dementia-Related 
= 27.3 
 
Suicide =  
18.2 
 
Injury =  
18.2 
Years of Education  
   (M+SD, range) 
15.0+2.4  
(10-20) 
14.5+2.4  
(10-18) 
15.7+1.4  
(13-18) 
Football as Primary Sport, 
% 80.6 72.7 90.9 
Total Years of Football 
Played (M+SD, range) 15.3+6.4 (3-25) 14.4+6.5 (3-25) 18.2+5.9 (5-24) 
Neuropathological Severity 
Stage, % 
Stage I = 8 
Stage II = 28 
Stage III = 31 
Stage IV = 33 
Stage I = 9.1 
Stage II = 31.8 
Stage III = 31.8 
Stage IV = 27.3 
Stage I = 0 
Stage II = 9.1 
Stage III = 36.4 
Stage IV = 54.5 
ApoE Genotype,b 
ε2/ε2=0 
ε2/ε3=3 
ε2/ε4=0 
ε3/ε3=63 
ε3/ε4=26 
ε4/ε4=9 
ε2/ε2 = 0 
ε2/ε3 = 4.5 
ε2/ε4 = 0 
ε3/ε3 = 63.6 
ε3/ε4 = 27.3 
ε4/ε4 = 4.5 
ε2/ε2 = 0 
ε2/ε3 = 0 
ε2/ε4 = 0 
ε3/ε3 = 54.5 
ε3/ε4 = 27.3 
ε4/ε4 = 18.2 
a3 subjects were asymptomatic; percentages within initial feature group are based on the percent 
of symptomatic subjects. 
b1 subject did not have ApoE genotyping 
OD=Overdose 
*Statistically significant between-group difference, p < 0.05 
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Eleven of the symptomatic cases were reported to have initial changes in 
cognitive functioning (e.g., episodic memory impairment, executive dysfunction) prior to 
behavioral or mood disturbance.  Initial changes in behavior (e.g., explosivity, 
impulsivity, violence) prior to mood or cognitive disturbance were reported in 13 
subjects.  Mood changes (e.g., depression, hopelessness) were reported as the initial 
feature in 9 subjects.  None of the subjects had motor disturbance as their initial feature. 
The subgroups with initial behavioral symptoms and mood changes were similar in age 
of initial presentation, age of death, and neuropathological stage, and were combined into 
a behavior/mood group (n=22). Subjects whose initial difficulties involved cognitive 
functioning comprised a cognition group (n=11). Tables 1-3 describe demographics and 
clinical features for the behavior/mood and cognition subgroups. 
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Table 1.2. Clinical Features and Course by Initial Clinical Presentation 
Variable 
Symptomatic 
Subjects 
(N=33)1 
Behavior/Mood 
Group 
(N=22)1 
Cognition 
Group 
(N=11)1 
% with Progressive Course 90.9% 86.4% 100% 
% with Dementia at Death 30.3% 18.2%* 54.5%* 
Age First Clinical Feature 
Observed (yrs) M + SD 
(range) 
42.5 + 17.8 
(19-82) 
34.5 + 11.6  
(19-59)* 
58.5 + 17.7  
(31-82)* 
Duration of Clinical Features 
(yrs) M + SD (range) 
14.9 + 12.9  
(0-51) 
17.0 + 14.3  
(0-51) 
10.7 + 8.5  
(1-30) 
Initial Clinical Domain (%) 
   Cognition 33.3% -- 100% 
   Behavior 39.4% 59.1% -- 
   Mood 27.3% 40.9% -- 
Clinical Domain(s) Ever Observed During Life (%) 
   Cognition 93.9% 90.9% 100% 
   Behavior 75.8% 86.4%* 54.5%* 
   Mood 84.8% 95.4%* 63.6%* 
   Motor 30.3% 27.3% 36.4% 
   Cognition & Behavior 75.8% 86.4% 54.5% 
   Cognition & Mood 81.8% 90.9% 63.6% 
   Cognition & Motor 30.3% 27.3% 36.4% 
   Behavior & Mood 72.7% 86.4% 45.5% 
   Behavior & Motor 27.3% 27.3% 27.3% 
   Mood & Motor 30.3% 27.3% 36.4% 
   Cognition, Behavior & 
Mood 
72.7% 86.4% 45.5% 
   Cognition, Behavior & 
Motor 
27.3% 27.3% 27.3% 
   Cognition, Mood & Motor 30.3% 27.3% 36.4% 
   Behavior, Mood & Motor 27.3% 27.3% 27.3% 
   All Four Domains 27.3% 27.3% 27.3% 
% with History of Headaches 34.4% 38.1% 27.3% 
Death by Suicide 18.2% 18.2% 18.2% 
% History of Substance 
Abuse 
39.4% 36.4% 45.5% 
(1)Three subjects were asymptomatic; percentages are based on the percent of symptomatic  
subjects. 
*Statistically significant, p < 0.05 
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Table 1.3. Specific Clinical Features by Initial Clinical Presentation 
Variable 
Symptomatic 
Subjects 
(N=33) 
Behavior/Mood 
Group 
(N=22)1 
Cognition 
Group 
(N=11)1 
Cognitive Features    
   Memory Impairment 84.8% 77.3% 100% 
   Executive Dysfunction 78.8% 72.7% 90.9% 
   Attention Difficulties 72.7% 63.6% 90.9% 
   Language Impairment 57.6% 54.5% 63.6% 
   Visuospatial Difficulties 54.5% 54.5% 54.5% 
Behavioral Features    
   Explosivity 57.6% 72.7%* 27.3%* 
   Impulse Control Problems 45.5% 54.5% 27.3% 
   “Out of Control” 51.5% 63.6%* 27.3%* 
   Physically Violent 51.5% 68.2%* 18.2%* 
   Verbally Violent 48.5% 73.6%* 18.2%* 
   Disinhibited Speech 0% 0% 0% 
   Disinhibited Behavior 3.0% 0% 9.1% 
   Socially Inappropriate 3.0% 0% 9.1% 
   Paranoia 18.2% 22.7% 9.1% 
Mood Features    
   Sadness/Depression 63.6% 86.4%* 18.2%* 
   Anxiety/Agitation 15.2% 13.6% 18.2% 
   Manic Behavior/Mania 3.0% 4.5% 0% 
   Suicidal Ideation/Attempts 30.3% 31.8% 27.3% 
   Hopelessness 63.6% 72.7% 45.5% 
   Apathy 6.1% 9.1% 0% 
13 subjects were asymptomatic; percentages are based on the percent of symptomatic subjects. 
*Statistically significant between-group difference, p < 0.05 
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Ten subjects were diagnosed with dementia; 4 were clinically diagnosed with AD, 
4 with “dementia pugilistica” or “football-related” dementia, and 2 with unspecified 
dementia.  All had stage IV CTE.  Of the 10, 7 exhibited cognitive symptoms initially, 2 
exhibited mood symptoms initially, and 1 initially presented with behavior changes.  The 
mean age of symptom onset for the dementia group was 57.7 (SD=18.3; range 25-82) and 
the mean age of dementia diagnosis was 72.6 (SD=8.5, range 56-83).  The mean length of 
time between dementia diagnosis and death was 8.0 years (SD=5.5, range <1-15).  Four 
subjects with dementia had gait difficulties, 3 had a history of falls, and 1 had a history of 
tremor.  Two (20%) subjects with dementia had a history of headaches, compared with 11 
(44%) subjects without dementia.  All 10 subjects had both memory and executive 
impairment, 7 had language deficits, and 2 had visuospatial difficulties.  Six of the 10 
were characterized by behavioral impairment, predominantly described as having a “short 
fuse” or being “out of control.”  Four of the 10 were physically violent and 2 were 
verbally violent.  Although 1 subject demonstrated disinhibited behavior, none of the 
subjects had disinhibited speech or socially inappropriate behaviors.  Of the 7 who were 
reported to have mood disturbance, 2 had predominantly sadness/depressive symptoms 
and 2 had anxiety symptoms.  The only 2 subjects in the entire sample reported to have 
had apathy were in the dementia group. 
The proportions of ApoE genotypes (i.e., ε4 homozygotes, combined ε4 
homozygotes and heterozygotes, and ε4 non carriers) in our CTE sample were 
significantly different from those found in an age-matched normative sample [17], (χ2 [2] 
= 6.63, p < .05).  A binomial test revealed that the primary difference between our CTE 
 19 
 
sample and population norms was a greater proportion of ε4 homozygotes in our sample 
(p < .05). When examining the two initial presentation groups, there were no differences 
between the behavior/mood group and the age matched normative sample (χ2 [2] = 0.46, 
p > .05).  However, there were proportionally more ε4 homozygotes in the cognition 
group than expected (χ2 [2] = 13.3, p < .05).  The relative proportions of ApoE genotypes 
in our 10 subjects with dementia were not significantly different from those seen in AD 
[18] (χ2 [2] = 1.52, p > .05). 
 
Discussion 
Consistent with earlier reports of boxers [4,7-10], our findings suggest that there 
may be two different clinical presentations of CTE, with one initially exhibiting 
behavioral or mood changes, and the other initially exhibiting cognitive impairment.  The 
behavior/mood group demonstrated symptoms at a significantly younger age than the 
cognition group. Although almost all subjects in the behavior/mood group demonstrated 
cognitive impairments at some point, significantly fewer subjects in the cognition group 
demonstrated behavioral and mood changes during the course of their illness.  There were 
distinctions between the two groups regarding specific features present in each domain.  
The behavior/mood group was significantly more explosive, out of control, physically 
and verbally violent, and depressed than the cognition group. Whereas all subjects in the 
cognition group were reported to have impaired episodic memory, approximately one 
quarter of the behavior/mood group did not have memory difficulties.  Subjects in the 
cognition group were significantly more likely to progress to dementia than those in the 
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behavior/mood group but were also significantly older at the time of death.  Given the 
small sample size in this study, however, it is unclear if these two these apparently 
distinct clinical subtypes are representative of all individuals with CTE. In addition, the 
subsample of cases with dementia is also small, thus limiting the generalization of the 
presentation of CTE dementia. Further research is needed to clarify and validate these 
findings. 
We examined the potential role of the ApoE ε4 allele as a susceptibility factor for 
CTE.  Our findings indicate that there were significantly more ε4 homozygotes in the 
sample than expected in a normal, age-matched population.  Furthermore, this effect was 
largely driven by the cognition group: 2 of 11 subjects in the cognition group and 1 of 22 
subjects in the behavior/mood group was homozygous for the ε4 allele.  In addition, 1 of 
the 10 CTE subjects diagnosed with dementia during life was ε4 homozygous.  Although 
interpretation and generalization of these results is difficult due to the small sample, the 
proportion of ε4 homozygosity is in contrast to population norms in which ε4 
homozygosity only occurs in 1-3% of the general population [17], and more consistent 
with the 10% of patients with AD who are ε4 homozygous [18].  The ApoE ε4 variant is 
the largest known genetic risk factor for sporadic AD [18].  It has been associated with 
beta-amyloid, but not tau, deposition in cognitively normal aging [19]. ApoE ε4 has also 
been associated with greater severity of cognitive deficits and longer recovery time 
following traumatic brain injury (TBI) and RBT in a variety of populations, including 
boxers and professional football players [20-24], and may increase the risk for clinical 
dementia following TBI [25]. It has been hypothesized that the ApoE ε4 isoform may 
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have direct neurotoxic effects leading to mitochondrial dysfunction and cytoskeletal 
changes, resulting in increased risk for neurodegeneration [26]. Despite the small sample 
size and other limitations in the current study, future research on the role of ApoE in CTE 
risk appears warranted.  However, other potential susceptibility genes also merit 
consideration, including mutations to the microtubule-associated protein tau (MAPT) 
gene, the progranulin (GRN) gene, and the chromosome 9 open reading frame 72 
(C9ORF72) gene.  Moreover, additional non-genetic risk factors for CTE should be 
examined in future research, including studies to determine what specific aspects of RBT 
exposure (e.g., types, severity, frequency, initial age, and duration of trauma) are 
associated with CTE, as well as what potential lifestyle variables (e.g., diet, exercise, 
obesity, steroid use) are associated with the disease initiation and variability in 
presentation. 
It is noteworthy that motor features, including parkinsonism, were not common in 
our sample.  This is in contrast to some earlier descriptions of CTE in boxers, in which 
these motor features were quite prominent [4]. However, our findings are consistent with 
other case reports of predominantly younger onset boxers, in which motor disturbance 
was not common [4,7-10]. It is not clear why some individuals with CTE develop motor 
features and others do not.  One possibility may be the differences in the biomechanics of 
injury. For example, in boxing, angular acceleration and torsional injury involving the 
brainstem and cerebellum is thought to be a pathogenic mechanism of traumatic brain 
injury following a hook or jab to the jaw, whereas transverse and linear acceleration and 
deceleration injury are more characteristic of football dynamics [27,28]. As a result, 
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degeneration of brainstem structures that produce parkinsonism, such as the substantia 
nigra, might occur earlier in the course of disease in boxers.  In contrast, football players 
might develop substantia nigra degeneration later in the course of their disease, at a time 
when widespread cortical and basal ganglionic degeneration mask the development of 
motor disturbance. Related mechanisms of injury leading to CTE have been suggested by 
recent experimental studies of blast neurotrauma [3]. 
Although many of the symptoms of CTE are similar to AD and other causes of 
dementia [11,29] there are factors that appear to clinically differentiate CTE from other 
age-related neurodegenerative diseases.  For example, behavioral changes observed early 
in the course of CTE could be confused with the behavioral variant of frontotemporal 
dementia (bvFTD), especially in a patient in his or her 50’s without any significant 
memory impairment.  However, common changes in bvFTD typically include 
disinhibited and inappropriate behavior and speech, as well as apathy [30]; these 
symptoms were not frequent in our case series.  In addition, the progressive memory 
impairment observed in over 80 percent of our CTE cases, and in all 10 of the subjects 
with dementia, could lead to an inaccurate diagnosis of AD when the underlying disease 
is CTE [12].   
It is not clear what neuropathological changes may lead to the two possible 
clinical presentations observed in this study.  It is unlikely that the small, focal cortical p-
tau lesions found in stage I and II CTE produce clinically meaningful behavioral and 
mood symptoms. However, these features may be associated with the neurofibrillary 
tangles in the locus coeruleus and amygdala found in younger subjects in a previous 
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report.1  The memory and executive dysfunction in the older cognition group may be due 
to the more extensive degenerative changes in the hippocampus and frontal cortices seen 
in CTE stages III and IV [1].  It is possible, however, that some of the features evident in 
the younger behavior/mood group were due to persistent post-concussion syndrome 
(PCS) [31], with unresolved or even progressive [32] axonal damage resulting from the 
initial traumas.  Axonal injury has been shown in all neuropathological stages of CTE, 
ranging from multifocal, perivascular axonal varicosities in the cortex and white matter in 
stages I–II, to more extensive, diffuse axonal loss in the cortex and white matter in stages 
III–IV [1]. Recent reports have demonstrated that repetitive subconcussive trauma is 
associated with white matter abnormalities on diffusion tensor imaging [33,34] and 
abnormal functional MRI tests [35].  Additional findings indicate that there may be 
persistent and progressive inflammation and white matter degeneration following even a 
single TBI [36].  Further research is required to delineate these clinicopathologic 
relationships. 
Three subjects in our case series were asymptomatic.  One of these cases was only 
17 years old and had stage I neuropathology.  Both of the other two cases were much 
older football players (one in 40’s, one in 80’s), had stage II neuropathology, and were 
homozygous for ApoE ε3.  Both also had advanced graduate degrees, were very 
successful in their professional careers, and were described as extremely intelligent.  
Although speculative, these findings raise the possibility that cognitive reserve [37] may 
play a role in protecting against the clinical manifestations of CTE. A recent report 
suggests that cognitive reserve may mitigate cognitive decline in older individuals with 
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earlier life TBI [38]. Future research examining the roles of cognitive reserve, genetics, 
and environmental factors in determining resilience to clinical manifestations and the 
progression of p-tau pathology will help elucidate the pathobiology of CTE.   
Although these findings are based on the largest cohort of subjects with 
neuropathologically confirmed CTE without comorbidities studied to date, interpretation 
and generalizability of these results is limited by several factors.  First, the overall sample 
size is small, and caution should be taken when generalizing these results to the larger 
population of athletes or to the overall clinical presentation of CTE. .  In addition, there 
are inherent selection biases imposed in a postmortem brain donation study.  For 
example, families choosing to donate may be more likely to have witnessed symptoms 
during life.  This could lead to reports of more severe symptoms than a typical CTE 
population, and could account for only having three asymptomatic cases.  From the 
broader CTE cohort in the CSTE brain bank, we selected a smaller sample by eliminating 
individuals with comorbid pathology and only including athletes; this restriction may 
further limit the generalizability of our findings.  Results from this study should not be 
interpreted in terms of population prevalence or generalized to living athletes with CTE.  
In addition, there is the potential for reduced reliability and validity of retrospective 
reports from family members following the death of a loved one.  However, several 
studies have demonstrated adequate reliability and validity of these verbal autopsies in a 
variety of patient populations, including those with dementia [15,16] and psychiatric 
disorders [39]. There also may be differences in the accuracy of informant reports when 
comparing younger and older subjects.  That is, informants of older subjects were asked 
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to recall early- or mid-life events possibly resulting in reduced accuracy compared to the 
informants of younger subjects.  Finally, there was no comparison group of former 
athletes without CTE.  This may limit the ability to draw conclusions that the clinical 
presentation described is specifically due to the effects of CTE.  In our available dataset 
of subjects whose tissue had been examined at the BU CSTE brain bank, there was not an 
adequate number of subjects without CTE to make such a comparison.  For example, 34 
of 35 former professional football players had neuropathologically confirmed CTE [1].  
Future research is needed to clarify the clinical presentation of CTE.  The development of 
biomarkers (e.g., blood, CSF, neuroimaging, and tau-specific radiotracers) will result in 
the ability to detect and diagnose CTE during life and subsequent studies of risk factors, 
epidemiology, and treatment [40]. 
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Chapter 2 
Clinical Subtypes of Chronic Traumatic Encephalopathy: Literature Review and 
Proposed Research Diagnostic Criteria for Traumatic Encephalopathy Syndrome 
 
Introduction 
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease 
characterized by the accumulation of hyperphosphorylated tau protein (p-tau) in neurons 
and astrocytes in a pattern that is unique from other tauopathies, including Alzheimer's 
disease (AD) and frontotemporal lobar degeneration. The p-tau deposition initially occurs 
focally, as perivascular neurofibrillary tangles and neurites at the depths of the cerebral 
sulci.  It then spreads to involve superficial layers of adjacent cortex, eventually resulting 
in widespread degeneration of the medial temporal lobes, frontal lobes, diencephalon, and 
brainstem [1,2].  Unlike AD, there is a paucity of beta amyloid neuritic plaques. CTE has 
been found most often in professional athletes involved in contact sports (e.g., boxing, 
American football) who have been subjected to repetitive blows to the head resulting in 
concussive and subconcussive trauma [3,4]. Neuropathologically confirmed CTE has 
been reported in individuals as young as 17 and in athletes who only played sports 
through high school or college. It also has been found in non-athletes who have 
experienced repetitive head impacts, including epileptics, developmentally disabled 
individuals who head bang, and victims of physical abuse [2]. Moreover, CTE has been 
neuropathologically diagnosed in military service members previously deployed in Iraq 
and Afghanistan with histories of repetitive brain trauma [2,5]. At this time, it is not 
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completely clear if all cases of neuropathologically confirmed CTE would demonstrate a 
progressive course if they lived long enough. 
All cases of neuropathologically confirmed CTE reported to date have had a 
history of repetitive head impacts, although there has been some suggestion that a single 
traumatic brain injury (TBI) may also lead to the neuropathological changes of CTE [6]. 
Although head impacts appear to be necessary for the initiation of the pathogenetic 
cascade that eventually leads to neurodegeneration, the history of head impacts is not 
sufficient and additional risk factors (including genetic susceptibility markers) remain 
unknown.  The incidence and prevalence of CTE are also unknown, though the number 
potentially affected could be quite large. Every year between 1.6 and 3.8 million 
individuals in the U.S. experience a sports-related concussion [7], with the number of 
youth sports-related concussions growing in recent years [8]. The incidence of repetitive 
subconcussive blows (i.e., hits to the head that produce enough force to hamper neuronal 
integrity, but do not result in clinical concussion symptoms) is much greater [9]. For 
example, a study by Broglio and colleagues found that high school football players 
receive an average of 652 hits to the head per season that exceed 15 g of force [10]. With 
over one million high school students playing American football each year, and with the 
size and speed of football players increasing [11], the public health impact of CTE may 
be quite significant in future years. 
In vivo diagnosis of CTE is needed to conduct research on risk factors and 
epidemiology and to perform clinical trials for prevention and treatment.  Sensitive and 
specific biomarkers for CTE are currently being developed and include structural and 
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neurochemical imaging techniques and positron emission tomography (PET) with new 
ligands that selectively bind to p-tau [4,12,13]. These approaches hold promise to detect 
underlying neuropathological changes of CTE.  However, the clinical features directly 
associated with these changes have only recently been described and have been based on 
retrospective reports of family members of deceased individuals who receive a 
neuropathological diagnosis of CTE [2,14].  
 In a recent paper from our group [14], we examined the clinical presentation of 36 
adult males selected from all cases of neuropathologically confirmed CTE at the Boston 
University Center for the Study of Traumatic Encephalopathy Brain Bank. The cases 
were all athletes, had no comorbid neurodegenerative or motor neuron disease, and had 
family member informants who provided retrospective reports of history and clinical 
features. The semi-structured “psychological autopsies” were conducted blind to the 
subjects’ neuropathological findings.  Three of the 36 subjects were asymptomatic.  In 
the remaining 33 symptomatic subjects, a triad of cognitive, behavioral, and mood 
impairments was found, with cognitive changes reported for almost all subjects at some 
time in the course of disease. However, two relatively distinct clinical presentations 
emerged: one group had initial features involving behavior (i.e., explosivity, physical and 
verbal violence, being “out of control,” impulsivity) and/or mood (i.e., depression, 
hopelessness) (n=22), and another group had initial features involving cognition (i.e., 
episodic memory impairment, executive dysfunction, poor attention and concentration) 
(n=11). Symptom onset for the “behavior/mood group” occurred at a significantly 
younger age than the “cognition group.” Most subjects in the behavior/mood group 
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eventually developed cognitive difficulties, though significantly fewer subjects in the 
cognition group eventually demonstrated behavioral and mood changes. Significantly 
more subjects in the cognition group developed dementia than those in the 
behavior/mood group.  Less than one third of the sample had reported motor features, 
including parkinsonism. 
 Although the study by Stern and colleagues involved the largest case series to 
date of neuropathologically confirmed cases of CTE without comorbid conditions and 
with clinical histories, the sample size was small and the generalizability of the findings 
was hampered by the potential bias of a sample comprised of former athletes whose 
family members agreed to their brain donation [14].  This limitation notwithstanding, the 
finding of two possible clinical subtypes of CTE was consistent with previous literature.  
In the present paper, we provide a review of the world’s literature on the clinical features 
exhibited by athletes with histories of repetitive head impacts.  Following the literature 
review, we provide proposed research diagnostic criteria for “traumatic encephalopathy 
syndrome,” derived from this literature review, and from our own research into the 
clinical presentation of CTE [1,2,14]. As described below, these criteria are meant to 
initially characterize what is known to date and provide a foundation for developing more 
precise clinical criteria informed by on-going and future research and clinical review.  
 
Historical Terms for CTE. In his seminal 1928 paper in the Journal of the 
American Medical Association, Martland [15] used the term “punch drunk” to describe 
boxers suffering from symptoms he believed to be related to the repetitive blows they 
 34 
 
received in the ring.  Since that time, various terms have been used to describe the 
clinical syndrome associated with repetitive head impacts, predominantly in studies of 
boxers.  In 1934, Parker published a paper in which he referred to the traumatic 
encephalopathy of pugilists [16].  In 1937, Millspaugh first used the term dementia 
pugilistica [17] that is still currently used by clinicians and researchers. Other terms 
coined through the decades include traumatic encephalitis [18], cumulative 
encephalopathy of the boxer [19], psychopathic deterioration of pugilists [20], chronic 
boxer’s encephalopathy [21], and traumatic boxer’s encephalopathy [22].  In 1949, 
Critchley first used the designation, chronic traumatic encephalopathy [23], or CTE, 
though later modified it to chronic progressive traumatic encephalopathy [24], because 
several cases apparently progressed from an early mild state to severe dementia [23-25].  
Johnson [26] suggested the latter term erroneously implies progression is inevitable. In 
his case-series, little to no deterioration is reported in half of the cases followed over 5 
years. In a recent reviews of the literature, Victoroff (alone [27] and with Baron [28]) 
suggested using the more general and inclusive term “traumatic encephalopathy.” 
 In 2005, Omalu and colleagues [29] described the first case of 
neuropathologically confirmed CTE in an American football player. Since that time, 
there has been increasing public attention to this disease, and reports of CTE in deceased 
football players, including several well-known athletes, have prompted a tremendous 
focus on what is commonly referred to as football’s “concussion crisis.”  The scientific 
community also has become dramatically more aware of CTE since it was discovered in 
American football players.  For example, a PubMed search using the terms “chronic 
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traumatic encephalopathy,” “traumatic encephalopathy,” “dementia pugilistica,” or 
“punch drunk” resulted in 14 publications in the five year period ending in December 
2001 compared with 116 publications in the five year period ending in December 2013. 
 
Early Concepts Regarding Subtypes. In a 1950 editorial for the British Medical 
Journal, Jokl [30] stressed that CTE was not a single syndrome but rather two kinds of 
chronic impairment, with either predominant “behavioral-psychopathic or neurological-
psychiatric” features. He described the behavioral-psychopathic subtype as involving 
“viciousness,” “murder committed from jealousy,” and delinquency. In contrast, he 
described the neurological-psychiatric subtype as involving cognitive deficits, dementia, 
and motor impairment [30-32]. Grahmann and Ule [33](1957) described three general 
subtypes: (1) a progressive dementia that typically involved cognitive impairment and 
developed following a latency from the time of boxing retirement; (2) a stable 
neurological presentation temporally and etiologically related to the head impacts and not 
representative of a progressive disease; and (3) a paranoid and psychotic subtype absent 
of cognitive changes.  Critchley maintained that there were three commonly recurring 
presentations of CTE that resembled, but could be distinguished from: (1) neurosyphilis 
(e.g., psychopathy, altered personality, and later dementia), (2) multiple sclerosis (e.g., 
scanning speech, tremor, progressive cognitive decline), and (3) frontal lobe tumor (e.g., 
executive impairments, headache, and eye ache) [23]. He later added a fourth 
presentation: striatal parkinsonian (e.g., masked facial features, tremor) [24]. In a study of 
17 retired boxers, Johnson [26] described four different “organic psychosyndromes,” 
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including cognitive problems with progressive dementia, behavioral issues related to 
“morbid jealousy,” behavioral issues related to rage and personality disorders, and mood 
and behavioral disturbance related to persistent psychosis. 
 
Literature Search Methods. 
To examine previous literature describing the clinical presentation of CTE 
associated with exposure to head impacts through sports participation, we conducted a 
literature search utilizing PubMed, PubMedCentral, and MEDLINE databases. Search 
terms included: chronic traumatic encephalopathy; punch drunk; traumatic 
encephalopathy; dementia pugilistica; chronic boxer’s encephalopathy; chronic 
progressive traumatic encephalopathy; psychopathic deterioration of pugilists; and 
repetitive brain injury. In addition, bibliographies of recent literature reviews were cross-
referenced [1,27,34-39]. It should be noted that most online databases are limited to 
articles published since the 1950s. Because essential work in this field began in 1928, 
archival research was carried out by hand and international works were obtained with 
assistance from the Boston University Medical Library Interlibrary Loan Department. 
Materials retained included: articles; reviews; dissertations; society transactions; 
association reports; and book chapters.  To be reasonably confident about the diagnoses 
used, several criteria were used to determine inclusion in this review: (1) only case series, 
and not individual case reports were included; (2) adequate information must be provided 
in the report to allow classification of cases as confirmed CTE, probable CTE, or possible 
CTE, using Jordan’s criteria [35,40,41]; and (3) only cases involving athletes were 
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included. 
 
Results of Literature Review 
 Following the exclusion of papers and cases that did not meet the above criteria, 
the literature review resulted in 202 cases from 20 published case series, 4 books, and 1 
medical dissertation.  The cases are summarized in Table 1 [2,16,22-26,29,31-33,42-54].  
Nineteen cases were published before 1950, 29 cases were published in the 1950s, 49 
were published in the 1960s, 13 were published in the 1970s, 4 were published in the 
1980s, 19 were published in the 1990s, and 69 were published since 2000.  Using 
Jordan’s criteria [35], we approximated that 29 would have possible CTE , 90 would have 
probable CTE , and 83 would have definite CTE.  Of the entire sample, 141 were boxers 
54 were American football players, five were ice hockey players, and two were 
professional wrestlers.  The clinical features described in all of the cases were classified 
into one of four categories: behavioral, mood, cognitive, and motor.  Table 2 summarizes 
the clinical features most commonly described across all cases. In 68% of cases, the 
course of the clinical syndrome was described as progressive.  In cases where a 
distinction in clinical syndrome was made, the behavioral and mood features were 
reported to be more stable, whereas the cognitive features were described as progressive, 
often resulting in dementia.  Compared with cases described as progressive, cases 
described as stable were substantially younger.  A large number of cases had a period of 
latency of several years between the end of exposure to head impacts and the presentation 
of clinical signs and symptoms.  In neuropathologically confirmed cases, authors 
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described the initial clinical presentation as involving mood and/or behavioral 
disturbance without cognitive impairment in 28%, as having cognitive impairment 
without concurrent mood or behavioral difficulties in 32%, and as having initial mixed 
cognitive and mood/behavioral disturbance in 40%.  
In recent years, some authors have made the distinction between “classic CTE” 
and “modern CTE” [34,36]. For example, McCrory and colleagues [36] define the classic 
CTE syndrome based on the clinical descriptions from Roberts [49] and the 
neuropathological reports from Corsellis and colleagues [50]. Based on these earlier cases 
of boxers, classic CTE is described as having prominent motor features, including gait 
disturbance, dysarthria and pyramidal problems, but without progressive cognitive, 
behavioral, or mood changes [36]. However, it is important to note that in his monograph, 
Roberts [49] clarifies that he is intentionally focusing on the description and 
quantification of motor signs related to neurological lesions, reducing his focus on “the 
evidence of dementia or personality change” which he viewed as occurring in a subset of 
cases [49]. In contrast, “modern CTE” [34,36], defined as any case report published in 
2005 or later, is characterized by predominant mood and behavioral symptoms, as well as 
later progressive cognitive deficits and dementia, but with less prevalent motor features. 
We view this distinction between the earlier and more recent descriptions of the clinical 
presentation of CTE as largely an artifact of different sources of trauma exposure (that is, 
predominantly boxers in the “classic” cases and predominantly football players in the 
“modern” cases). 
To explore this issue, we examined further the cases of neuropathologically 
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confirmed pure CTE described in the series of McKee and colleagues [2] and compared 
the presence of motor features reported for the deceased professional boxers to those 
reported for the professional football players. The percentage of professional boxers with 
motor features (71%) far exceeded that of professional football players (13%). 
Additionally, it was found that in cases with the most advanced stage of CTE 
neuropathology, there was a striking difference in the presence of cerebellar pathology in 
professional boxers (83%) and professional football players (57%).  The likely cause of 
this may be related to the differences in the biomechanics of the head trauma that is 
experienced through the practice of these two different sports [14]. 
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Table 2.1. Summary of published cases describing the clinical features of Chronic 
Traumatic Encephalopathy 
Clinical Features 
Study 
Sample 
Total 
n=202 
Behavioral Mood  Cognition Motor 
Parker 
(1934) 
[16] 
Boxers 
(n=3)  
 
 
Social 
inappropriateness 
Childish 
behavior 
 
Anxiety 
Labile 
emotions 
Fatigue 
 
Reduced 
intelligence 
Memory 
impairment 
Impaired 
attention 
Visuospatial 
difficulties 
Ataxia 
Clonus 
Dragging 
gait 
Dysarthria 
Muscle 
weakness 
Spasticity 
Tremor 
Herzog 
(1938) 
[42] 
Boxers 
(n=7)   
 
Boastfulness 
Personality 
changes 
Impulsiveness 
Loss of control 
 
Apathy 
Flat affect 
 
General 
cognitive 
impairment  
Memory 
difficulties 
Perseveration  
Language 
difficulties 
Alogia 
Dementia 
Dysarthria 
Masked 
facies 
Shuffling 
gait 
Truncal 
ataxia 
Knoll et al 
(1938) 
[43] 
Boxers 
(n=3)  
 
Personality 
changes 
Apathy 
Flat affect 
Loss of 
interest 
Prolix 
General 
cognitive   
 impairment  
Memory 
impairment  
Visuospatial 
difficulties 
Alogia  
Dementia 
Ataxia 
Dysarthria 
Masked 
facies 
 
Jokl 
(1941) 
[31] and 
Jokl and 
Guttmann 
(1933) 
[32] 
Boxers 
(n=3)  
 
Boastfulness 
Childish 
behavior 
Paranoid 
delusions 
Personality 
changes 
Physical violence 
Psychosis 
Short fuse 
Explosivity 
Apathy 
Depression 
Euphoria 
Fatigue 
Flat affect 
Insomnia 
Irritability 
Labile 
emotions 
Loss of 
interest 
Reduced 
intelligence 
Executive 
dysfunction 
Memory 
impairment 
Impaired 
attention 
Altered 
concentration 
Language 
Ataxia 
Dysarthria 
Masked 
Facies 
Muscle 
weakness 
Shuffling 
gait 
Tremor 
Unsteady 
gait 
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Social 
inappropriateness 
Verbal violence 
 
Mania 
Mood 
swings 
 
difficulties 
Dysgraphia 
Visuospatial 
difficulties  
 
 
Schwarz 
(1953) 
[44] 
Boxers 
(n=3)  
 
Personality 
changes 
Short fuse 
Explosivity  
 
Fearfulness 
Irritability 
Labile 
emotions 
 
Memory 
impairment 
Altered 
concentration 
Language 
difficulties 
 
Ataxia 
Dysarthria 
Masked 
facies 
Muscle 
weakness 
Stamping 
gait 
Tremor 
Unsteady 
Gait 
Soeder & 
Arndt 
(1954) 
[45] 
Boxers 
(n=5) 
 
Boastfulness  
Disinhibited 
behavior  
Inappropriate 
speech 
Paranoia 
Personality 
changes 
Physical violence 
Psychosis 
Short fuse 
Explosivity 
Social 
inappropriateness 
Apathy 
Depressed 
mood 
Euphoria 
Fatigue 
Flat affect 
Insomnia 
Mania 
Mood 
swings 
Prolix 
General 
cognitive   
 impairment  
Executive 
dysfunction 
Memory 
impairment 
Impaired 
attention 
Altered 
concentration 
Language 
difficulties 
Alogia 
Clonus 
Dysarthria 
Masked 
facies 
Rolling gait 
Tremor  
Truncal 
ataxia 
Unsteady 
gait  
Grahmann 
& Ule 
(1957) 
[33] 
Boxers 
(n=4) 
Confirmed 
CTE (n=1) 
 
Childish 
behavior 
Disinhibited 
behavior  
Disinhibited 
speech 
Impulsivity 
Loss of control 
Physical violence 
Personality 
changes 
Short fuse 
Explosivity 
Social 
inappropriateness 
Apathy 
Depressed 
Euphoria 
Labile 
emotions   
Fatigue 
Flat affect 
Irritable 
Mood 
swings 
Prolix 
 
General 
cognitive   
 impairment   
Executive 
dysfunction 
Memory 
impairment 
Impaired 
attention 
Altered 
concentration 
Dementia 
Dysarthria 
Swaying gait 
Masked 
facies 
 
Muller 
(1958) 
Boxers 
(n=3) 
Social isolation 
Personality 
Fatigue 
Irritability 
General 
cognitive   
Dysarthria 
Unsteady 
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[46]  changes 
Lack of insight 
 
 
 
 impairment  
Executive 
dysfunction 
Impaired 
attention 
Memory 
impairment 
Altered 
concentration 
Dementia 
gait 
Spastic gait 
 
Spillane 
(1962) 
[47] 
Boxers 
(n=5) 
 
Childish 
behavior 
Disinhibited 
behavior 
Impulsivity 
 
Anxiety 
Depressed 
mood 
Euphoria 
Mania 
Mood 
swings 
General 
cognitive   
 impairment  
Reduced 
intelligence 
Memory 
impairment 
Visuospatial 
difficulties 
Dysgraphia 
Lack of 
insight 
Dementia 
Ataxia 
Dysarthria 
Dragging 
gait 
Muscle 
weakness 
Tremor 
Unsteady 
gait  
Mawdsley 
& 
Ferguson 
(1963) 
[22] 
Boxers 
(n=10)  
 
 
Impulsivity 
Loss of control 
Physical violence 
Psychosis 
Paranoid 
delusions 
Personality 
changes 
Short fuse 
Explosivity 
Social 
inappropriateness 
Verbal violence 
Apathy 
Depression 
Insomnia 
Irritability 
 
General 
cognitive   
 impairment  
Reduced 
intelligence 
Memory 
impairment 
Language 
difficulties 
Dysgraphia 
Dementia 
 
Ataxia 
Dysarthria 
Dragging 
gait 
Masked 
Facies 
Muscle 
weakness 
Tremor 
Unsteady 
gait 
 
Critchley 
(1949, 
1957, 
1964) [23-
25] 
Boxers 
(n=17) 
 
Disinhibited 
speech 
Disinhibited 
behavior  
Impulsivity 
Lack of insight 
Physical violence 
Personality 
changes 
Social 
inappropriateness 
Depressed 
Labile 
emotions   
Euphoria 
Insomnia 
Irritable 
Loss of 
interest 
Fatigue 
General 
cognitive   
 impairment 
Reduced 
intelligence 
Memory 
impairment 
Impaired 
attention 
Altered 
concentration 
Ataxia 
Clumsy 
Dysarthria 
Masked 
facies 
Muscle 
weakness 
Tremor 
Unsteady 
gait 
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Short fuse Visuospatial 
difficulties  
Dementia 
Payne 
(1968) 
[48] 
Boxers 
(n=6) 
 
Disinhibited 
behavior  
Impulsivity 
Paranoid 
delusions 
Physical violence 
Psychotic 
Verbal violence 
Depressed 
mood 
Labile 
emotions 
Insomnia 
Mania 
Mood 
swings 
Suicidal 
ideation 
General 
cognitive 
impairment 
Reduced 
intelligence 
Altered 
concentration 
Visuospatial 
difficulties  
Memory 
impairment 
Ataxia 
Dysarthria 
Unsteady 
gait 
Johnson 
(1969) 
[26] 
Boxers 
(n=17)  
 
Loss of control  
Paranoid 
delusions 
Personality 
changes 
Psychotic 
Short fuse 
Explosivity 
Verbal violence 
Anxiety 
Labile 
emotions 
Irritability 
 
General 
cognitive 
impairment 
Reduced 
intelligence 
Memory 
impairment 
Dementia 
 
Ataxia 
Dysarthria 
Tremor 
Dragging 
gait 
Masked 
Facies 
Muscle 
weakness 
Roberts 
(1969) 
[49] 
Boxers 
(n=11) 
 
Lack of insight 
Paranoid 
delusions 
Psychosis 
Short fuse 
Explosivity 
Apathy 
Depression 
Euphoria 
Flat affect 
Labile 
emotions 
 
Reduced 
intelligence 
Executive 
dysfunction 
Memory 
impairment 
Perseveration 
Impaired 
attention 
Altered 
concentration 
Language 
difficulties 
Dysgraphia 
Visuospatial 
difficulties  
Dementia 
Ataxia 
Dysarthria 
Dragging 
gait 
Masked 
Facies 
Muscle 
weakness 
Shuffling 
gait 
Spasticity 
Tremor 
Unsteady 
gait 
Corsellis 
(1973) 
[50] 
Boxers 
(n=13) 
Confirmed 
CTE 
(n=13) 
 
Childish 
behavior 
Paranoid 
delusions 
Personality 
changes 
Short fuse 
Anxiety 
Labile 
emotions 
Irritability 
 
General 
cognitive 
impairment 
Reduced 
intelligence 
Memory 
impairment 
Ataxia 
Dysarthria 
Masked 
Facies 
Muscle 
weakness 
Tremor 
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Explosivity 
Social 
inappropriateness 
Social isolation 
Verbal violence 
Dementia Staggering 
gait 
Shuffling 
gait 
Unsteady 
gait 
Sabharwal 
(1987)  
[51] 
Boxers 
(n=4) 
 
Inappropriate 
speech 
 
Depression 
Irritability 
Labile 
emotions 
Mood 
swings 
Reduced 
intelligence 
Memory 
impairment 
 
Ataxia 
Spasticity 
Dysarthria 
Jordan 
(1997) 
[52] 
 
 
Boxers 
(n=19) 
 
Disinhibited 
speech 
Disinhibited 
behavior  
 
Depression 
Irritability 
Flat affect 
Mania 
 
Impaired 
attention 
Altered 
concentration 
Memory 
impairment 
 
Ataxia 
Clonus 
Dysarthria 
Spasticity 
Tremor 
Unsteady 
gait 
Omalu 
(2005, 
2006, 
2010) 
[29,53,54] 
Football & 
Wrestling 
(n=5) 
Confirmed 
CTE (n=5) 
Paranoid 
delusions 
Social isolation 
Physical violence 
 
Suicidality 
Anxiety 
Labile 
emotions 
Irritability 
Insomnia 
Depression 
General 
cognitive   
 impairment 
Memory 
impairment 
Language 
difficulties 
Executive 
dysfunction 
Impaired 
attention 
- 
Mckee et 
al, (2013) 
[2] 
Boxing, 
American 
football, 
ice hockey, 
wrestling 
(n=64) 
Confirmed 
CTE 
(n=64) 
Explosivity 
Aggression 
Impulsivity 
Paranoia 
 
Depression 
Hopelessness 
Suicidality 
Mood 
swings 
 
Memory 
impairment 
Executive 
dysfunction 
Impaired 
attention 
Language 
Visuospatial  
Dementia 
Dysarthria 
Gait 
disturbance 
Parkinsonism 
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Table 2.2. Summary of Clinical Features of CTE Found in the Literature 
Behavioral features Mood features Cognitive features Motor features 
Explosivity 
Loss of control 
Short fuse 
Impulsivity 
Aggression 
Rage 
Physical violence 
Verbal violence 
Inappropriate speech 
Boastfulness 
Childish behavior 
Social  
   inappropriateness 
Disinhibited speech 
Disinhibited behavior  
Paranoid delusions 
Personality changes 
Psychosis 
Social isolation 
Depression 
Hopelessness 
Suicidality 
Anxiety 
Fearfulness 
Irritability 
Labile emotions 
Apathy 
Loss of interest 
Fatigue 
Flat affect 
Insomnia 
Mania 
Euphoria 
Mood swings 
Prolix 
 
Dementia 
Memory impairment 
Executive dysfunction 
Lack of insight 
Perseveration 
Impaired attention and 
   concentration 
Language difficulties 
Dysgraphia  
Alogia  
Visuospatial  
   difficulties  
General cognitive   
  impairment 
Reduced intelligence 
 
Ataxia 
Dysarthria 
Parkinsonism 
Gait Disturbance 
Tremor 
Masked facies 
Rigidity 
Muscle weakness 
Spasticity 
Clonus 
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Previously Published Diagnostic Criteria. To date, there have been two 
published sets of diagnostic criteria for the clinical diagnosis of CTE.  The first 
diagnostic criteria, proposed by Jordan [35,40,41], were developed specifically to 
represent the likelihood of underlying CTE neuropathology.  As such, the following four 
diagnostic classifications are used: (1) definite CTE  (“any neurological process 
consistent with the clinical presentation of CTE along with pathological confirmation”); 
(2) probable CTE  (“any neurological process characterized by two or more of the 
following conditions: cognitive and/or behavioral impairment; cerebellar dysfunction; 
pyramidal tract disease or extrapyramidal disease; clinically distinguishable from any 
known disease process and consistent with the clinical description of CTE”); (3) possible 
CTE  (“any neurological process that is consistent with the clinical description of CTE 
but can be potentially explained by other known neurological disorders”); and (4) 
improbable CTE (“any neurological process that is inconsistent with the clinical 
description of CTE and can be explained by a pathophysiological process unrelated to 
brain trauma”) [35].  
In contrast to Jordan’s diagnostic criteria, which are focused on the prediction of 
underlying CTE neuropathology, the diagnostic criteria of Victoroff [27] are focused on a 
broad set of clinical signs and symptoms representing a diverse set of possible etiologies 
and are not meant to predict underlying CTE neuropathology. These provisional research 
diagnostic criteria for clinically probable traumatic encephalopathy (TE) and clinically 
possible TE were based on the frequency of clinical symptoms and signs reported in TE 
case reports published between 1928 and 2010. The Victoroff criteria represent an 
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important addition to the literature but have several limitations.  For example, for a 
diagnosis of clinically probable TE, there is a requirement for two symptoms and three 
signs.  However, there is tremendous overlap and redundancy between the symptoms and 
the “neurobehavioral signs,” including the use of the following terms included as both 
symptoms and signs: memory loss, irritability, apathy, impulsivity, depression, lability, 
euphoria, paranoia, and others. Another required criterion for clinically probable TE is 
the “persistence of both symptoms and signs for at least two years after the traumatic 
exposure” [27].  This is not consistent with numerous cases of neuropathologically 
confirmed CTE for which a delayed onset of the clinical presentation is often observed, 
representing the neurodegenerative nature of the disease [2,14]. An additional limitation 
to the Victoroff criteria is the lack of any subtyping of the clinical presentation.  That is, 
the same diagnosis of clinically probable TE could be given to an 80 year old with 
memory loss, mental slowing, headache, and nystagmus, and to a 22 year old with 
depression, anxiety, irritability, and anger. This lack of diagnostic subtyping for a 
condition with such clinically diverse signs and symptoms would reduce the utility of the 
criteria for research aimed at elucidating specific clinico-pathological relationships or 
clinical trials requiring greater specificity of diagnosis to assure meaningful target 
outcomes. The criteria are presented in a single table without accompanying descriptive 
prose, making implementation of the criteria potentially subject to individual 
interpretation.  Finally, the Victoroff criteria do not include or recommend the future use 
of objective diagnostic tests, such as neuroimaging or other potential biomarkers, to 
improve upon the diagnostic accuracy, specificity, or ability to detect CTE during life. 
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Proposed Research Diagnostic Criteria for TES and CTE 
We propose research diagnostic criteria that address many of the limitations of the 
previously published criteria by Jordan [35,40,41] and Victoroff [27].  These new criteria 
are derived from the previous literature on CTE reviewed above, as well as the specific 
findings from the studies by Stern and colleagues [14] and McKee and colleagues [2] on 
the clinical presentation of neuropathologically confirmed cases of CTE.  The term, 
“traumatic encephalopathy syndrome” (TES) was selected instead of “chronic traumatic 
encephalopathy” (CTE) for the following reasons: (1) we view the designation, “CTE” as 
a neuropathologically defined disease (which is defined by the characteristic deposition 
of p-tau pathology) rather than a clinical syndrome; (2) TES is meant to describe the 
clinical presentation of CTE as well as other possible long-term consequences of 
repetitive head impacts (e.g., chronic or progressive axonopathy without tauopathy), but 
is not meant to include the acute or post-acute manifestations of a single concussion, 
post-concussion syndrome, or moderate-to-severe TBI; (3) the use of the word, “chronic” 
in CTE inaccurately connotes a stable condition, rather than a progressive disorder [27]; 
and (4) the inclusion of the term “syndrome” appropriately describes the cluster of 
clinical features that make up this condition.  The proposed research diagnostic criteria 
for TES include five general criteria , three core clinical features , and nine supportive 
features , that are used to define subtypes of TES: a behavioral/mood variant, a cognitive 
variant, a mixed variant, and TES dementia. The modifiers “progressive course,” “stable 
course,” and “unknown/inconsistent course” are used to describe the clinical course, and 
if specific motor signs are evident, the additional modifier “with motor features” is 
 49 
 
added.   
The selection of the five general criteria  was based on the literature reviewed 
above and was designed to favor sensitivity over specificity.  This decision is consistent 
with the previously published diagnostic criteria [27,35], and is appropriate at this early 
stage of clinical research into this area.  To be included as a core clinical feature, the sign 
or symptom must have been reported in a minimum of 70% of the cases in the Stern et al. 
study [14] of neuropathologically confirmed cases of pure CTE.  This is in contrast to the 
algorithm employed in the Victoroff [27] diagnostic criteria for which a sign or symptom 
was included if it was present in at least 7% of the case reports he reviewed from the 
literature. The nine supportive features were selected to increase specificity once the 
general criteria are met and are based on features reported in the previous literature. 
The clinical diagnosis of TES is not meant to imply a certainty of underlying CTE 
neuropathological changes (for example, p-tau accumulation). Rather, TES is meant to be 
a diagnosis of a clinical syndrome associated with a history of repetitive brain trauma. It 
is expected that some individuals with TES do indeed have CTE neuropathological 
changes. However, it is also possible that some individuals with TES have other 
underlying causes of their clinical presentation, including, but not limited to, progressive 
white matter degeneration [55] or AD. For this reason, a separate diagnostic classification 
for “possible CTE,” “probable CTE,” and “unlikely CTE” is included, based on the 
presence of additional supportive features, such as biomarkers, which indicate the degree 
to which the underlying etiology of the clinical presentation of TES is likely due to the 
CTE pathophysiological process. Finally, we offer six cases (see boxes) as exemplars of 
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the implementation of the TES criteria; each case is a composite of several patients, 
created specifically for this purpose.  
At this time, risk factors for CTE (above and beyond brain trauma) remain 
unknown.  Amongst possible variables under investigation by our group and other labs 
include: the quantity and/or severity of the brain trauma, the initial age and overall 
duration of head impact exposure, lifestyle factors, and genetic susceptibility.  Based on 
current research findings, it is expected that TES is the clinical manifestation of 
underlying damage or dysfunction of cortical and/or subcortical brain structures and is 
associated with a history of repetitive brain trauma, including both symptomatic 
concussions and subconcussive trauma.  Although some investigators have suggested that 
a single moderate to severe TBI may lead to CTE [37] and/or AD [56], at this time the 
use of the clinical diagnosis of TES is meant to be used for individuals with repetitive 
impacts to the head, as defined below. We have included a requirement for a specific 
minimal amount of exposure to head impacts. This is based on previous findings of post-
mortem confirmed CTE cases [1,2,5,50] and will be subject to future revisions as 
additional research is conducted on exposure variables. 
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General Criteria for Traumatic Encephalopathy Syndrome.  
All five criteria must be met for a diagnosis of TES: 
1) History of multiple impacts to the head (or to the body resulting in impulsive force 
transmitted to the head). Multiple impacts are defined based upon (a) the types of 
injuries and (b) the source of exposure.  
a) Types of injuries: 
i) Mild traumatic brain injury (mTBI) or concussion, defined according to the 
Zurich 2012 Consensus Statement on Concussion in Sport [57] as a “complex 
pathophysiological process affecting the brain, induced by biomechanical 
forces…caused either by a direct blow to the head, face, neck or elsewhere on 
the body with an ''impulsive' force transmitted to the head…the acute clinical 
symptoms largely reflect a functional disturbance rather than a structural 
injury and, as such, no abnormality is seen on standard structural 
neuroimaging studies. Concussion results in a graded set of clinical symptoms 
that may or may not involve loss of consciousness.”  History of this form of 
trauma can be based on documented records from health care providers or on 
self- or informant-reports, after being given an appropriate definition of 
“concussion [58].” If there is no reported exposure to other repetitive hits to 
the head, there should be a minimum of 4 documented mild traumatic brain 
injuries or concussions. 
ii) Moderate/severe (TBI), defined as having loss of consciousness of at least 30 
minutes, alteration of consciousness/mental state of more than 24 hours, post-
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traumatic amnesia of more than 24 hours, and Glasgow Coma Scale score of 
less than 13 [59]. If there is no reported exposure to other repetitive hits to the 
head, there should be a minimum of two moderate/severe TBIs. 
iii) “Subconcussive” trauma, defined as biomechanical force to the head or body 
similar to, or less than, that required for symptomatic concussion, but without 
symptoms and clinical presentation consistent with concussion [3,4].  
b) Source of exposures:  
i) Involvement in “high exposure” contact sports (including, but not limited to, 
boxing, American football, ice hockey, lacrosse, rugby, wrestling, and soccer) 
for a minimum of 6 years, including at least 2 years at the college level (or 
equivalent) or higher. 
ii) Military service (including, but not limited to, combat exposure to blast and 
other explosions as well as non-combat exposure to explosives or to 
combatant or breach training). 
iii) History of any other significant exposure to repetitive hits to the head 
(including, but not limited to, domestic abuse, head banging, vocational 
activities such as door breaching by police). 
iv) For moderate/severe TBI, any activity resulting in the injury (e.g., motor 
vehicle accident). 
2) No other neurological disorder (including chronic residual symptoms from a single 
TBI or persistent post-concussion syndrome) that likely accounts for all clinical 
features, although concomitant diagnoses of substance abuse, post-traumatic stress 
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disorder (PTSD), mood/anxiety disorders, or other neurodegenerative diseases (for 
example, AD and frontotemporal dementia) or a combination of these can be present. 
3) Clinical features must be present for a minimum of 12 months. However, if treatment 
(for example, “antidepressant” medication) results in an improvement in select 
symptoms, the clinician should use her/his best judgment to decide whether the 
symptoms would have persisted or progressed if treatment had not been initiated. 
4) At least one of the core clinical features  must be present and should be considered a 
change from baseline functioning.  
5) At least two supportive features must be present. 
 
Core Clinical Features of Traumatic Encephalopathy Syndrome.  
At least one of the core clinical features  must be present. 
1) Cognitive.  Difficulties in cognition: 
a) as reported either by self or informant, by history of treatment, or by clinician’s 
report of decline; and  
b) substantiated by impairment on standardized mental status or neuropsychological 
tests of episodic memory, executive function and/or attention, as defined by 
scores of at least 1.5 SD below appropriate norms. 
2) Behavioral. Being described as emotionally explosive (for example, having a “short 
fuse,” or “being out of control”), physically violent, and/or verbally violent, as 
reported either by self or informant, by history of treatment, or by clinician’s report. 
A formal diagnosis of intermittent explosive disorder would meet this criterion but is 
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not necessary. 
3) Mood. Feeling overly sad, depressed, and/or hopeless, as reported either by self or 
informant, by history of treatment, or by clinician’s report. A formal diagnosis of 
Major Depressive Disorder or Persistent Depressive Disorder would meet this 
criterion though is not necessary. 
 
Supportive Features of Traumatic Encephalopathy Syndrome.  
A minimum of two of the following features must be present for a diagnosis of TES: 
1) Impulsivity. Impaired impulse control, as demonstrated by new behaviors, such as 
excessive gambling, increased or unusual sexual activity, substance abuse, excessive 
shopping or unusual purchases, or other similar activities. 
2) Anxiety. History of anxious mood, agitation, excessive fears, or obsessive compulsive 
behavior (or both), as reported by self or informant, history of treatment, or 
clinician’s report. A formal diagnosis of anxiety disorder would meet this criterion 
though is not necessary. 
3) Apathy. Loss of interest in usual activities, loss of motivation and emotions, and/or 
reduction of voluntary, goal-directed behaviors, as reported either by self or 
informant, history of treatment, or clinician’s report. 
4) Paranoia. Delusional beliefs of suspicion, persecution, and/or unwarranted jealousy. 
5) Suicidality. History of suicidal thoughts or attempts, as reported either by self or 
informant, history of treatment, or clinician’s report. 
6) Headache. Significant and chronic headache, with at least one episode per month for 
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a minimum of 6 months. 
7) Motor Signs. Dysarthria, dysgraphia, bradykinesia, tremor, rigidity, gait disturbance, 
falls, and/or other features of parkinsonism.  If present, the modifier, “with motor 
features” should be used (see below). 
8) Documented Decline. Progressive decline in function and/or a progression in 
symptoms and/or signs, based upon repeated formal testing, clinician examination, or 
other formal measurement (for example, informant questionnaire) for a minimum of 
one year.  
9) Delayed Onset. Delayed onset of clinical features after significant head impact 
exposure, usually at least 2 years and in many cases several years after the period of 
maximal exposure. It should be noted, however, that individual cases may begin to 
develop the clinical features of TES during their period of head impact exposure (for 
example, while still actively involved in a collision sport), especially older 
individuals or those who have been engaged in the high-exposure activity for many 
years. It may also be difficult to differentiate the clinical presentation of prolonged or 
persistent post-concussion syndrome (pPCS) from that of TES. Therefore, there could 
be cases for whom there is overlap of resolving pPCS and the initial features of TES, 
thus masking any delayed onset of TES. 
 
Traumatic Encephalopathy Syndrome Diagnostic Subtypes 
1) TES behavioral/mood variant (TES-BMv)  
a) Behavioral or mood core features (or both) without cognitive core features. 
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2) TES cognitive variant (TES-COGv).  
a) Cognitive core features without behavioral and/or mood core features. 
3) TES mixed variant (TES-MIXv).  
a) Both cognitive core features and behavioral or mood core features (or both). 
4) TES dementia (TES-D) 
a) Progressive course of cognitive core features with or without behavioral or mood 
core features (or both). 
b) Evidence of “functional impairment,” defined as cognitive impairment (or 
cognitive impairment exacerbated by behavioral or mood impairment or both) that 
is severe enough to interfere with the ability to function independently at work or 
in usual activities, including hobbies, and instrumental activities of daily living.  
The determination of functional impairment is based on clinician’s judgment, 
taking into account informant reports as well as consideration of individual 
differences with regard to level of expected responsibility and daily challenges. 
c) If the clinical presentation is not distinguishable from that of dementia due to AD 
or another neurodegenerative disease (for example, frontotemporal dementia), 
both diagnoses may be given, either with one being “primary” and the other being 
“secondary,” or with the term “mixed” used if neither is presumed primary. 
 
“With Motor Features” Modifier. For each TES subtype, the modifier “with motor 
features” should be added if the individual demonstrates dysarthria, dysgraphia, 
bradykinesia, tremor, rigidity, gait disturbance, falls, and/or other features of 
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parkinsonism. 
 
Clinical Course. For each TES subtype, one of the following additional modifiers 
should be selected: ‘stable course’, to be used when the history or objective testing (or 
both) indicates that there has been little if any change in symptoms, signs, or other 
measures; ‘progressive course’, to be used when there is a clear indication of progressive 
worsening of clinical features for at least a 2-year period; and ‘unknown/inconsistent 
course,’ to be used when either there is too little information available about the clinical 
course or the course has been inconsistent, with periods of stability, worsening, and/or 
improvement. By definition, TES dementia has a progressive course and does not require 
this modifier. 
 
“Possible CTE ” and “Probable CTE.” As stated above, CTE is a neuropathological 
diagnosis, whereas TES is a clinical diagnosis. As with other neurodegenerative diseases, 
such as AD, it is not possible at this time to diagnose the underlying disease with 
certainty during life. However, again as with other neurodegenerative diseases and in 
keeping with the diagnostic criteria for CTE proposed by Jordan [35,40,41], we propose 
provisional diagnostic classifications of ‘probable CTE’, ‘possible CTE’, and ‘unlikely 
CTE’. Because the scientific study of the clinical presentation of CTE is only in its 
infancy, it is not yet possible to create meaningful diagnostic criteria for ‘probable CTE’ 
based solely on clinical features and course, such as those employed for the National 
Institute on Aging-Alzheimer’s Association (NIA-AA) AD diagnostic criteria for 
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probable AD dementia [60], a condition that has been carefully studied for many decades. 
Rather, we propose, as a starting point, several potential in vivo biomarkers for CTE that 
can be used to support a provisional diagnosis of ‘probable CTE’. This diagnosis would 
be analogous to the NIA-AA diagnosis of probable AD dementia with evidence of the 
AD pathophysiological process [60]. However, because of the early stage of research into 
potential CTE biomarkers, we refrain from using this type of nomenclature. The 
following list of potential biomarkers for underlying CTE is meant only as a guideline at 
this early point in CTE diagnostic research. Many of these biomarkers are the focus of 
current research but have not yet been formally validated. Future biomarker validation 
studies will likely add to or delete (or both) items on this list. Moreover, we do not in any 
way recommend that the specific tests used for these potential biomarkers be conducted 
for clinical purposes at this time. 
 
Potential Biomarkers for the Diagnosis of Probable Chronic Traumatic 
Encephalopathy.  
1) Cavum septum pellucidum. Report of cavum septum pellucidum, cavum vergae, or 
fenestrations based on neuroimaging study. 
2) Normal beta amyloid cerebrospinal fluid (CSF) levels. CSF beta amyloid levels in the 
normal range for age and not diminished as would be suggestive of Alzheimer’s 
disease. 
3) Elevated CSF p-tau/tau ratio. CSF p-tau/total tau ratio above the normal range for 
age. 
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4) Negative amyloid imaging. PET amyloid imaging (for example, florbetapir and 
flutemetamol) in the normal range, not suggestive of AD. 
5) Positive tau imaging. PET paired helical filament tau imaging suggestive of abnormal 
tau deposition. It should be noted that this remains an experimental procedure and 
requires additional validation prior to its use as a research tool for diagnostic 
purposes. 
6) Cortical Thinning. Based on magnetic resonance imaging (MRI) measurement, 
evidence of abnormal cortical thinning indicative of neurodegeneration. 
7) Cortical atrophy. Based on MRI or computed tomography, generalized cortical 
atrophy beyond what is expected for age, and, in particular, frontal, thalamic, 
hippocampal, and/or amygdalar atrophy. 
 
Chronic Traumatic Encephalopathy Classification. 
1) Probable CTE. Meets classification for any TES subtype, progressive course; does 
not meet diagnostic criteria for another disorder more consistently than TES; and has 
a minimum of one positive potential biomarker for CTE. 
2) Possible CTE. Meets classification for any TES subtype, progressive course, and (1) 
has not undergone any potential biomarker testing, (2) has had negative results on one 
or more biomarkers with the exception of PET tau imaging (that is, if a negative PET 
tau imaging finding, the current classification would be “unlikely CTE”), or (3) meets 
the diagnostic criteria for another disorder that, on its own, could account for the 
clinical presentation.. 
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3) Unlikely CTE . Does not meet TES diagnostic criteria or has had a negative PET Tau 
Imaging scan or both.  
 
Case A.  A 45-year-old married man with a history of playing multiple contact sports, 
including soccer (ages 5 to 13), hockey (ages 7 to 12), and football (ages 9 to 22) 
presented to his primary care physician. He played college football at a Division 1 
university and was an offensive lineman. He had no reported or formally diagnosed 
concussions, although when provided with a definition of concussion, he stated that he 
likely had 20 to 30 throughout high school and college. Since graduating from college, he 
has worked as an auditor for state government. His work performance evaluations had 
been routinely positive, although for the past two years they have been marred by reports 
of ‘careless errors’, reduced productivity, and one episode of yelling at his immediate 
supervisor. His wife of 16 years reports that he has had a 5- to 7-year history of 
worsening behavior, with frequent episodes of having a ‘short fuse’ and losing his temper 
with their two young children. Though always a social drinker, he has had frequent 
episodes of binge drinking over the past 2 to 3 years. She states that his personality has 
changed from a kind, even-keeled, loving man to an argumentative, explosive, and 
moody individual. Both he and his wife state that he was high-functioning, without any 
cognitive, mood, and behavioral problems during the time period between college and 
about age 35. He recently underwent formal neuropsychological evaluation that 
demonstrated moderately impaired sustained attention, mildly impaired delayed recall on 
a word list, and moderately impaired executive functioning as measured by a card-sorting 
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test. All other areas of functioning were within the normal range. A self-report measure 
of syndromal depression indicated mild to moderate severity. Other than the recent work-
performance evaluations, there were no other reports of significant functional decline. 
The result of a recent brain MRI was unremarkable other than some mild, scattered white 
matter abnormalities. Other medical history, laboratory findings, and neurological 
examination were unremarkable. Diagnosis: TES-MIXv, progressive course; possible 
CTE. 
 
Case B.  A 31-year-old single female Army veteran was referred to the VA Medical 
Center Behavioral Health Clinic for a 14-month history of suicidal thoughts, agitation, 
and aggressive behavior. She had reached the rank of staff sergeant and was a logistics 
specialist. She was honorably discharged 1 year ago, began working in her family’s 
grocery store, but had to stop working 6 months ago because of her neuropsychiatric 
symptoms. She had two deployments to Afghanistan and denied being directly involved 
in combat. However, she reported that 20 months prior to her discharge, she was thrown 
off a truck when it struck an improvised explosive device. She was told she landed on her 
head and lost consciousness for 2 to 3 minutes. Upon regaining consciousness, she 
reported ‘seeing stars’ and had a headache that lasted 3 to 4 days. She denied these 
symptoms to the medic when questioned and remained on active duty. About 3 months 
later, a heavy box fell on her head, throwing her to the floor. She denied loss of 
consciousness but was nauseated and had balance difficulties for several hours. She 
complained of being in a fog and irritable for 2 days following the accident. Her tour of 
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duty ended 2 weeks later and she returned home. Other than those two injuries, she 
denied any TBIs or concussions. These symptoms completely cleared, and she described 
her functioning, including her mood, as ‘completely fine’ between that time and about 14 
months ago. Prior to enlisting, she was an avid ice hockey player, having played since the 
age of 5, and was the captain of her high school team. Her medical and psychiatric 
histories were unremarkable, and laboratory results of tests ordered by her primary care 
physician were normal. At the current evaluation, a mental status examination was 
conducted and the results were generally within normal limits. She denied having any 
cognitive complaints. A psychiatric interview revealed significant overall distress, with 
suicidal ideation without any active plan. Her primary complaints included poor sleep, 
sadness, anxiety, agitation, and being overly aroused by loud noises. She denied having 
any flashbacks or night terrors. A sibling was interviewed and corroborated the 
description and history but added that for the past year she had been verbally aggressive 
and explosive, frequently yelling at family members for no apparent reason, and that 
these episodes seemed to turn off and on without any warning. The sibling stated that 
these abnormal behaviors have been somewhat consistent over the past year. A PTSD 
specialist examined the patient, reported that she would not meet criteria for PTSD, and 
questioned whether the symptoms were residual from her TBIs in Afghanistan. The result 
of a brain MRI was unremarkable. Diagnosis: TES-BMv, stable course; possible CTE.  
 
Case C. A 59-year-old man presented to his primary care physician with complaints 
of progressive memory and concentration problems. Prior to going to college, the patient 
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entered the Army, where he boxed competitively for 4 years. He did not experience any 
combat. He was an avid rugby player in college and continued playing in formal 
competitive clubs until the age of 54, when he stopped because of a cervical disk injury. 
He received an MBA and had been a successful business consultant. He was divorced at 
the age of 45 and lived alone. He reported one concussion at the age of 30, when he 
briefly lost consciousness during a rugby game, although he stated he got his ‘bell rung’ 
countless times in boxing and rugby. He reported to his primary care physician that he 
had been having difficulty remembering details of conversations and meetings at work 
and that this was beginning to interfere with his productivity. His medical history was 
significant for the cervical disk injury and for migraine headaches for many years. He 
was referred to a local academic medical center memory clinic, where a formal 
neuropsychological evaluation demonstrated moderately impaired performance on a word 
list recall task, compared with age and education norms, as well as severely impaired fine 
motor dexterity. All other areas were intact, although his performance on a measure of 
psychomotor speed and response set maintenance was slightly below expected levels 
given his history. A neurological examination revealed mild bilateral resting tremor and 
mild upper extremity rigidity. An MRI scan was read as normal, and all laboratory 
findings were within normal limits. As part of a clinical research study, he was given two 
PETs: one with a new tau radiotracer and another with an amyloid tracer. Results 
indicated no meaningful amyloid uptake, although his tau scan was abnormal with 
scattered increased tracer uptake in the dorsolateral frontal cortex and the medial 
temporal lobes. Diagnosis: TES-COGv, with motor features, progressive course; probable 
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CTE. 
 
Case D. A 69-year-old former National Football League (NFL) football player was 
seen in consultation following a 10-year progressive decline. He had seen several 
physicians and had been given multiple diagnoses, including frontotemporal dementia 
and dementia due to AD. He had played professional football for 9 years as a linebacker. 
He began playing football in high school and played for a Division 1 college for 4 years, 
playing both as a linebacker and as an offensive lineman. Following retirement from the 
NFL, he had a successful career in commercial real estate until he was forced to retire at 
the age of 62 because of ‘poor decision-making and judgment’. His wife of 25 years 
stated that, in retrospect, he was demonstrating poor memory and judgment for about 3 
years prior to his retirement and that these problems had progressively worsened through 
the years. She stated that he also began having significant difficulties with multi-tasking 
and ‘numbers’ at age 61 and was having difficulty with household finances and hobbies. 
After retirement, he became increasingly withdrawn and refused to socialize. In contrast 
to his previous jovial and easy-going manner, he became verbally aggressive toward his 
wife and children, ‘blowing up over small things’. On two occasions, he became 
physically aggressive toward his wife, requiring her to call the police. He never 
demonstrated any disinhibited or socially inappropriate behavior, nor was there any 
report of hallucinations or movement disturbance. In the past 2 years, his functioning has 
worsened; he now has no ‘short-term memory’, watches television all day long, and has 
an erratic sleep cycle. He is functionally impaired in all instrumental activities of daily 
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living as well as in some basic activities of daily living. His medical history is significant 
for a myocardial infarction at age 54, hypertension, severe arthritis, and multiple lumbar 
disk surgeries. There is no family history of dementia. Upon examination, he was 
disoriented to time and place, was perseverative, and could not recall recent current 
events. He exhibited some frontal release signs, although the result of his motor 
examination was otherwise normal. His Mini-Mental Status Exam score was 9, and his 
Clinical Dementia Rating was 2.0. A neuropsychological evaluation was conducted and 
demonstrated severe episodic memory impairment as well as profoundly impaired 
performance on most tests of executive functioning. In contrast, attentional capacity was 
within normal limits and language was relatively intact. A brain MRI revealed significant 
global atrophy with marked hippocampal atrophy as well as a cavum septum pellucidum. 
An amyloid PET scan demonstrated only minimal uptake, not commensurate with the 
degree of dementia. Diagnosis: TES-D; probable CTE. 
 
Case E. A 31-year-old male stockbroker saw his primary care physician because of 
an 18-month history of recurrent headaches, irritability, agitation, and a worsening ‘short 
fuse’. He had been taking oxycodone (left over from previous oral surgery) for his 
headache pain. He was referred to a neurologist, who specialized in headache and who 
diagnosed him with tension headache. However, when asked if he had ever had 
headaches previously, the patient reported that he frequently had them as a teenager after 
his varsity high school football games and when he played rugby for 2 years in college. 
Because of this history of prior exposure to repetitive head impacts and possible 
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symptomatic concussions, the neurologist referred him to a psychiatrist colleague to 
evaluate him for possible depression and suicidality, based on the neurologist’s belief that 
the patient might have CTE; he had recently attended a talk on sports injuries. The 
consulting psychiatrist interviewed the patient, who acknowledged that he had frequent 
suicidal ideation following the breakup of his marriage about 1 year earlier but that these 
thoughts had now diminished. Although the patient formally met criteria for TES-BMv, 
the psychiatrist felt that the headache symptoms, suicidality, short fuse, and irritability 
were likely associated with the divorce. The patient was prescribed citalopram as well as 
regular therapeutic massage for his tension headache and was seen in 3 months, at which 
time he reported substantial improvement of his mood and behavioral symptoms and a 
complete resolution of his headaches. Diagnosis: adjustment disorder, persistent with 
mixed anxiety and depressed mood; unlikely CTE. 
 
Case F. An 81-year-old widowed man enrolled in a research study examining the 
long-term consequences of TBI. He reported having sustained a moderate TBI in a motor 
vehicle accident at the age of 46 with loss of consciousness for approximately 1 hour. He 
was hospitalized for 3 days because of confusion and memory difficulties that mostly 
resolved prior to discharge. He was unable to return to work as a high school physical 
education teacher and coach for several weeks because of continued cognitive 
difficulties, headache, and balance problems. He reported that, once he returned to work, 
he ‘didn’t feel normal’ for several months. He continued working until retirement at age 
60. He played high school and college football and reported having had  his ‘bell rung’ 
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‘all the time’. According to his adult son (with whom he lived), he was 72 when he began 
having memory problems that gradually progressed over the course of 5 to 6 years. In the 
past few years, the memory problems worsened significantly, such that he could not 
recall events that occurred more than an hour earlier. In addition, he had worsening 
problems with judgment, decision-making, multi-tasking, and word-finding. He no longer 
drove and was dependent in most areas of instrumental activities of daily living. He 
lacked interest in all activities and appears ‘depressed’ according to his son. His medical 
history was significant for prostate cancer, controlled hypertension, arthritis, and 
glaucoma. Two brothers died in their 80s with ‘dementia’. Neuropsychological testing 
revealed significant impairments in episodic memory, confrontation naming, 
psychomotor speed, and many aspects of executive functioning. Research-based MR 
revealed frontal and temporal atrophy and a pronounced cavum septum pellucidum; 
diffusion tensor imaging and tractography demonstrated significant reductions in corpus 
callosum fiber bundles. PET amyloid imaging showed elevated uptake consistent with 
AD. Diagnosis: dementia due to AD pathophysiological process and TES-D, mixed; 
possible CTE. 
 
Discussion 
The current proposed research diagnostic criteria for TES are meant to be a starting 
point that should be modified and updated as new research findings in the field become 
available and as future research using these criteria are published. These proposed criteria 
are not meant to be used for a clinical diagnosis or as evidence of an underlying disease. 
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Rather, they should be viewed as research criteria that could be employed in studies of 
the underlying causes, risk factors, differential diagnosis, prevention, and treatment of 
TES. Future studies comparing these proposed diagnostic categories with post-mortem 
neuropathological diagnoses, as well as with appropriate in vivo biomarkers for CTE and 
other conditions, will help lead to the transition from ‘research’ criteria to ‘clinical’ 
criteria. It also would be critical for these proposed criteria to undergo a formal expert 
consensus approval process, such as that used for the NIA-AA Diagnostic Guidelines for 
Alzheimer’s Disease [60]. 
One important factor that must be addressed in future iterations of these criteria is that 
of base rates. That is, the population prevalence of most of the core clinical features and 
many of the supplemental features of TES presented below is relatively high. Therefore, 
it is possible to meet criteria for TES and yet have an idiopathic disorder or a situationally 
based condition that is unrelated to the earlier history of head impact exposure. The 
inclusion of supportive features is meant to reduce this lack of specificity to a degree, but, 
at this time, we acknowledge that these criteria will likely result in very high sensitivity at 
the expense of specificity. With the utilization of future research findings and subsequent 
criteria revisions, it is likely that the specificity will increase. An important additional 
issue regarding the use of these criteria involves the impact of litigation or disability 
determination (or both) on the validity of symptom reporting and neuropsychological test 
performance. It is therefore recommended that this issue be taken into account when 
interpreting the individual’s self-reported functioning and test performance and that 
formal symptom validity checking be conducted as part of any formal evaluation. Until 
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future research yields accurate biomarkers and allows clarification and modification of 
the proposed criteria, the decision as to whether an individual meets the TES diagnostic 
criteria and associated ‘probable CTE’ diagnostic criteria should be left up to the 
individual researcher, clinician, or, preferably, a multidisciplinary diagnostic adjudication 
process. 
 
Conclusions 
The long-term consequences of repetitive head impacts have been known since 
the beginning of the 20th century. Although the clinical presentation of CTE is varied and 
non-specific, there are adequate reports to date to suggest that there may be two clinical 
subtypes: one subtype involving primarily behavioral or mood features (including 
explosivity or violence) or both, and the other involving cognitive deficits (including 
impairments in episodic memory, executive functioning, and attention). Many individuals 
progress to dementia, with impaired functional independence, and some individuals 
develop motor impairments (including parkinsonism, ataxia, and dysarthria). We propose 
research diagnostic criteria for TES that we hope will facilitate research into this area. 
There are expected limitations to the development of diagnostic criteria based primarily 
on a relatively small number of case reports. The goal of proposing these criteria at this 
time is to facilitate research in this nascent area of study. It is expected that these criteria 
will undergo modification and revision as new research findings become available, 
additional biomarkers are validated, and future research using these criteria are published. 
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Chapter 3 
 
Beta-Amyloid Deposition in Chronic Traumatic Encephalopathy 
 
Copyright © 2015, Springer-Verlag Berlin Heidelberg (outside the USA) 
 
Introduction 
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease likely 
caused by repetitive traumatic brain injury (RTBI).  Many contact sports have now been 
linked to CTE, including American football, boxing, hockey, soccer, and rugby.  In 
addition, we have found CTE in military personnel exposed to an explosive blast [10, 
29].  The clinical features of CTE typically manifest years or decades after the initial 
RTBI and consist of impairments in mood (depression, suicidality, irritability), behavior 
(explosivity, violence, impulsivity), cognition (impaired memory, executive dysfunction, 
diminished concentration), and motor functioning (parkinsonism, dysarthria, gait 
changes, weakness) [32, 33, 46].  The reported clinical symptoms following RTBI can 
vary widely, and different subtypes have been identified in neuropathologically 
confirmed cases of CTE [46].  Research clinical diagnostic criteria have recently been 
proposed [32], but investigations to establish reliability and diagnostic accuracy in 
predicting underlying CTE pathological changes are ongoing [32].  In some cases the 
clinical features can overlap with and be clinically indistinguishable from those of 
Alzheimer’s disease (AD).  An analysis of neuropathologically confirmed CTE without 
co-morbid disease demonstrated that in 11% of subjects overall and in 40% of demented 
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subjects the clinical presentation is indistinguishable from AD.  Moreover, as in AD, 
there is a spectrum of pathology in CTE, and some, but not all, subjects with pathological 
CTE will have dementia or CTE-related clinical symptoms [46].  A more complete 
understanding of the pathology may help explain and predict the clinical outcomes. 
CTE is a tauopathy characterized by neurofibrillary tangles, tau-positive 
astrocytes, and tau-positive cell processes that preferentially involve the cortical sulci, 
medial temporal lobe, diencephalon, and brainstem.  In CTE the tau pathology is 
characteristically perivascular, most pronounced at the sulcal depths, and preferentially 
involves the superficial cortical layers.  This pattern of tau pathology is distinct from 
other tauopathies, including Alzheimer’s disease.  Recently, the US National Institute of 
Neurological Disorders and Stroke convened a panel of expert neuropathologists to 
establish consensus criteria for CTE [42].  It was determined that the pathognomonic 
lesion in CTE was an abnormal perivascular accumulation of tau in neurons, astrocytes, 
and cell processes in an irregular pattern at the depths of the cortical sulci, and that CTE 
could be reliably distinguished from other tauopathies including AD, progressive 
supranuclear palsy, argyrophilic grain disease, corticobasal degeneration, Guamanian 
Parkinsonism Dementia Complex, and primary age-related tauopathy [4].   
The role of Aβ in CTE has been controversial.  At one point, Aβ deposition was 
thought to be a universal feature [39], but subsequent analyses found Aβ pathology 
within only a subset of individuals.  In our reported cohort of 68 athletes and military 
veterans with CTE, 44% had some deposition of primarily diffuse plaques, and 10% met 
the criteria for AD [30].  Some epidemiologic evidence exists that suggests moderate to 
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severe TBI is a risk factor for AD [13, 24, 27, 38] although most reports linking TBI and 
AD have relied on a clinical diagnosis of probable AD without neuropathological 
verification and a definitive link has yet to be established [17].  It has been shown that 
acutely following TBI, amyloid precursor protein (APP) and Aβ increase in tissue and 
CSF, and there can be rapid formation of diffuse Aβ plaques in the cortex [9, 16, 36, 40, 
41].  Therefore, the release of Aβ into surrounding tissue following injury may be a basis 
for plaque formation [41, 43].  The relation of Aβ deposition in CTE to genetic factors, 
other pathological lesions, and to the clinical course has yet to be determined.   
Here we set out to test the hypotheses that Aβ deposition is altered in CTE 
compared to a control population, Aβ accumulation in CTE differs from AD, and the 
presence of diffuse or neuritic plaques increases pathological severity and worsens 
clinical outcomes in CTE.  To test these hypotheses we examined the brains of 114 
participants with a history of RTBI and compared the pattern of neuropathological lesions 
in subjects with and without Aβ to each other, to the brains of individuals with 
neuropathologically confirmed AD without a known history of RTBI, and to the reported 
pathology of a large non-selected autopsy cohort of 2,332 normal aging cases [2].  
 
Materials and Methods 
Subjects. A total of 114 subjects were evaluated from Boston University’s 
Chronic Traumatic Encephalopathy Center including former athletes, military veterans, 
and civilians with a history of repetitive mild traumatic brain injury.  Next of kin 
provided written consent for participation and brain donation.  Institutional review board 
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approval for brain donation was obtained through the Boston University Medical Center 
and the Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA.  Institutional 
review board approval for post-mortem clinical record review, interviews with family 
members, and neuropathological evaluation was obtained through Boston University 
Medical Center. The brains from an additional 319 subjects from the Boston University 
AD Center were included for comparative analysis.  
 
Clinical assessment. Concussion and RTBI history, history of cognitive and 
behavioral changes and clinical status leading up to death were determined through post-
mortem interviews with next of kin performed by physicians, neuropsychologists, and 
doctoral candidates trained to assess for RTBI, dementia, and neurodegenerative diseases 
(J.M., T.S., D.H.D., P.H.M., and R.A.S.).  Interviewers were blind to the results of the 
neuropathological examination at the time of interview, and the neuropathologists were 
blind to the results of the clinical interviews at the time of neuropathological examination 
and diagnosis.  Informants were interviewed before receiving the results of the 
neuropathological examination.  The interview was semi-structured and conducted by 
telephone.  Medical record review was also performed (J.M., T.S., P.K., D.H.D, P.H.M, 
T.D.S., A.C.M, and R.A.S.).  Recorded clinical measures included the presence or 
absence of CTE symptoms including mood, behavioral, or cognitive changes (reviewed 
in [32]), age of symptom onset, presence of symptoms associated with parkinsonism (e.g. 
tremor, bradykinesia, rigidity, gait disturbance, ataxia, dysarthria, dysphagia), and 
behavioral or cognitive variant of CTE [46].  We recorded dementia status using a 
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conservative definition of dementia based on a diagnosis made during life.  In the subset 
of AD subjects selected for ELISA and Aβ plaque burden, subjects and their informants 
were asked during life about a history of contact sports play or head injury including 
RTBI and those without such history were selected for comparison. 
 
Pathological Diagnoses  
Chronic traumatic encephalopathy. The diagnosis and staging of CTE followed 
the definitions and criteria described previously [30] and adapted to include: (i) 
perivascular foci of hyperphosphorylated tau immunoreactive neurons, astrocytes, and 
cell processes; (ii) irregular cortical distribution of hyperphosphorylated tau 
immunoreactive neurons and astrocytes with a predilection for the depths of cerebral 
sulci; and (iii) hyperphosphorylated tau-positive neurons in the cerebral cortex located 
preferentially in the superficial layers.  Supportive features include: (iv) clusters of 
subpial and periventricular astrocytic tangles in the cerebral cortex, diencephalon, basal 
ganglia and brainstem.  CTE stages varied from I to IV based on the extent and severity 
of tau pathology as previously described [30].  Briefly, Stage I CTE is characterized by 
isolated perivascular foci of hyperphosphorylated tau within neurons, astrocytes, and cell 
processes present at the sulcal depths.  In stage II the tau pathology extends to involve the 
superficial cortical layers into the gyral crest.  In stage III there is additional involvement 
of the parietal and temporal lobes as well as medial temporal lobe tau pathology (i.e. 
hippocampus, amygdala, entorhinal cortex).  By stage IV all cortical lobes are involved 
with severe tau pathology though it is still most severe at the sulcal depths and around 
 80 
 
blood vessels.  In addition, there is abnormal tau accumulation within the diencephalon, 
brainstem, and cerebellum. 
Alzheimer’s disease. Neuropathological diagnosis of AD required an intermediate 
or high degree of neuropathological changes as defined by the ABC score.  Subjects with 
AD changes had a low degree of neuropathological change as defined by the ABC score 
[15, 34].  Neuritic and diffuse plaques were assessed with Bielschowsky silver staining 
and using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 
scoring system for plaque pathology [31].  
Lewy body disease. The presence or absence of Lewy bodies was determined by 
immunohistochemical staining for alpha-synuclein.  The regions examined in each case 
included the olfactory bulb, medulla, substantia nigra, amygdala, hippocampus, and 
cingulate gyrus. 
 
Immunohistochemistry. Human tissue was fixed in periodate-lysine-
paraformaldehyde, and tissue blocks were paraffin-embedded and cut at 10 µm for 
immunohistochemistry.  Antigen retrievals were performed by formic acid treatment for 
2 min for Aβ antibodies.  Sections were incubated at 4oC overnight with antibodies to 
phosphorylated PHF-tau (AT8; Pierce Endogen, Rockford IL; 1:2,000), Aβ1-40 
(AB5074P; EMD Millipore, Billerica, MA; 1:2000), Aβ1-42 (AB5078P; EMD Millipore; 
1:2000), alpha-synuclein (rabbit polyclonal; Chemicon, Temecula, CA; 1:15,000), and 
pTDP-43 (pS409/410 mouse monoclonal; Cosmo Bio Co, Tokyo, Japan; 1:2,000).  For 
determination of Aβ deposition in the medial temporal lobe (section of the hippocampal 
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formation, parahippocampal gyrus, transentorhinal region, and portions of 
occipitotemporal gyrus), the monoclonal anti-Aβ antibody (Clone 4G8; Covance, 
Dedham, MA, 1:100,000) was used.  After three washes with PBS (pH 7.4), sections 
were treated with biotinylated secondary antibody and labeled with a 3-amino-9-
ethylcarbazol HRP substrate kit (Vector Laboratories).  Sections were counterstained 
with Gill's Hematoxlin (Vector Laboratories H-3401) and then coverslipped with 
Permount mounting medium. 
 
Quantitative ELISA Measurement of Aβ and tau. The buffer conditions, 
protease inhibitors, and centrifugation protocols have been reported previously [51].  
Briefly, a 4mm tissue punch was used to isolate and remove gray matter from the gyral 
crests and sulcal depths of the middle frontal gyrus and neighboring sulci and superior 
temporal gyrus and sulcus.  Brain tissue was homogenized in 5-fold volume of 5M 
Guanidine Hydrochloride/50mM Tris-HCL, pH 8.0, with protease inhibitors (Thermo 
Scientific, 78439) and phosphatase inhibitors (Sigma, P5726 and P0044).  Tissue was 
homogenized using a mechanical homogenizer for 25 strokes followed by ultrasonic 
disruption on ice.  The homogenates were shaken at room temperature overnight.  
Samples were diluted 10 fold with 0.4% Block Ace (Dainippon Pharmaceuticals Co, 
Japan) and centrifuged at 14,000rpm for 15 min at 4oC.  Enzyme-linked immunosorbent 
assay (ELISA) was performed for Aβ1-38, 1-40, and 1-42 using a multiplex plate from 
Meso Scale Discovery (MSD, Rockville, MD) as well as for levels of phosphorylated tau 
(Thr231) following the manufacturer’s instruction. 
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 Aβ plaque deposition was determined using Aβ1-40 and Aβ1-42 immunostaining 
and quantified as reported previously [37].  Briefly, digital images were captured at 200x 
magnification and a threshold optical density was obtained, which discriminated staining 
from background.  The amyloid burden was defined as the total percentage of cortical 
surface area covered by either Aβ1-40 or Aβ1-42 deposition over three sections and was 
calculated for the bottom third of the sulcus (depth of the sulcus) and the top third of the 
gyrus (gyral crest).   
 
APOE Genotyping. DNA was extracted from brain tissue samples using a Qiagen 
QIAamp DNA extraction kit (Qiagen, Valencia, CA).  Two single nucleotide 
polymorphisms (National Center for Biotechnology Information SNPs rs429358 and 
rs7412) were examined using TaqMan assays (Applied Biosystems, Foster City, CA).  
Allelic discrimination was automated using the manufacturer’s software.  Positive 
controls, consisting of DNA of each of the 6 possible APOE genotypes (ε2/ε2, ε2/ε3, 
ε2/ε4, ε3/ε3, ε3/ε4, ε4/ε4), were included on each plate and genotyped with restriction 
isotyping.  
 
Statistical methods. Both SPSS version 20.0 (IBM Inc., Chicago, Illinois) and 
SAS version 9.3 (SAS Institute, Cary, North Carolina) were utilized for statistical 
analyses.  Significance was set a priori at alpha = 0.05.  Neuropathologically confirmed 
CTE tauopathy cases were divided into two subgroups based on the presence or absence 
of Aβ plaques and further distinguishing between diffuse and neuritic types.  Group 
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comparisons were based on demographic (e.g., age at death), clinical (e.g., symptom 
onset, presentation subtype), genotype (APOE), exposure (e.g., sport, RTBI history), and 
lesion (e.g., Aβ, LBD, TPD-43) characteristics.  Spearman’s rank order correlation was 
used to determine the statistical association between CTE stage and all linear variables of 
interest.  For non-linear independent variables, the Wilcoxon–Mann–Whitney U test was 
used for independent variables with only two groups (e.g. presence of neuritic plaques).  
A two-sample chi-square test weighted by sample size and a logistic regression model 
were used to compare the frequency of Aβ deposition in the medial temporal lobe by age 
in our CTE cohort to a published non-selected community-based autopsy series of 2,332 
subjects [2].  The chi-square statistical method is nonparametric and therefore makes no 
assumptions about the population distribution.  Linear regression analysis was performed 
to determine the relationship of Aβ deposition and age at death and CTE stage.  The 
interaction effect between age and Aβ pathology in predicting CTE stage was calculated 
when appropriate.  Logistic regression models were used to generate odds ratios (OR) 
while adjusting for age and CTE stage when appropriate. 
 
Results 
Beta-Amyloid Pathology in CTE, AD, and Aging. We first set out to determine 
whether the frequency of plaques differed in our cohort of CTE versus AD and normal 
aging.  Beta-amyloid plaques can be either diffuse or neuritic as defined by the presence 
of abnormal tau-positive neurites.  In our cohort of 114 subjects with CTE (mean age at 
death = 60 yrs, all men), we found Aβ deposition in the form of diffuse plaques in 52% 
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with Aβ immunostaining and neuritic plaques (CERAD > 0) in 36% using Bielschowsky 
silver staining.  The percent of cases with both diffuse and neuritic Aβ deposition 
increased with CTE stage (Table 1).  When compared to AD subjects from the Boston 
University’s AD Center, stage IV CTE had a similar frequency of diffuse Aβ plaques.  
However, there were significantly fewer neuritic plaques in stage IV CTE compared to 
AD (Table 1, Z = -9.94, p < 0.001).  
The mean age at death was significantly higher in CTE subjects with Aβ plaques 
compared to those without (Figure 1a and Table 3).  To evaluate the age-dependent 
increase of Aβ deposition in our CTE cohort and to determine whether it differs from 
normal aging, we grouped the age at death of our subjects into decades and plotted the 
frequency of cases positive for Aβ deposition in the medial temporal lobe (available in n 
= 104 subjects) as assessed by the anti-Aβ antibody 4G8 (Figure 1b).  Aβ pathology first 
appeared in CTE cases aged 41 to 50, with a frequency that was significantly higher in 
later decades (Figure 1b).  The odds of developing Aβ pathology in CTE increased 2.7 
fold for every decade (p < 0.0001).  A clear age-dependent increase in Aβ plaque 
deposition was also reported in the medial temporal lobe using identical methods in a 
non-selected community-based autopsy series of 2,332 subjects [2].  When compared to 
this normal aging population, the frequency of Aβ deposition in our CTE cohort was 
higher in CTE subjects in the decades between the 50s and 90s and significantly higher 
for CTE subjects in their 60s (χ2 = 13.7, p < 0.001) and 70s (χ2 = 7.76, p = 0.005), and 
the overall risk of developing plaque pathology was higher for the CTE group (Figure 
1b).  In fact, the odds of developing plaque pathology were 3.8 times higher in CTE than 
 85 
 
in normal aging (p < 0.0001).  To test the hypothesis that the Aβ plaque frequency in 
CTE and normal aging are not derived from a common distribution we performed a 
weighted two-sample chi-square test.  Importantly, this demonstrated a distinct 
distribution of Aβ by age in the CTE cohort compared to normal aging (χ2 = 721, p < 
0.0001).  This suggests that Aβ deposition in CTE is not simply accelerated aging, but 
rather a distinct process with altered dynamics. 
 
Table 3.1.  Frequency of Aβ deposition in CTE   
 n Mean age at 
death (yr) 
APOE ε4   
% (+/-)* 
DP Freq 
(%) 
NP Freq 
(%) 
CTE (all) 114 60 33% (27/55) 52% 36% 
   Stage I 13 35 33% (3/6) 15% 0% 
   Stage II 30 52 32% (7/15) 33% 20% 
   Stage III 34 62 23% (6/20) 44% 27% 
   Stage IV 37 75 44% (11/14) 87% 70% 
AD 319 80 59% (13/9) 84% 100% 
CTE, Chronic traumatic encephalopathy; DP, diffuse plaques; NP, neuritic plaques; 
AD, Alzheimer's disease 
* % of both ε4 hetereozytes and homozygotes out of those cases with genotypes 
(n=82) 
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Figure 3.1. The presence of neuritic Aβ plaques (NPs, CERAD > 0) was associated with 
age at death and was accelerated in CTE. a Subjects with neuritic plaques were 
significantly older at death than those without neuritic plaques (CERAD = 0). b When 
compared to the gradual age-dependent increase in the frequency of Aβ plaques in the 
medial temporal lobe of a non-selected autopsy series [2], the frequency of Aβ plaques in 
CTE is significantly higher in subjects in their 60 s (*χ2 = 13.7, p < 0.001) and 70 s (**χ2 
= 7.76, p = 0.005). 
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APOE ε4 Allele is Enriched in CTE Subjects with Aβ. We next set out to 
determine whether the proportion of APOE ε4 was enriched in CTE cases overall and in 
those with Aβ versus those without.  First, we tested the hypothesis that the proportion of 
ε4 alleles is elevated in our CTE cohort overall.  Although there were more ε4 alleles in 
the overall CTE cohort (20%) when compared to an age-matched normative sample (15% 
from [28]), the difference was not quite significant (Table 2, Z = 1.48, p = 0.069, z-test).  
Similar to what was reported previously in a subset of these cases [46], there was a 
significantly greater proportion of ε4 homozygotes (Z = 1.94, p = 0.026) and a non-
significant increase in heterozygotes in the overall CTE cohort compared to the 
normative sample.  To test the hypothesis that the ε4 proportion is elevated in CTE 
subjects with Aβ, but not in those without, we compared the proportions of these 
different groups to a control population [28].  In CTE subjects without either diffuse or 
neuritic plaques, the proportion of ε4 alleles (14%) was not significantly different from 
population norms (15%).  However, the proportion of ε4 alleles was significantly greater 
than a control population in CTE subjects with diffuse plaques (27%, Z = 2.92, p = 
0.002) or neuritic plaques (25%, Z = 2.01, p = 0.022).  We also examined the other 
APOE allele frequencies.  In CTE subjects with diffuse plaques there was a decrease in 
the number of ε3 alleles (65%) compared to the control population (77%, Z = -2.51, p = 
0.012).  Differences in the ε2 allele frequency were not detected (Table 2).  Finally, to 
directly test the hypothesis that the ε4 allele is associated with Aβ in our CTE cohort, we 
performed a Fisher’s exact test and found that ε4 was significantly associated with the 
presence of diffuse plaques (p = 0.035), but not quite for neuritic plaques (p = 0.086).  
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Table 3.2. APOE allele frequencies in CTE     
Group ε2 allele count n(%) 
p-value 
(Z score)* 
ε3 allele  
count 
p-value 
(Z score)* 
n(%) 
ε4 allele 
count 
p-value 
(Z score)** 
CTE overall 12 (7.3%) 0.726 (-0.348) 120 (73%) 0.298 (-1.04) 32 (20%) 0.069 (1.48) 
   CTE without Aβ 5 (6.4%) 0.596 (-0.534) 64 (82%) 0.258 (1.13) 11 (14%) 0.386 (-0.294) 
   CTE with DPs 6 (7.0%) 0.711 (-0.368) 56 (65%) 0.012 (-2.51) 23 (27%) 0.002 (2.92) 
   CTE with NPs 3 (5.4%) 0.459 (-0.742) 39 (70%) 0.219 (-1.23) 14 (25%) 0.022 (2.01) 
Population norms,  
ages 42-70 yrs [28] 758 (8.1%)   7205 (77%)   1439 (15%)   
APOE, apolipoprotein E gene; CTE, chronic traumatic encephalopathy; DPs, diffuse plaques; NPs, neuritic plaques; 
significant p-values in bold (Z test vs population norms), *two-tailed, **one-tailed 
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Sulcal Versus Gyral Aβ Levels. If traumatic injury influences the deposition of 
Aβ, we would hypothesize that more Aβ would be present at the sulcal depths due to the 
putative stress concentration there [45].  Therefore, we next examined a subset of cases 
that met the neuropathological criteria for both AD and CTE (CTE-AD; Supplementary 
Table 1) for differences in Aβ levels at the sulcal depths of the middle frontal sulcus 
versus the gyral crests.  We also examined subjects with CTE and neuritic plaques that 
did not reach the full criteria for an AD diagnosis (CTE+NPs).  These groups were 
compared to subjects without any history of RTBI or professional contact sports play, 
including those with pathologically diagnosed AD, and to those with neuritic plaques that 
did not have AD (AD changes; Supplementary Table 1).  In subjects with only AD, there 
was no difference in Aβ1-40 or Aβ1-42 plaque deposition between the sulcus and the 
gyrus (Figure 2).  However, in CTE-AD subjects, the Aβ1-40 plaque burden was 
significantly greater in the sulcus compared to the gyral crest (t = 2.21, p = 0.029, 
Student’s t-test), but this difference was not present for Aβ1-42.  The Aβ1-42 plaque 
burden was similar between AD and CTE-AD subjects.  In contrast, there was a 
significantly lower Aβ1-40 plaque burden in the gyral crest in CTE-AD compared to AD 
subjects (Figure 2, t = -2.80, p = 0.013).  Subjects with AD changes and subjects with 
CTE+NPs had similar plaque burden levels for both Aβ1-40 and Aβ1-42 in both the 
gyrus and the sulcus, and all were significantly less compared to the AD subject groups 
(p < 0.05, Student’s t-test).   
To determine whether total levels of various species of Aβ were elevated in the 
sulcus compared to the gyrus in subjects with CTE compared to those without, we next 
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used ELISA to measure the total levels of Aβ1-38, Aβ1-40, and Aβ1-42 isolated from the 
sulcal depths of the middle frontal cortex and compared them to levels in the gyral crests.  
Similar to the data on Aβ plaque burden, we found significantly more Aβ1-40 in the 
sulcus compared to the gyrus in CTE-AD subjects (paired t = 1.965, p = 0.045) and no 
difference between sulcal and gyral levels of Aβ1-42 (Figure 3).  Surprisingly, we also 
found a trend of elevated Aβ1-40 levels in the middle frontal sulcus compared to the 
gyrus of AD subjects without a history of RTBI; however, this did not reach significance 
(t = 2.16, p = 0.059, paired t-test).  As expected, subjects with CTE without neuritic 
plaques had very low levels of Aβ1-38, Aβ1-40, and Aβ1-42 (Figure 3). 
 
Supplementary Table 3.1. Characteristics of subjects examined with 
immunohistochemistry and ELISA 
 
n              
IHC 
(ELISA) 
Average 
age (yr) 
Braak & 
Braak  
NFT Stage 
CERAD plaque 
density 
CTE Stage 
Mean±SEM 
AD 13 (10) 79 V-VI Moderate to Frequent - 
CTE-AD 9 (8) 70 V-VI Moderate to Frequent 3.5±0.2 
AD 
changes 9 (-) 93 0-III Sparse to Moderate - 
CTE+NPs 7 (-) 81 0-III Sparse to Moderate 3.6±0.2 
CTE (5) 65 0-III None 3.4±0.2 
AD, Alzheimer's disease; CTE-AD, Chronic traumatic encephalopathy with Alzheimer's 
disease; NPs, neuritic plaques; NFT, neurofibrillary tangle 
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Figure 3.2. Aβ and tau pathologies were concentrated within the sulcal depths as 
compared to the gyral crests of the dorsolateral frontal cortex in CTE-AD.  
 
 
Figure 2. a–d Immunostaining for tau showed a greater accumulation of tau-positive neurons, 
astrocytes, and cell processes in the sulcus of CTE-AD subjects (d) as compared to the gyrus (c), 
but no difference in AD subjects (a, b). e–l Immunostaining for Aβ1-40 and Aβ1-42 showed no 
difference between the gyrus (e, i) and sulcus (f, j) of AD subjects. However, there were a greater 
number of plaques in the sulcus of subjects with CTE-AD (h, l) as compared to the gyrus (g, k) 
although the difference in Aβ1-40 was most pronounced (k, l). Scale bar 200 μm. (m, n) 
Quantitation of the percent amyloid burden showed significantly increased Aβ1-40 (m), but not 
Aβ1-42 (n) within the sulcus compared to the gyrus in the dorsolateral frontal cortex of CTE-AD 
subjects (*p = 0.029, Student’s t test). There was no difference between sulcal or gyral plaque 
burden for Aβ1-40 or Aβ1-42 in subjects with AD, AD changes, or CTE with neuritic plaques 
(CTE+NPs). 
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Figure 3.3. Total levels of Aβ in subjects with AD, CTE-AD, or CTE alone as measured by ELISA. Subjects with both CTE and 
AD (CTEAD) had a significantly higher Aβ1-40 burden within the sulcus compared to the gyrus (*p = 0.045, paired t test). There 
was no difference between sulcal or gyral Aβ1-42 levels in subjects with AD or CTEAD. Subjects with CTE alone had low levels 
of Aβ1-38, Aβ1-40, and Aβ1-42 that were not significantly different between sulci and gyri. 
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Effect of Aβ on CTE tauopathy. To test the hypothesis that the development of 
Aβ pathology relates to an increased severity and progression of CTE tauopathy, several 
regression analyses were employed.  The CTE stage is a measure of the degree and 
distribution of tau pathology [30] and was significantly increased in subjects with co-
morbid neuritic plaque pathology (Figure 4a).  In the overall CTE cohort, age was also 
significantly associated with CTE stage.  Therefore, we also tested for an interaction 
between neuritic plaques and age on CTE stage.  The overall linear regression model 
showed that CTE stage was significantly predicted by neuritic plaques (β = 2.43, p = 
0.018) when adjusted for age (β = 0.029, p = 0.001) and the two-way interaction (age x 
neuritic plaque, β = -0.028, p = 0.047).  Taken together, Aβ pathology and age accounted 
for almost half of the total variance in the progressive development of CTE stage (r2 = 
0.47) although the contribution of age to the development of CTE tau pathology had a 
small effect (β coefficient < 0.25).  Figure 4b illustrates the nature of this interaction by 
separately plotting the regression of age and CTE stage in subjects with neuritic plaques 
versus those without.  Notably, there was a significant association between age at death 
and CTE stage in subjects lacking neuritic plaques (β = 0.032, p < 0.001), but not in CTE 
subjects with neuritic plaques (β = 0.004, p = 0.740).  The slope of the linear regression 
line between age and CTE stage was significantly greater in CTE subjects without 
neuritic plaques compared to those with neuritic plaques (F = 4.147, p = 0.044).  This 
demonstrates that the presence of neuritic plaques modifies the relationship between age 
and CTE stage.  When broken down by decade, CTE stage was significantly increased in 
subjects in their 60s with neuritic plaques, but not younger subjects (Figure 4c).  After 
 94 
 
age 70, the average CTE stage plateaued to near its maximum level for subjects both with 
and without NPs.  To examine this relationship even further, we employed binary logistic 
regression and found the odds of a case progressing to the most severe stage of CTE, 
stage IV tauopathy, was 3.90 times higher in subjects presenting with co-morbid neuritic 
plaques compared to those without (p = 0.008) while adjusting for age.  Overall, this data 
demonstrates that the presence of neuritic plaques was associated with more severe CTE-
related tauopathy independent of age.   
Quantitative levels of tau phosphorylated at threonine 231 (ptau231) were also 
measured by ELISA in the middle frontal cortex in a subset of subjects (Supplementary 
Table 1).  Ptau231 was significantly increased in CTE subjects with neuritic plaques 
compared to those without (Figure 5, t = 2.10, p = 0.045) and was further increased in 
CTE-AD subjects.  CTE-AD subjects had similar levels of ptau231 as AD subjects 
despite an average age at death almost a decade earlier (70 years in CTE-AD versus 79 
years in AD).  This further supports the hypothesis that Aβ deposition is associated with 
more severe tau pathology in CTE.  
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Figure 3.4. CTE subjects with neuritic 
Aβ plaques (CERAD > 0) had an 
accelerated tauopathy. a The median 
CTE stage was significantly greater in 
CTE subjects with neuritic plaques (*p 
< 0.001, Mann– Whitney U test). b 
Scatter plots of CTE tau pathology 
(stage) versus age are shown with 
separate regression lines for subjects 
without neuritic plaques (CERAD = 0) 
and those with neuritic plaques 
(CERAD > 0). There was a significant 
correlation between age and CTE stage 
in subjects without neuritic plaques, 
but not in CTE subjects with neuritic 
plaques. The slope of the regression 
line between age and CTE stage was 
significantly greater (p = 0.044) in 
CTE subjects without compared to 
those with neuritic plaques. c The 
increase in CTE stage in subjects with 
neuritic plaques was significant in the 
7th decade of life (*p < 0.002, Mann–
Whitney U test), while older subjects 
had similarly elevated CTE stages. 
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Figure 3.5.  Levels of tau phosphorylated at threonine 231 (ptau231) in the middle frontal gyrus 
measured with ELISA. Subjects with CTE and neuritic Aβ plaques (CTE + NPs) had significantly 
more ptau231 than subjects with CTE alone (p = 0.045). Subjects with CTE and AD (CTE-AD) 
had the greatest amount of ptau231 and had levels similar to subjects with Braak & Braak stage 
V-VI AD (AD, n = 4, Student’s t-test). 
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Clinical and mTBI Exposure Associations. We next set out to determine whether 
the presence of Aβ was associated with worse clinical outcomes.  First, we found no 
significant difference between the number of years of athletic exposure.  Subjects with 
diffuse or neuritic plaques did have an increased number of reported concussions 
compared to CTE subjects without Aβ, but this difference was not significant (Table 3).  
Both the age at death and the age at symptom onset were significantly greater in CTE 
subjects with Aβ (either diffuse or neuritic plaques) compared to those without Aβ (Table 
3, p < 0.001). 
There was a significantly greater frequency of dementia in subjects with Aβ 
compared to those without.  A logistic regression analysis controlling for age shows that 
dementia remained significantly enriched in the CTE with Aβ subgroups (Table 3).  In 
fact, the odds of developing dementia were 3.9 times higher in persons with diffuse 
plaque pathology (OR= 3.93, p = 0.013) while controlling for age (p < 0.001) and 4.5 
times higher in persons with neuritic pathology (OR = 4.45, p = 0.012) while controlling 
for age (p < 0.001).  In addition, the proportion of subjects with CTE clinical symptoms 
was greater in those subjects with either diffuse or neuritic plaques (neuritic: p = 0.028, 
Pearson χ2 test), although this difference was not significant when controlling for age 
(Table 3).   
Two distinct clinical presentations of CTE have been reported: some subjects 
present with cognitive symptoms (cognitive variant) and others present with behavioral 
or mood symptoms (behavioral-mood variant) [46].  The frequency of the cognitive 
variant was increased in CTE subjects with Aβ, but this difference did not reach 
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significance (Table 3). 
Motor symptoms including parkinsonism have been reported in a subset of CTE 
subjects.  Moreover, Lewy body disease has been associated with Aβ deposition [11].  
We therefore tested whether Aβ is associated with Lewy body disease and parkinsonism 
in our CTE cohort.  We found a significantly higher frequency of both Lewy body 
disease pathology and parkinsonism in CTE subjects with Aβ compared to those without.  
A logistic regression analysis controlling for age shows that both Lewy body pathology 
(neuritic: OR = 5.01, p = 0.009; diffuse: OR = 7.09, p = 0.019) and parkinsonism 
(diffuse: OR = 8.86, p = 0.050) are significantly enriched in the CTE with Aβ subgroups 
(Table 3).   
The CTE cohort is a heterogeneous group with multiple comorbidities, including 
a history of substance abuse (present in 44% of subjects, n = 94) and symptoms of 
depression (65%).  To test whether these comorbidities may influence the association of 
Aβ with dementia, parkinsonism, and Lewy body disease, we performed a logistic 
regression analysis controlling for them.  Aβ deposition was still significantly associated 
with dementia, parkinsonism, and Lewy body disease, but neither a history of substance 
abuse nor symptoms of depression were significantly associated (data not shown).  
Furthermore, to test whether these comorbidities are associated with Aβ deposition in the 
CTE cohort, we performed a logistic regression analysis with the presence of diffuse 
plaques as the dependent variable and found a positive association with age (β = 0.081, p 
< 0.001), but a non-significant negative association with a history of substance abuse (β = 
-0.762, p = 0.148) and symptoms of depression (β = -0.088, p = 0.874).  Results were 
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similar for neuritic plaques suggesting that substance abuse and depression do not 
influence Aβ deposition in the CTE cohort. 
Because forces associated with RTBI likely differ with the type of exposure, we 
hypothesized that Aβ deposition would also differ with the type of exposure.  Thus we 
compared Aβ plaque deposition across CTE subjects with different exposure histories, 
specifically boxing, American football, hockey, and military combat (Table 4).  Overall, 
we found that boxers in our series had a significantly greater CTE stage when compared 
to football players, hockey players, or military veterans (Table 4, Mann-Whitney U test).  
The boxers also had the greatest frequency of neuritic plaques (50%) compared to 
football players (34%), hockey players (40%), and military veterans (33%), although the 
difference was not significant.  Similarly, boxers had a greater, but non-significant, 
frequency of diffuse plaques compared to football or hockey players or military veterans 
(Table 4).  
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Table 3.3.  Clinical, exposure, and pathological findings in CTE with and without Aβ deposition 
 CTE  CTE with DPs   CTE with NPs   
  n Mean±SEM  n Mean±SEM p*  n Mean±SEM p*  
Age at death 55 48.2 ± 2.6  59 71.6 ± 1.4 <0.001  41 73.6 ± 1.4 <0.001  
Athletic exposure  51 15.0 ± 1.0  46 15.9 ± 0.9 0.500  31 16.7 ± 1.2 0.22  
Concussion no. 48 11.5 ± 3.0  41 24.2 ± 6.6 0.071  28 17.5 ± 5.4 0.99  
Age at Sx onset  43 36.2 ± 2.3  42 54.2 ± 2.3 <0.001  30 56.4 ± 2.7 <0.001  
 CTE   CTE with DPs    CTE with NPs   
Freq (+/-)   Freq (+/-) p** p^  Freq (+/-) p** p^ 
CTE Sx 76% (37/12)   90% (43/5) 0.059 0.419  94% (31/2) 0.028 0.164 
Dementia 20% (10/39)   73% (35/13) <0.001 0.013  82% (27/6) <0.001 0.012 
Cognitive variant 58% (23/17)   76% (31/10) 0.067 0.382  76% (22/7) 0.15 0.597 
Parkinsonism 2.1% (1/48)   25% (12/36) 0.001 0.050  27% (9/24) 0.010 0.113 
LBD pathology 3.7% (2/52)   35% (19/35) <0.001 0.019  42% (16/22) <0.001 0.009 
TDP-43 pathology 67% (37/18)   84% (48/9) 0.030 0.810  93% (38/3) 0.003 0.097 
For statistical tests, CTE with DPs compared to CTE without DPs (labeled CTE in table) and CTE with NPs compared to CTE 
without NPs (data not shown) 
DP, diffuse plaques, NP, neuritic plaques;  
*Student's t-test; **Pearson χ2 test; ^logistic regression controlling for age 
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Table 3.4.  CTE Stage and frequency of Aβ deposition by sport or military history 
 n Mean age at death (yr) 
CTE stage    
Mean±SEM 
p-
value* 
APOE ε4      
% (+/-)* 
DP      
Freq (%) 
NP       
Freq (%) 
Boxing 10 67 3.80±0.13 - 29% (2/5) 70% 50% 
Football 88 61 2.78±0.11 0.002 35% (22/41) 51% 34% 
Hockey 5 57 2.60±0.40 0.012 40% (2/3) 40% 40% 
Military 9 55 2.22±0.12 0.002 20% (1/4) 44% 33% 
DP, diffuse plaques, NP, neuritic plaques;  
*Mann-Whitney U test compared to boxing;  
*% of both ε4 heterozygotes and homozygotes out of those cases with genotypes 
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Discussion 
Here we show that Aβ plaque deposition was present in 52% of all subjects with 
pathologically diagnosed CTE in our series (mean age at death=60 yrs).  We find that Aβ 
deposition occurred at a younger age and at an accelerated rate in our cohort of subjects 
with a RTBI history and a neuropathological diagnosis of CTE when compared to a 
community-based autopsy series [2] (Figure 1b).  In addition, there were elevated levels 
of Aβ1-40 within the sulcus compared to the gyrus in subjects with CTE-AD.  When Aβ 
plaques were present in CTE, they were significantly associated with more severe tau and 
Lewy body pathology and worse clinical outcome independent of the effect of age.     
 While it is possible that the presence of Aβ simply represents the development of 
co-morbid Alzheimer's disease pathology, Aβ deposition occurred at an accelerated rate 
in subjects with a neuropathological diagnosis of CTE when compared to a community-
based cohort (Figure 1b), which suggests that exposure to RTBI or the presence of 
hyperphosphorylated tau might be a modifying factor in Aβ accumulation.  In fact, a 
weighted two-sample chi-square test demonstrated that the age-dependent distribution of 
Aβ was significantly different in our CTE cohort compared to normal aging (χ2 = 721, p 
< 0.001), suggesting that RTBI is not simply accelerating an aging process, but is altering 
the normal dynamics of Aβ deposition.  All the subjects in our CTE cohort were men, 
which is not the case in the normal aging cohort.  However, men develop Aβ pathology at 
a significantly slower rate than women [2], suggesting that the actual increase in 
frequency of Aβ deposition in CTE may be greater than what we report.  There was a 
high frequency of substance abuse history (44%) and symptoms of depression (65%) in 
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the CTE cohort.  However, neither of these comorbidities was significantly associated 
with Aβ deposition, suggesting that other factors drive plaque formation in CTE.  
Moreover, the pattern of Aβ deposition was altered in CTE-AD subjects with elevated 
levels of Aβ1-40 at the sulcal depths compared to the gyral crests.  This sulcal 
predilection of Aβ corresponds to regions of axonal injury in gyrencephalic animals after 
acceleration-deceleration injury [44], which may be a result of stress concentration at the 
sulcal depths following trauma [3].  Altogether, these findings suggest that repetitive mild 
traumatic injury may accelerate and alter Aβ accumulation and deposition.  
 The presence of Aβ was associated with disease progression in CTE.  Subjects 
with neuritic plaques had a significantly increased stage of CTE tauopathy even when 
controlling for age.  Although an association between neuritic plaques and advanced tau 
pathology might be expected given that neuritic plaques require tau-positive neurites and 
are associated with neurofibrillary tangles in AD, the pattern of tau pathology associated 
with the various CTE stages is unique, and an association between Aβ deposition and 
tauopathy severity in CTE has not previously been shown.  We further found that levels 
of ptau231 in CTE were increased in the presence of Aβ.  Along with this increase in tau 
pathology, there was a significantly higher frequency of dementia in the presence of Aβ 
with the age-adjusted odds of developing dementia in CTE 4.5 times higher in persons 
with Aβ pathology than without.  Taken together, this suggests that CTE with Aβ 
pathology is a distinct subtype of CTE—one that has a more aggressive pathology and 
clinical course. 
 Deposition of Aβ is strongly associated with Lewy body disease, the formation of 
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alpha-synuclein inclusions, and higher levels of insoluble alpha-synuclein [11, 20].  In 
vitro studies have shown that Aβ promotes the formation of alpha-synuclein oligomers 
and polymers as well as inclusions in transfected cell lines [25].  In our CTE cohort we 
found a significant association of Aβ with LBD even when controlling for age.  
Moreover, the age-adjusted odds for developing parkinsonism was 8.9 times higher in 
CTE subjects with diffuse Aβ deposition compared to those without Aβ.  Thus, Aβ may 
lead to Lewy body pathology and parkinsonism in addition to causing a more severe 
tauopathy in CTE. 
 The ε4 allele of APOE is a common genetic factor that appears to render 
individuals susceptible to Aβ deposition.  The APOE ε4 allele is a major risk factor for 
Alzheimer's disease with homozygotes possessing a more than 10-fold greater risk for 
developing AD dementia and heterozygotes a threefold greater risk [8, 26].  In clinical 
control populations, the ε4 allele is associated with biomarkers indicating greater Aβ 
deposition [35, 50].  Moreover, the ε4 allele is associated with increased Aβ levels 
following TBI [6], and several studies have demonstrated worse clinical outcomes in ε4 
carriers following a traumatic brain injury or concussion [19, 21, 23, 48].  Here we show 
that the APOE ε4 allele was significantly associated with Aβ deposition in CTE.  In fact, 
when subjects with Aβ were excluded, there was no significant difference in the 
proportion of ε4 alleles between CTE and population norms although our sample size was 
small. Although additional effects of the ε4 allele cannot be ruled out, it may be that the 
ε4 allele increases the likelihood of Aβ accumulation and deposition following RTBI and 
this, in turn, worsens the pathological and clinical outcomes. 
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 Although CTE is a distinct disease, there are similarities to AD.  Trauma has long 
been thought to be a risk factor for developing AD, and moderate to severe TBI has been 
shown to acutely increase Aβ levels and plaque formation [36, 16].  An increased 
percentage of Thioflavin-S-positive plaques has been shown in subjects many years after 
single TBI compared to age-matched controls, suggesting that even a single TBI may 
accelerate and alter Aβ deposition [18].  Axonal injury is a proposed source of elevated 
Aβ in acute and moderate to severe TBI, and we found increased Aβ at the depths of sulci 
in CTE where there is also evidence of significant axonal injury in animal models of mild 
TBI.  This suggests that the axonal injury provoked by mild TBI might also alter the 
chronic deposition of Aβ in CTE.  We found increased Aβ1-40 at the sulcal depths 
compared to the gyral crests, but the level of Aβ1-42 was unchanged in subjects with 
both CTE and Alzheimer's disease.  The reason for this difference is unclear.  Neuritic 
plaques are composed of both Aβ1-40 and Aβ1-42 while diffuse plaques are composed of 
Aβ1-42 [5, 12, 14].  Therefore, the increase in Aβ1-40 may result in more neuritic 
plaques in CTE. 
Abundant genetic and experimental evidence suggests that Aβ can lead to the 
abnormal phosphorylation and accumulation of tau [1].  Our finding that the deposition of 
Aβ in CTE was associated with more severe tau pathology supports the hypothesis that 
Aβ can accelerate a tauopathy.  These findings have important implications for 
diagnosing CTE before death.  The interpretation of blood and cerebrospinal fluid 
biomarkers and Positron Emission Tomography (PET) neuroimaging using both amyloid 
and tau ligands will need to consider the possibility of Aβ pathology in persons older than 
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50 with CTE (see Figure 1).  
 There also may be differences in tau and amyloid pathology depending on the 
type of traumatic exposure.  Studies in boxers using anti-Aβ immunohistochemistry with 
formic acid pretreatment demonstrated diffuse cortical Aβ plaques in 27 of 28 (96.4%) 
subjects [39, 49].  In contrast to the original reports of CTE in boxers, the majority of 
cases in our cohort were football players.  The nature, frequency, and intensity of 
traumatic impacts in different sports may lead to differences in CTE pathology.  Here we 
show that boxers had a significantly greater CTE stage compared to football players, 
hockey players, or military veterans (Table 4).  There was also a trend toward greater 
frequency of Aβ deposition in boxers although the difference was not significant, which 
may be due to the small sample size.    
 There are several limitations to our study. This is an autopsy-based study 
involving a heterogeneous cohort of individuals with a history of RTBI that came largely 
by self or family referral.  The study subjects may not be representative of the entire 
RTBI population.   Moreover, the clinical histories are retrospectively obtained and are 
subject to bias.  Our subjects lived in the United States, and although the prevalence of 
AD does not vary much between the USA and European countries [47], it is unknown 
how differences in ethnicity may affect Aβ deposition.  Ethnic differences have been 
shown to affect ε4 allele frequency.  For instance, a recent study showed ε4 frequency 
increased with latitude [22].  We compared our cohort to a large meta-analysis that 
included data from multiple countries [28], and other US-based studies found similar ε4 
allele frequencies [7, 50], supporting the use of this control population.  Future 
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longitudinal, prospective studies are needed to address the frequency and type of 
pathologies present in population-based cohorts and to obtain less restrictive clinical 
histories and evaluations.  Better quantitation of subject exposure to RTBI and correlation 
to in vivo biomarkers as well as neuropathological diagnoses at autopsy will be critical to 
clearly understand the role of RTBI on Aβ aggregation and deposition and CTE 
pathogenesis. 
Overall, our work suggests that CTE with Aβ pathology is a distinct pathological 
subtype of CTE that shows a greater degree of tauopathy, a greater likelihood of LBD, 
and has a worse clinical outcome compared with CTE without Aβ.  RTBI may alter and 
accelerate the deposition of Aβ in some individuals, and Aβ, in turn, may accelerate tau 
and Lewy body pathologies and worsen the clinical course in CTE.  It remains to be 
determined whether individuals susceptible to Aβ deposition can be identified in life with 
biomarkers, what genetic factors, in addition to APOE ε4, may influence susceptibility to 
Aβ deposition, and what minimum burden of head trauma is necessary for induction of 
CTE and modulation of Aβ deposition. 
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Chapter 4  
Clinical Features of Repetitive Traumatic Brain Injury and Chronic Traumatic 
Encephalopathy 
 
Copyright © 2015, International Society of Neuropathology 
 
Introduction 
The Participating in contact sports is thought to increase an individual’s risk for 
later-life impairments and neurodegeneration. Both active and retired athletes who report 
multiple concussions are significantly more likely to have problems with depression, 
emotional liability, executive function, attention and memory. In a study commissioned 
by the National Football League (NFL), it was reported that retired players were 20 times 
more likely than age-matched controls to receive a diagnosis of dementia, Alzheimer’s 
disease (AD), cognitive impairment or related memory impairment disorders [93]. 
Lehman et al, for the National Institute for Occupational Safety and Health, found that 
neurodegeneration was listed as the cause of death three times more often in NFL players 
than in the general US population [46,47]. Mounting evidence suggests chronic traumatic 
encephalopathy (CTE) may be the major underlying etiology in these reports. In fact, a 
recent study with the National Alzheimer’s Coordinating Center Uniform Data Set 
reported an atypical, tau predominant pathology in cases of suspected AD after grouping 
participants with significant traumatic brain injury (TBI) histories [73]. Recently, the 
Chronic Traumatic Encephalopathy Center (CTEC) added 68 new cases of CTE to the 
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literature [52], which doubled the number of cases reported in the world’s literature. Of 
the 68 new cases, it is particularly concerning that six cases of neuropathologically 
confirmed CTE were identified in high school level athletes [17]. As a result, the 
National Institutes of Health and the National Institute of Neurological Disorders and 
Stroke (NINDS) have teamed up with investigators to provide financial support for 
multicenter and multidisciplinary investigations into this condition. The purpose of this 
article is to review (i) the acute effects of sports-related TBI, including clinical criteria for 
concussions, post-concussion syndrome (PCS); second impact syndrome  (SIS) (ii); the 
chronic effects of sports-related TBI, including CTE (iii); review new clinical diagnostic 
criteria for CTE; and (iv) provide clinical and pathological details from two cases of 
neuropathologically con- firmed CTE from a professional football player and a 
professional boxer. 
 
Traumatic Brain Injury 
Concussion. The word “concussion” derives from the Latin concutere, meaning “to 
shake violently.” Concussions are just that—a shaking of the brain inside the skull, which 
alters the alertness of the injured person or produces symptoms that fall into four major 
categories: (i) Somatic: headaches, nausea, vomiting, balance and/or visual problems, 
dizzy spells and issues such as sensitivity to light and noise. (ii) Emotional: sadness to the 
point of depression (even suicide), nervousness and irritability. (iii) Sleep  disturbance: 
sleeping  more  or  less  than  usual  and trouble falling asleep. (iv) Cognitive: difficulty 
concentrating, troubles with memory, feeling mentally slow or as if in a fog that will not 
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lift.  
Changes in alertness can be relatively mild (slightly dazed) or profound 
(unconscious), yet both situations fall within the definition of concussion. Although 
concussion is often classified as a form of mild TBI (MTBI), when the profound potential 
effects are considered, many clinicians do not view a concussion as a necessarily mild 
injury. It is, however, generally agreed that: (i) Both direct and indirect head trauma 
produce linear and rotational forces on the brain, with rotational forces being the most 
injurious [14]. (ii) Concussions do not typically cause structural changes seen on routine 
imaging studies, such as computed tomography (CT) and magnetic resonance imaging 
(MRI) scan, but rather exert their pathological changes at the microscopic and 
biomechanical levels from the brain being shaken within in the skull [13]. (iii) Following 
a concussive event, there is a destructive pathophysiological and biomechanical response 
that initiates a chain of neurometabolic and neurochemical reactions that include [79]: 
• Activation of inflammatory response. 
• Imbalance of ionic concentrations. 
• Increase in the excitatory amino acids. 
• Dysregulation of neurotransmitter release and synthesis. 
• Imbalance   of    mitochondrial   functions   and   energy metabolism. 
• Productions of free radicals. 
(iv) While an individual prognosis cannot be determined, all concussions are initially 
managed with both cognitive and physical rest [12, 15, 31]. (v) Following a concussive 
event, even after resolution of all symptoms, there may be long-lasting, ultrastructural 
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and functional brain alteration as shown by [79]: 
• Susceptibility weighted imaging MRI. 
• Diffusion tensor imaging (DTI) MRI. 
• Functional MRI. 
• Magnetic resonance spectroscopy MRI. 
• Positron emission tomography MRI. 
(vi) Because of the unique features of the maturing brain, young athletes are more 
vulnerable to the effects of a concussion than adults [32, 76]. 
Post-Concussion Syndrome. While there are two well-recognized definitions of 
PCS [2, 65] (Tables 1 and 2), most clinicians recognize PCS as the persistence of 
concussion symptoms lasting beyond a month. 
Individuals at increased risk for this condition include athletes with multiple 
concussions, those with concussions in close proximity to each other and athletes 
subjected to a double hit such as a direct helmet-to-helmet hit and then the head hitting 
the ground as the athlete falls [18]. At even higher risk is an athlete that experiences 
additional head trauma while they are symptomatic from a prior concussion through the 
course of the same game or match. PCS is usually very debilitating, but it typically clears 
up in a matter of months. Although rare, there are reports where post-concussion 
symptoms take as long as 5 years to clear up after trauma [18]. For those who are able to 
recover from PCS, especially those with shorter courses, many are able to safely return to 
competitive sports. For those who do not recover, it is presently not possible to rule out 
incipient CTE. 
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Table 4.1. International classification for diseases 10th revision clinical 
criteria for post-concussion syndrome 
A. Head injury usually severe enough to cause loss of consciousness 
within 4 weeks of symptom onset 
B. Preoccupation with symptoms and fear of brain damage with 
hypochondrial concern and adaptation of sick role 
C. Three from below 
Headache, dizziness, malaise, fatigue, noise intolerance 
Irritability, depression, anxiety, emotional lability 
Concentration, memory or intellectual deficit without 
neuropsychological evidence of deficit 
Insomnia 
Reduced alcohol intolerance 
 
 
Table 4.2. Diagnostic and statistical manual of mental disorders fourth 
edition criteria for post-concussion syndrome 
A. History of severe concussion 
B. Neuropsychological evidence of attention or memory impairment 
C. At least three of the following occurring shortly after injury lasting for 
3 months 
Fatigue 
Sleep impairment 
Irritability or aggression 
Anxiety, depression, or labile affect 
Headache 
Dizziness 
Personality Change 
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Second-Impact Syndrome. The most concerning concussion-related problem is 
SIS. Autoregulation, the process by which our brain normally maintain a constant blood 
flow, is the basis of this serious condition. When the brain’s blood pressure rises, there is 
a concurrent restriction in the diameter of arterioles. When the blood pressure falls, the 
opposite occurs: arterioles dilate, or relax, to maintain constant blood flow (Figure 1A–
C).  
SIS disrupts autoregulation (Figure 1D). Instead of constricting when blood 
pressure is normal or elevated, arterioles dilate and allow blood to rush through. The 
result: a massive inflow of blood to the brain accompanied by an equally dramatic 
increase in intracranial pressure—a highly dangerous situation, which often leads to brain 
herniation and death. The patients who survive are almost always severely disabled.  
Each year, a few athletes lose their lives to SIS, although the exact number is 
unclear. Since 1987, the senior author of this paper has been involved in a research study 
that tracks catastrophic injuries causing death, permanent brain injury  or  spinal  cord 
damage among high school and college football players in the United States. During a 
13-year interval, 15 cases of SIS were identified out of 94 cases of catastrophic head 
injury [9]. In that study, approximately 40% of athletes were kept on the field despite 
having concussion symptoms. With a greater commitment to keeping players with 
concussion symptoms off the field, deaths from SIS could be drastically reduced or 
eliminated. 
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Figure 4.1.  Autoregulation of brain arterioles and pathophysiology. Baseline (A): When 
blood pressure is normal, brain arteriole blood vessels are neither constricted nor dilated. 
Increased blood pressure (B): The brain seeks to maintain a constant blood flow. The 
brain arteriole blood vessels constrict. Decreased blood pressure (C): As pressure falls, 
brain arteriole dilation occurs. Blood flow to the brain remains unchanged. 
Dysautoregulation or second impact syndrome (D): A serious disruption occurs. The 
brain acts as if blood pressure is low when it is not low; it is normal or may be elevated. 
Brain arteriole blood vessels dilate and blood rushes into the brain and results in a 
massive rise in intracranial pressure. Within minutes, the brain can herniate, resulting in 
coma.  
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Subconcussive Brain Trauma. A concussion is well recognized as an etiological 
factor for a spectrum of neurological conditions, including PCS and risk for developing 
CTE, a neurodegenerative disorder occurring later in life.  The role of subconcussive 
head trauma, defined as head trauma that does not result in recognized concussion 
symptoms or signs, is not well known. In our published work from the Center for the  
Study  of Traumatic  Encephalopathy at  Boston  University Medical School, we have 
seen cases of CTE in deceased athletes who  never  had  a  recognized  concussion. These 
athletes had, however, sustained many thousands, often more than 10,000 subconcussive 
blows during their athletic career [53]. For athletes who have sustained concussions, our 
experience tells us that the risk of CTE occurrence correlates best with total head trauma, 
including both concussive and subconcussive blows [52].  
Recent publications clearly point to the damaging effects of repetitive 
subconcussive trauma in male contact sport athletes when compared with age-matched 
male noncontact sport athletes [16]. Significant abnormal changes in DTI MRI, including 
fractional anisotropy (FA) and mean diffusivity, were observed in contact sport athletes. 
Abnormalities were most robust in the corpus callosum, external capsule and inferior 
fronto-occipital fasciculus areas of the brain containing long myelinated axonal fiber 
tracts. These abnormal findings were not only seen preseason in the contact vs. 
noncontact groups, but increased when the groups were compared with preseason to 
postseason. An alarming  finding, this preseason-postseason difference suggests long-
term  effects  from  the  repeated  head  trauma  associated  with playing just one season 
of a contact sport. A study of 50 Division I football players compared with 25 matched 
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controls found that the volume of the hippocampus (part of the brain important for 
memory) was reduced by 15%–25% in the football players [77]. This diminished brain 
volume reflected neuronal loss and was correlated with decreased cognitive activity and 
reaction time. The study further found hippocampus size to be inversely correlated with 
an athlete’s total years of play. These findings suggested that subconcussive hits have a 
harmful effect on young brains. These data validate the idea that brain injury can occur 
from the repetitive impacts sustained in contact sports, even in the absence of clinically 
apparent TBI. These subconcussive hits still impart resultant linear and rotational 
accelerations on the brain as it violently shakes inside the skull.  
What makes the author’s findings so compelling and concerning is that in the last 
year alone, multiple reports in peer-reviewed journals have shown significant differences 
in preseason vs. post- season values in contact sport athletes using a variety of tests. 
These findings have included metabolic brain function as measured by functional MRI 
[87], neurocognitive testing (ImPACT) [87] and structural breakdown of the blood–brain 
barrier as manifested by S100B protein in the blood [50] structural changes seen on DTI 
imaging [46]. While the majority of these studies have involved American football 
players, some have included soccer and hockey athletes.  
This demonstrates that all head trauma, even at the subconcussive level, can result 
in brain damage in susceptible individuals. It can be argued that the subconcussive group 
may have included some unrecognized concussions. It is necessary to carry out additional 
studies beyond the immediate postseason, up to 3, 6 or 12 months, to see in what 
percentage the abnormalities persist and result in permanent injury. 
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Cumulative Exposure. In those exposed to repetitive head trauma, there are 
several possible long-term outcomes that may occur: (i) none, that is, there is no 
appreciable neurological signs or symptoms; (ii) static deficits that are a result of the head 
trauma but do not progress; and (iii) a neurodegenerative process, with the repetitive head 
trauma as either a risk  factor (eg, AD) or cause of, for example, CTE. To characterize the 
clinical features associated with repetitive head trauma, there may be no better groups to 
examine than football players and boxers. These athletes, particularly those who make it 
to the professional level, are exposed to thousands of blows to the head over the course of 
many years. Quantifying such exposure is among the major challenges in the field of 
TBI. Research efforts are underway to define “clinically practical” measurements of 
blows to the head among contact sport athletes. For now, the “gold standard” for 
determining a lifetime history of TBI is retrospective self-reports or proxy reports 
obtained in a structured interview. These include the NINDS common data elements and 
recommendations from the Center for Disease Control and Prevention [23, 24, 34]. The 
researchers at the CTEC developed novel questionnaires to obtain athletes’ athletic and 
concussion histories and to provide meaningful and accurate estimates of overall 
repetitive TBI (RTBI) exposure [5, 6, 70]. While there are inherent limitations of 
retrospective self-reports, numerous studies have demonstrated their usefulness in 
evaluating the association between long-term RTBI exposure and latent impairments with 
an accept- able level of reliability [23, 45]. For example, the CTEC recently reported a 
link between previous football experience and executive dysfunction in older retired 
football players [74]. In their study, 64 retired college and professional football players 
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were compared with healthy adults.  Subjects were  administered the Behavior Rating 
Inventory of Executive Function, adult version, to evaluate nine areas of executive 
functioning with scores compared with published age-corrected normative scores for 
healthy adults. Relative to healthy adults, the football players indicated significantly more 
problems overall, as well as on seven of the nine clinical scales, including inhibit, shift, 
emotional control, initiate, working memory, plan/organize and task  monitor. These 
symptoms were greater in athletes aged 40 and older, indicating that although RTBI 
experienced by  football players is associated with both short-term and long-term self-
reported  executive  dysfunction, these symptoms may develop or worsen in the fifth 
decade of life.  
In the absence of a direct measure of a subject’s cumulative trauma exposure, 
there are several potential surrogates, such as number of fights, fights per year, number of 
knockouts and years of fighting, that have been utilized in studies with boxers. Among 
football players, the total number of seasons, primary position and level achieved (high 
school, college, professional) have been utilized as well. However, each of these 
variables may actually have a slightly different influence on the development of long-
term impairments and underlying neuropathology, including CTE. Number of fights, for 
example, may act as a proxy for amount of training. Some have postulated that the effects 
of repeated blows to the head—even at a subconcussive level—that occur during sparring 
may play an important role in causing cumulative brain injury as the boxing match itself. 
Investigations using electroencephalography (EEG) and CT in professional boxers 
reported a stronger association between total number of years/bouts fought than to the 
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total number of knockouts (KOs), implicating cumulative subconcussive effects [19, 72]. 
Frequency of fighting may be a complementary variable that requires consideration; 
fighting more frequently may reduce the time the brain has to fully recover from prior 
trauma and be a risk factor that interacts with number of fights. On the other hand, when 
the period of unconsciousness exceeds 1 minute, KO may reflect the more severe end of 
the spectrum of MTBI. However, in the majority of cases where loss of consciousness 
(LOC) is only seconds, LOC is not correlated with a severe MTBI. While the number of 
KOs sustained in sanctioned professional fights  can be tracked from commonly available 
records, KOs that may have occurred at other times are harder to trace. 
Aside from the specific aspects of RTBI exposures (eg, severity, location and 
frequency), the timing of exposure in relation to brain maturation may also influence 
long-term outcomes.  Recently, Cantu and Hyman hypothesized that the age at which an 
individual is first exposed to RTBI could play a major role in the pathological cascade 
that leads to CTE [13]. In the book “Concussions and Our Kids [13],” the authors provide 
a theoretical groundwork for why certain developmental ages are particularly vulnerable 
to the effects of RTBI. Experimental evidence to support this hypothesis first appeared in 
a study of amateur boxers in 1971 [39]. In this study, Jedlinksi et al demonstrated a 
stronger correlation between neurological presentations and pathological EEG (r = 0.47), 
and psychiatric findings (r = 0.60) in boxers who began their fighting careers at age 15, 
16 or 17, showing a stepwise change in the association with each year [39]. Since this 
publication, there has been little additional research into the subject of “age at first 
contact sport exposure.” Having identified this gap [13], a new study lead by Julie Stamm 
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[83] demonstrated similar findings in American style football players. In this study, an 
association was made between participation in tackle football prior to age 12 and a 
greater cognitive impairment later in life; this  was determined based on objective 
neuropsychological tests in a sample of 41 former NFL players (ages 40–69). 
In a another recent study group of 730 National Collegiate Athletic Association 
Division I Football Championship Series athletes, it was demonstrated that while there 
were no significant differences between position groups in the number of diagnosed 
concussions, there were significant differences between position groups in the number of 
undiagnosed concussions (P = 0.008) and “dings” (P < 0.001), with offensive linemen 
reporting significantly greater numbers than any other positions [3]. It is therefore 
reasonable to suggest that positions with greater risk of concussion have a greater 
likelihood for cumulative and latent neurodegeneration. Indeed, Lehman et al attempted 
to subgroup NFL players into “speed” and a “non-speed” groups for analysis, but were 
limited by the available sample size [48]. To date, no method has been shown to reliably 
predict which athletes are likely to develop late-life impairments and CTE disease, other 
than to roughly classify risk as involvement in contact sports [47]. 
A contemporary study designed to better understand the effect of repetitive head 
trauma on clinical and subclinical outcomes is the Professional Fighters Brain Health 
Study (PFBHS). The PFBHS is a longitudinal study of active professional fighters 
(boxers and mixed martial arts), retired professional fighters and age-/education-matched 
controls [6]. The main objective of the PFBHS is to determine the relationships between 
measures of head trauma exposure, along with other potential modifiers and changes in 
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brain imaging and neurological/behavioral function over time. Initial results from the 
PFBHS indicate that increased exposure to head trauma, as measured either by number of 
professional fights or years of professional fighting, is associated with imaging and 
performance findings. Because of its ability to potentially reflect white matter integrity, 
MRI-based DTI has been studied in many different groups exposed to repetitive head 
trauma. In the PFBHS, a relationship was found between number of KOs and DTI 
measures in several white matter and subcortical grey matter regions [75]. Moreover, 
striking changes were seen in transcallosal motor pathways. These fibers transverse a 
long distance, and given the torsional movement of the brain that can occur with head 
trauma, may be particularly susceptible to injury. Specifically, in 17 active fighters—
scanned two times with approximately 1-year interval— transverse diffusivity (P = 
0.055) and FA (P = 0.018) in a motor pathway, defined by DTI tracking from  the left M1 
seed, were significantly related to number of professional fights over a period of a year 
(see Figure 2).  
While findings have been reported in a variety of sports and military settings, 
there is no uniform method for DTI analysis that can be applied at an individual level on 
differing MRI equipment. Measurement of MRI volumes may be a more practical tool, as 
methods for automated volumetrics are commercially available. Cross-sectional analysis 
of over 200 active fighters have shown significant correlations between higher number of 
fights or years of fighting and lower volumes of the thalamus and caudate (see Figure 3) 
[5]. 
Overall, these findings cannot be interpreted as being indicative of risk for any 
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specific long-term outcome (e.g., CTE). However, additional research examining the 
relationship between different potential RTBI exposure variables (e.g., age of first 
exposure, subconcussions, years of fighting) and neuropathologically confirmed CTE 
lesions is warranted. 
 
 
 
 
Figure 4.2. A representative diffusion tensor imaging tracking in a motor pathway. 
Tracking was conducted from the left M1 seed in 17 paired fighters. 
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Figure 4.3. Left thalamus volume and years of professional fighting in retired boxers. 
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Chronic Traumatic Encephalopathy 
Historical Context. As a result of its early discovery in boxers, CTE has been 
variously referred to as “cumulative encephalopathy of the boxer [20],” “chronic 
progressive traumatic encephalopathy [27]” and “chronic traumatic encephalopathy [26, 
62]” to reflect its trauma etiology and clinical presentation. In the earlier half of the 20th 
century, it was suggested that the punch-drunk condition was unique to the sport of 
boxing. The first neuropathologically characterized case of CTE was reported by 
Brandenberg and Hallervorden in 1954 [10]. As additional cases appeared [21, 33], an 
association formed between the blows endured from boxing and the subsequent 
development of neurofibrillary tangle predominant dementia. Augustus Thorndike MD, a 
Massachusetts General Hospital with the Harvard University Athletic Department (1952) 
declared in the New England Journal of Medicine: “The college health authorities are 
conscious of the pathology of the ‘punch-drunk’ boxer. Just how much one should permit 
recurrence of cerebral concussion in college athletes is a matter of opinion (p. 556) 
[88].” New research shows that CTE is more common in former contact sport athletes 
than previously realized. Interest in this condition has grown considerably since 2005, 
following the first post-mortem autopsy report characterizing the pathological hallmarks 
of CTE in a professional football player [64]. Additional neuropathological evidence of 
CTE has been reported in many sports other than professional boxing and football, 
including professional soccer, mixed martial arts, rugby, ice hockey, wrestling and 
baseball [52, 53, 84]. 
CTE with Motor Neuron Disease (MND). MND has been reported in a subset of 
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cases with CTE [54, 57]. It is not yet clear whether the pathology in these cases 
represents a variant of CTE or CTE with overlapping comorbid disease. Recent data 
suggest that professional American football players have more than four times the risk of 
dying from amyotrophic lateral sclerosis (ALS) MND than age- and gender-matched 
controls [47]. Our recent review of the world’s literature [61] uncovered the first case of  
CTE MND ever reported [57] with pathological evidence to support the link between 
sport-related RTBI and atypical ALS. Meyers et al reported clinical and 
neuropathological findings from a 41-year-old retired professional boxer who presented 
clinically with signs of progressive motor weakness [57]. The subject had a significant 
boxing history, with a career that began at age 14 and included only two known KOs, 
which were verified by the Pennsylvania Boxing Commission. This case is historically 
important because the findings reported by Meyers et al corroborate the findings reported 
in our more recent case series [52, 54]. In 2010, the members of the CTEC reported the 
first case series with neuropathologically confirmed CTE and ALS in two football players 
and one boxer (54). Among our recent series of 68 cases, approximately 11% 
demonstrated pathological evidence of MND [52]. The predominant presentation (63%) 
involved motor weakness, atrophy and fasciculations in addition to cognitive and 
behavioral symptoms.  
 
Preclinical CTE. Analogous to other neurodegenerative diseases, there were 
neuropathologically  confirmed CTE  cases in our sample that lacked overt clinical 
symptoms or impairment [52, 81]. As is the case in preclinical AD, developing methods 
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to identify persons at this early stage of CTE disease is crucial for investigating 
preventative methods and  treatments. Additionally, preclinical  cases could provide 
invaluable information about the etiology and development of  symptoms in  living  
individuals. Several studies in boxers and football players support the interpretation that 
asymptomatic head trauma can cause long-term brain damage that may only become 
apparent once the normal aging process has contributed to neuronal degeneration [89]. 
 
Clinical Symptoms of CTE. The symptoms associated with CTE pathology 
typically manifest in one of four clinical domains: (i) cognitive, (ii) behavior, (iii) mood 
and (iv) motor [61, 86]. Table 3 summarizes the clinical symptoms identified in our 
recent systematic review of 202 previously published cases of male athletes with histories 
of RTBI that met review criteria for possible, probable and neuropathologically 
confirmed CTE [61]. The sample included 141 boxers, 54 American football players, 5 
ice hockey players and  2  professional wrestlers,  making  this  the largest pooled case 
review of the clinical features in CTE to date. Progression was identified in 137 cases 
(68%), most often reported in cognitive symptoms, resulting in dementia. The cases 
described as “stable” were notably younger in age. Symptoms typically manifest 8–10 
years after initial RTBI. The clinical course of CTE is slow, much slower then AD or 
Frontotemporal dementia, with a progression rate estimated at 11–14 years between 
pathological stages [52]. 
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Table 4.3. Symptoms of chronic traumatic encephalopathy  
Cognitive Features Behavioral Features Mood Features Motor Features 
aMemory impairment 
aExecutive dysfunction 
aImpaired attention 
bDysgraphia 
Lack of insight 
Perseveration 
Language difficulties 
Dementia 
Alogia 
Visuospatial difficulties 
Cognitive impairment 
Reduced intelligence 
aPhysical violence 
aVerbal violence 
aExplosivity 
aLoss of control 
aShort fuse 
bImpulsivity 
bParanoid delusions 
Aggression 
Rage 
Inappropriate speech 
Boastfulness 
Childish behavior 
Socially inappropriate 
Disinhibited behavior 
Personality changes 
Psychosis 
Social isolation 
aDepression 
aHopelessness 
bSuicidality 
bAnxiety 
bFearfulness 
bIrritability 
bApathy 
bLoss of interest 
Labile emotions 
Fatigue 
Flat affect 
Insomnia 
Mania 
Euphoria 
Mood swings 
Prolix 
 
bAtaxia 
bDysarthria 
bParkinsonism 
bGait 
bTremor 
bMasked facies 
bRigidity 
Weakness 
Spasticity 
Clonus 
 
aCore diagnostic clinical feature, defined as any feature that appeared in 70% or more of the 
neuropathologically confirmed CTE cases without comorbid disease. 
bSupportive diagnostic feature, defined as any feature that appeared in neuropathologically 
confirmed CTE cases without comorbid disease.  
Table adapted from Montenigro et al [61] with permission. 
  
 133 
 
Clinical Subtypes of CTE. Similar to other neurodegenerative conditions, the 
clinical features in CTE are heterogeneous. Stern et al, identified two relatively distinct 
clinical presentations: one consisting of behavioral and mood symptoms with an earlier 
age at onset [mean age at onset 34.5 standard deviation (SD) = 11.6] and another 
consisting of cognitive impairment with a later age at onset (mean age at onset 58.5, SD = 
17.7) [86]. Among cases with initial behavioral and mood symptoms, 86% progressed to 
include cognitive symptoms whereas only 46% of cognitive cases developed behavior 
and mood symptoms. In addition to the two subtypes described in Stern et al, Montenigro 
et al identified an additional “mixed subtype”  (mean  age  at  onset  43.0,  SD = 14.0) in 
neuropathologically confirmed cases where the predominant presentation was neither 
behavioral-mood or cognitive, but rather a combination of the two [61]. Consistent with 
recent subtype descriptions [61, 86], earlier studies in boxers also reported having 
identified recurring subtypes in the presentation of CTE. Classifications identified in the 
earlier literature [61] were based on various clinical features, including initial  
presentation, progression, age at onset  and  occurrence of dementia. For example, Ernst 
Jokl (founder of the American College of Sports Medicine) distinguished between the 
two types of chronic impairment in punch- drunk boxers, namely a “behavioral-
psychopathic” type and a “neurological-psychiatric” one [60]. The former involved cases 
with presentations involving “viciousness,” “murder committed from jealousy” and 
“delinquency.” Research involving these subtypes represents an opportunity to refine 
risk-factor definitions, develop targeted prevention strategies and someday assess 
treatment responsiveness. 
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Clinical Diagnostic Criteria. To date, the only definitive means of diagnosing 
CTE is through post-mortem autopsy. However, the ability to diagnose CTE during life is 
critical to conduct epidemiologic studies on CTE and to eventually plan treatment trials. 
To address this gap, Montenigro et al proposed new clinical research diagnostic criteria 
for CTE [61] that overcome the limitations identified [49, 58] in the previous criteria [40, 
43, 44, 92]. The new criteria are based on a systematic review of the previous literature, 
as well as on the clinical features reported in neuropathologically confirmed cases of  
CTE without comorbid disease [52, 53, 86]. The proposed diagnostic criteria include five 
general criteria, three core clinical features and nine supportive features to identify the 
“traumatic encephalopathy syndrome” (TES). The term TES is used to describe the 
“syndrome” of clinical features that comprise this condition when the underlying 
pathology is speculative (Table 4). Criteria for the behavioral/mood variant, cognitive 
variant, mixed variant and TES dementia phenotypes are also provided (Table 5). 
Additional biomarker evidence is required to indicate the likelihood that the etiology 
underlying TES is caused by the CTE pathology. Several potential biomarkers for 
“probable CTE,” “possible CTE” and “unlikely CTE” are proposed based on recent and 
ongoing biomarker research (Table 6) [4, 59, 80]. Additional research is needed to 
validate the usefulness of the proposed biomarkers for CTE. Efforts to validate the utility 
of the proposed clinical criteria [61] are currently underway (Table 4–6). 
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Table 4.4. General diagnostic criteria for traumatic encephalopathy [61] 
All five criterion (1-5) must be met for diagnosis 
1. History of multiple impacts  
Types of 
injuries 
Concussion or mTBI. If no other RTBI then minimum of 4. 
Moderate/severe TBI. If no other RTBI then minimum of 2. 
Sub-concussive trauma.  
Source of 
exposures 
Contact sports. Minimum of 6 years. 
Military service. 
Other RTBI exposures. E.g. domestic abuse. 
2. Other neurological disorder that likely accounts for all clinical features 
Exclude if 
A single TBI. 
Or persistent PCS. 
Can be present 
Substance abuse. 
Post-traumatic stress disorder (PTSD). 
Mood/anxiety disorders. 
Other neurodegenerative diseases. 
3. Clinical features must be present for a minimum of 12 months 
4. “Core clinical features” of traumatic encephalopathy syndrome 
At least 
one must 
be 
present 
Cognitive. Difficulties identified by standardized mental status or 
cognitive neuropsychological test at least 1.5. STD below normal 
Behavioral. Described as explosive, short fuse, out of control, physically 
and/or verbally violent. Or intermittent explosive disorder. 
Mood. Feeling overly sad, depressed, or hopeless. Or diagnosis of major 
depressive disorder or persistent depressive disorder. 
5. “Supportive features” of traumatic encephalopathy syndrome 
At least two 
must be present 
Documented decline (1 year), Delayed onset, Impulsivity, Anxiety, 
Apathy, Paranoia, Suicidality, Headache, Motor features. 
 
  
 136 
 
Table 4.5. Criteria for diagnostic subtypes with modifiers [61] 
A. TES diagnostic variants 
Select 
one 
‘Cognitive’ Cognitive core features without behavioral/mood. 
‘Behavioral/mood’ Behavioral/mood core features without cognitive. 
‘Mixed’ Both cognitive and behavioral/mood core features.  
‘Dementia’ Progressive cognitive core & functional impairment. 
B. “With motor features” modifier 
‘With motor features’ Dysarthria, dysgraphia, bradykinesia, tremor, rigidity, gait change, falls, and/or other features of parkinsonism.  
C. Clinical course modifier   
Select 
one 
‘Stable’ History or tests indicate little if any change. 
‘Progressive’ Clear indication of progression over 2 years. 
‘Unknown/inconsistent’ Unknown or inconsistent information  
 
 
Table 4.6. Chronic Traumatic Encephalopathy (CTE) likelihood criteria [61] 
‘Probable CTE’ 
Does not satisfy criteria for another disorder more consistently  
Meets classification for any TES variant. 
Progressive course. 
At least one positive 
‘potential biomarker’ 
Positive PET tau imaging. 
Negative PET amyloid imaging. 
Normal beta amyloid CSF levels. 
Elevated CSF p-tau/tau ratio. 
Cavum septum pellucidum. 
Cortical thinning or atrophy. 
‘Possible CTE’ 
May satisfy diagnostic criteria another disorder. 
Meets classification for any TES variant. 
Progressive course. 
No testing or one negative biomarker except for PET tau. 
‘Unlikely CTE’ Does not meet General criteria (1-5) for TES. Or has had negative PET tau imaging. 
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Treatment and Disease Management. The treatment of CTE is currently 
theoretical and remains to be validated with prospective treatment trials. Treatment and 
management are likely to vary from case to case. Once deficits related to CTE appear, 
rehabilitation and medications to treat specific symptoms may still be useful [49]. For 
behavioral and/or mood issues (e.g., aggression, violence) potentially useful treatments 
may include antipsychotics, lithium, antidepressants, sedatives, anxiolytics, 
anticonvulsants, opiate antagonists and beta blockers [22, 56]. To reduce drug-induced 
extrapyramidal symptoms, risperidone and other neuroleptics drugs can be useful to treat 
behavioral issues (i.e., psychotic behavior) [56]. In a limited number of cases treated for 
psychotic symptoms, medications such as trifluoperazine were effective [22, 36]. 
Methylphenidate may be used to treat apathy, as well as cognitive symptoms [35, 49]. 
Anti-parkinsonian medications have had mixed results in case reports [41, 56]. One case 
report documented successful stereotactic surgical treatment of parkinsonian features [7]. 
Cholinergic dysfunction is thought to underlie cognitive impairments in CTE [90], 
however, the use of anti-cholinergic treatments (e.g., tacrine, donepezil) for CTE remains 
speculative and further investigation is required [42, 66]. In another case report, verbal 
memory, but not visual memory, improved following treatment with physostigmine and 
lecithin [42]. Additionally, there are no known preventative interventions for CTE, 
although it has been suggested that treatments demonstrating effectiveness for AD and 
TBI might also show promise for CTE [49]. For example, one candidate is amantadine, 
which is considered to be a safe and effective treatment for severe TBI [68]. Recent 
preliminary investigations have suggested that nonpharmacological interventions may 
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benefit contact sport athletes. Studies of professional football players report statistically 
significant improvements in neurocognitive function for up to 6 months with dietary 
supplementation (eg, omega-3 fatty acids) [1, 78]. Additional research is needed to 
determine whether or not reported improvements were maintained in the long term [49]. 
Because of the severe behavioral mood manifestations of this disease, counseling and 
cognitive behavioral therapy may also help to mitigate the aberrant behavioral and mood 
manifestations of this disease [49]. 
 
CTE then and Now. Recently, certain authors have made  a  distinction  between 
“classic” and “modern”  descriptions  of CTE [30,  51]. The “classic” entity, proposed by 
McCrory et al, is defined by the cases reported by Roberts and Corsellis et al in their 
boxing subjects [25, 71]. This particular description highlighted early cases that had 
prominent motor features, including dysarthria, difficulties with gait and pyramidal 
problems. It was noted that early reports in boxers identified progression in “the physical 
signs and problems, but not the cognitive deficits” (p. 2) [30], which is the distinguishing 
factor from what are considered to be “modern” CTE cases. Alternatively, “modern” 
cases (i.e., cases published after 2004) are characterized by prominent mood, behavior 
and progressive cognitive features, but with a reduced frequency of motor symptoms. Our 
assessment of  the  evidence  suggests that  this  distinction between “classic” and 
“modern” CTE presentations is largely an artifact of review bias. The first source of this 
bias involves the “classic CTE” article by Roberts, who writes: “more attention has been 
paid, intentionally, to the clinical signs which indicate lesions of cerebellar, pyramidal 
 139 
 
and extra-pyramidal systems, than to the evidence of dementia or personality change (for) 
lesions in these systems are readily comparable.  Leaving aside for later consideration the 
question of dementia and psychiatric disturbance, which undoubtedly occurs” (p. 47) 
[71]. This methodological  limitation  prevents  any  reasonable inferences about the 
frequency of behavior, mood and cognitive  symptoms in classic cases. Although, “in the 
first case described,” Roberts emphasized that in addition to motor features “dementia 
had clearly progressed over the years” with “development of a paranoid illness” (p. 44) 
[71]. This evidence does  not  support the definition of “classic” CTE, rather it suggests 
that some of the perceived differences in symptoms reported in earlier cases were caused 
by the methodological limitations and biased review. For instance, the distinction 
between “classic” and “modern” presentations  also  does  not account for possible group 
effects related to different sport exposures, that is,  the “classic” presentation is derived 
from boxers while the “modern” presentation is predominantly derived from American  
football players [61]. It is our hypothesis that sport- specific differences in exposure alter 
the course and severity of certain   clinical manifestations in CTE.  In the sections that 
follow, we explore our hypothesis by re-examining the CTE case evidence in boxers and 
football players previously reported by McKee et al [52, 53] and provide two detailed 
clinical and pathological case reports from two professional level athletes, a former US 
professional lightweight boxing champion and an American NFL player. 
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Boxing and American Football 
Trauma Risk Factors for CTE. All reported neuropathologically confirmed CTE 
cases have a significant history of brain trauma, usually repetitive, which suggests that 
RTBI is a necessary factor in acquirement of CTE degenerative pathology. Not every 
case of CTE has a history of concussions, leading to the belief that subconcussive 
impacts may be sufficient to induce  neuronal degeneration  and  subsequent 
neurodegeneration. Alternately, not every individual that is exposed to RTBI, either 
concussive or subconcussive, necessarily develops CTE [37]. It is not known what 
specific aspect of exposure (sport, age, level, position, severity, frequency and 
mechanics) influences the risk of acquiring CTE. The threshold of damage required for 
induction and progression of tau pathology is likely multifactorial and may incorporate 
genetic, environmental and/or nutritional factors [85]. Most of what we know about CTE 
comes from limited information provided in post-mortem case series. Investigations with 
confirmed cases have identified factors that influence the severity [52] and phenotype 
[86] of CTE pathology. In American football players with neuropathologically confirmed 
CTE, there is a positive correlation with the severity of pathology and the total number of 
years played (Spearman’s test, r = 0.805, P < 0.0001), as well as years since retirement 
(Spearman’s test, r = 0.753, P < 0.0001) and age at death (Spearman’s  test, r = 0.806, P < 
0.0001) [52]. Conversely, informant-reported number of concussions (Spearman’s test, r 
= 0.259, P = 0.184), years of education (Spearman’s test, r = 0.258, P = 0.134) and 
lifetime steroid use (Wilcoxon–Mann–Whitney test, P = 0.731) were not significantly 
correlated. In boxers with neuropathologically confirmed CTE, the severity of the tau 
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pathology appears to correlate with the total number of years exposed [53]. 
 
Impact Type and Biomechanics. The types of impacts athletes endure differ by 
sport. However, each impact is composed of both linear and rotational forces [13, 14]. 
Rotational acceleration (Figure 4A,B) occurs when a force is eccentric or tangential to the 
center of gravity of the head. In boxing, when a punch is directed toward the lateral side 
of an opponent’s face (i.e., “hook punch”) or chin (i.e., “upper cut”), the force of the 
impact will cause the head to twist and rotate outward along  the  fixed spinal  axis  
(Figure 4A) [13, 38]. The sudden rotational acceleration of the skull and hyperextension 
of the neck causes brain deformation at mechanically rigid inflection points, such as the 
cerebellopontine angle (Figure 4B). Regions of the brain that are  composed of multiple 
tissue types with different tensile strengths near rigid boney structures, such as the 
midbrain, are  particularly  vulnerable to  shearing forces that  stretch and injure vessels, 
axons and glia. The greatest risk a boxer faces for concussion is the result of impacts that 
generate  rotational accelerations, such as the hook punch [8]. Linear acceleration (Figure 
4C,D) occurs when a force is applied directly through the center of gravity of the head, 
such as in the anterior to posterior direction [14, 67]. Investigations with accelerometers 
placed in helmets have shown that the majority of impacts in American-style football 
occur from helmet-to-helmet impacts at the top-front of the helmet (Figure 4C). This is 
true of all levels (e.g., youth, high school, college, professional) and positions, with the 
exception being the quarterback position. The forces generated in this type of impact are 
absorbed at the point of origin, which is nearest the frontal lobes (anterior), and 
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transmitted through the brain,  down to the brainstem and cerebellum (posterior) (Figure 
4D). The helmet-to-helmet impacts in American football generate a larger net linear 
acceleration experienced by the frontal lobes, when compared with the net rotational 
acceleration generated by the hook punch in boxing [91]. The significance of impact 
differences between sports on long-term consequences and neurodegeneration is not yet 
known. Cumulative exposure to different impact types has the potential to influence the 
onset, type, location, severity and progression of underlying neuropathology. 
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Figure 4.4. Impact mechanics in boxing and football. Hook punch (A). Primarily 
rotational acceleration (B). Helmet-to-helmet impact (C). Primarily linear acceleration 
(D). Figures A and C each depict the impact type that typically leads to injury, including 
concussions, for each sport, respectively. Figures B and D depict the biomechanics of 
each impact, including the predominant acceleration involved and its transmission into 
brain. 
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CTE in Boxers and American Football Players. As the types of impact and 
predominant forces differ between sports (Figure 4), it was hypothesized [61] that the 
phenotype of CTE would also differ with the type of sport exposure. Some authors 
question whether the underlying pathology between CTE in American football players 
and boxers is really the same [8, 30, 51, 63]. To explore this issue and to test our 
hypothesis, we compared the frequency and severity of motor symptoms in addition to 
cerebellar pathology in professional boxers  and  professional American football players 
with neuropathologically confirmed CTE previously described by McKee et al [52]. 
Because of the spectrum of pathology in CTE stages I through IV, cases were grouped 
into early CTE (stages I and II) and late CTE (stages III and IV). In CTE, neurofibrillary 
tangle (NFT) lesions progress from a multifocal state (stage II) to a widespread state 
(stage III) [55]. This grouping allowed us to be reasonably confident that any significant 
difference between groups was caused by the differences in sport exposure and not the 
natural progression of CTE disease (Table 7).  
Our analysis found that the proportion of boxers with motor symptoms 
(parkinsonism, gait changes and dysarthria) was significantly greater (Table 7 , P < 0.05, 
Fisher’s exact test) than the proportion in American football players. The proportion of 
boxers identified with NFT pathology in their cerebellum dentate (71%) was also greater 
than American football players (57%), although this trend did not quite reach 
significance. However, we also compared the proportion of  cases  that  had  severe  
(++/+++) NFT pathology in the cerebellum dentate and found that boxers had 
significantly more  severe  NFT  deposition  (Table 7,  P < 0.05, Fisher’s exact test) than 
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American football players. The lack of significance in frequency of cerebellar 
involvement between the two sports suggests either one of two possibilities: (i) our 
sample size was too small to detect the difference or (ii) the severe NFT deposition in the 
cerebellum dentate of boxers reached clinical thresholds for motor symptoms, whereas in 
football players it did not. In summary, the results of our secondary analysis (Table 7) of 
previously reported CTE cases [52] supports the hypothesis that impacts in boxing cause 
greater strain to the midbrain and cerebellum (Figure 4B) than and therefore having a 
greater frequency of motor symptoms in boxers with confirmed CTE than football 
players. This was also evidenced by the severity of CTE NFT pathology in the 
cerebellum dentate. Although preliminary, these results suggest that different 
biomechanic exposure profiles influence the risk for specific CTE phenotypes and alter 
the underlying pathological severity. 
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Table 4.7. Comparison CTE clinicopathological features in boxers versus football players. 
Novel (secondary) analysis of previously reported cases  
in McKee et al [52] Pro Football Pro Boxing 
Late stage CTE (III-IV) 25 7 
Mean decade age at symptom onset  50-60 50-60 
Mean decade age at time of death 70-80 80-90 
Late stage CTE “with motora features”   18.8% (3/16)b 83% (5/6)b 
Late stage CTE with cerebellar dentate NFTs  57% (12/21) 71% (5/7) 
Late stage CTE with severe (++/+++) dentate NFTs 17% (2/12)b 80% (4/5)b 
aMotor symptoms include parkinsonism, gait changes, and dysarthria, unrelated to MND.  
bStatistically significant difference in the proportions between-groups (Fisher’s Exact Test). 
NFT = neurofibrillary tangles 
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Case Studies 
The history and clinical presentation of the following cases were obtained through 
post-mortem telephone interviews with family members while  the  interviewer  remained  
blind to neuropathological diagnosis and apolipoprotein E status. Semi-structured 
interviews and well-characterized informant questionnaires were utilized in combination 
with  medical  records.  For  a  detailed description of the methods used, see Stern et al 
[86]. Post-mortem pathological analysis and diagnosis methods are described in McKee 
et al [52]. 
 
NFL Player, Case 1. Clinical history: 56-year-old Caucasian male with a history 
of high blood pressure and a basal ganglia cerebral vascular accident at 54 and death 
from a myocardial infarction at age 56. He participated in American football for a total of 
17  years, beginning at age 12, and played for 7 years in the NFL at the running back and 
full back positions. He endured approximately 20 concussions, 10 in the NFL level and 
five in college. Two concussions resulted in loss of consciousness. At 54, he awoke with 
symptoms of leg weakness and an MRI demonstrated “a small lacunar infarct to the  
basal ganglia.” Post-stroke changes were mild and stable, with slowness in movement 
and complaints of fatigue. After 3 months of rest, he returned to his work as a bank vice 
president and did well. Around the time that he retired from the NFL, he  began to 
experience recurring posterior headaches, with onset at age 32. Family informants 
reported that his mood changed in his mid-30s and indicated that he struggled with 
feelings of sadness and depression. His depression was further sup- ported   with the 
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informant  short version of the geriatric depression scale (GDS) [11] (total GDS = 6), as 
well as having been prescribed with Wellbutrin. In the year prior to death, he developed a 
sense of worthlessness and hopelessness.  His behavior was characterized as emotionally 
explosive and easily frustrated.  He  would  often  have  sudden  angry  reactions  and 
“little things would set him off.” Overall, he had a “short fuse” and was easily frustrated. 
Difficulties with rage did not worsen; however, in the year prior to his death, he began 
acting out of character, becoming somewhat  detached and started listening to old  music. 
Post-stroke neurology follow-up visits indicated improvement in motor symptoms and 
family informants reported no new symptoms in the time leading up to his death. A 
change in  his  cognitive  function  was  observed by family  informants during the 5 
years leading up to his death. The family version of the cognitive difficulties scale 
identified mild to moderate cognitive difficulties in short-term memory, attention and 
concentration and language [28, 82].  Several  of  these  changes  were reported to have 
occurred prior to his stroke and with progression. In contrast, results on the functional 
activities questionnaire (total score = 0) and the modified AD8 informant interview for 
dementia (total score = 1) did not indicate significant functional impairment or dementia 
[29, 69]. He did not serve in the military nor did he receive a diagnosis related to 
dementia, parkinsonism or AD. 
Clinical diagnosis [61]: TES mixed variant; progressive course; possible CTE. 
Pathological findings: brain weight was 1550 g. Gross findings include a corpus callosum 
that is thinned throughout its extent, ventricular enlargement, pallor of the substantia 
nigra and pallor of the locus coeruleus. Microscopic (Figure 5A–D) findings were 
 149 
 
diagnostic of CTE [52] and included numerous tau-immunoreactive NFTs, neurites and 
astrocytic tangles in the perivascular, sulcal depth, superficial cortical, subpial and glial 
distribution. No beta- amyloid protein was found. Pathology diagnoses [52]: CTE stage 
III/IV; vascular disease. 
 
Boxer, Case 2. Clinical  history: 61-year-old Caucasian male with a history of 
hepatitis C virus and significant liver cirrhosis that led to a transplant at age 58. The 
subject died from liver failure and complications of pneumonia. He was a former 
professional boxer and a US lightweight boxing champion. His boxing career began 
when he was 8, lasting a total of 26 years. He went on to win the Golden Gloves 
championship and was ranked the top US lightweight boxing champion for several years, 
with a total of 36 professional bouts in his 12 years at the professional level. He retired at 
age 34. Over the  course  of his career, he reported that he had suffered multiple 
concussions with only one with loss of consciousness, although the specific number of 
concussions he experienced is not known. He was also involved in one motor vehicle 
accident at the age of 56, at which time he experienced headaches, backache and signs of 
a concussion. A noncontrast brain CT scan found no acute intracranial process and  
therefore he “did not require medical care.” His brain CT did, however, discover that his 
ventricles and sulcal  spaces showed  prominent “cerebral atrophy,” including decreased 
attenuation within the periventricular white matter suggestive of small vessel disease, 
both of “uncertain significance.” There was also evidence of chronic fractures in the nasal 
and orbital bones. He did not serve in the military nor did he receive a diagnosis related 
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to dementia, parkinsonism or AD. Family informants described him as being violent and 
hot-headed since childhood, but noted that his behavior deteriorated significantly starting 
at age 30, with onset of impulsivity, spousal abuse, intermittent explosivity and generally 
being out of control. In his early 50s, his mood was depressed and he developed feelings 
of hopelessness and worthlessness. At age 55, cognitive symptoms related to executive 
dysfunction became apparent to the family. At age 56, an altercation with his daughter 
lead to a formal psychiatric consultation, which noted he had “increased memory 
problems (frequently forgets placement of personal items and previous conversations),” 
as well as worsening dysphoria, irritability and paranoid delusions that his girlfriend was 
attempting to kill him. He also suggested that the boxing association had officially 
diagnosed him with “pugilistic dementia.” In his late 50s he reported falling at home 
from “feeling unsteady and weak.” Motor impairments were obvious in the year prior to 
his death; he was never diagnosed with parkinsonism or ALS, however, he lost ability to 
speak, developed dysphagia for food and liquids and his handwriting deteriorated. 
Clinical diagnosis [61]: TES mixed variant; with motor features; progressive 
course; probable CTE. Pathological findings: brain weight was 1230 g. Gross findings 
include  generalized  atrophy  of  the  cerebral  cortex,  atrophy, atrophy of the fornix, 
cavum septum (1.0 cm), multiple septal fenestrations  posteriorly  and   atrophy  of   the   
thalamus  and mammillary bodies. There was pallor in the substantia nigra and locus 
coeruleus. Microscopic (Figure 5E–H) findings were diagnostic of CTE [52] and 
included numerous tau-immunoreactive NFTs, neurites and astrocytic tangles in the 
perivascular, sulcal depth, superficial cortical, subpial and glial distribution. No beta- 
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amyloid protein was found. The tau pathology in the substantia nigra, basis pontis and 
cerebellum was particularly severe. There was mild proliferation of protoplasmic 
astrocytes consistent with hepatic disease. Pathological diagnosis [52]: CTE with classic 
microscopic of stage III/IV with mild transactive response DNA binding protein (TDP-
43) proteinopathy. 
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Figure 4.5. Neuropathology and cerebellar degeneration in a former professional boxer 
and football player. Case 1 (A–D): A 56-year-old former National Football League 
(NFL) player had chronic traumatic encephalopathy (CTE) characterized  by 
phosphorylated tau-positive neurofibrillary tangles present at the sulcal depths (A,  AT8 
immunostain). His cerebellum appeared intact with a well-populated Purkinje cell layer 
(B, Bielschowsky silver stain) and dentate nucleus (C, Luxol hematoxylin and eosin). 
There was no phosphorylated tau accumulation present within the  dentate nucleus (D). 
Case 2 (E–H):  A 61-year-old former professional boxer had a similar degree of CTE-
related tauopathy (E, AT8 immunostain). In  fact, both the NFL player and the  boxer met 
neuropathological criteria [49] for CTE stage III tauopathy. However, in contrast to the 
NFL player, there is marked degeneration within the cerebellum with marked Purkinje 
cell loss (F, Bielschowsky silver stain; arrowhead, Basket cell processes without Purkinje 
cells “empty Baskets”). There is also loss of neurons within the dentate nucleus (G), 
which contains scattered phosphorylated tau-positive neurons (H, arrow) and processes 
(H, arrowhead). These two cases illustrate the need for  careful clinical phenotyping and 
demonstrate the utility of recently published criteria [61]. Scale bars, A, C, E and G, 100 
μm; B and F, 100 μm; D and H, 50 μm.  
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Conclusions and Future Directions 
Participating in a contact sport is now thought to increase an individual’s risk for 
later-life impairment and possibly developing CTE. CTE has been diagnosed in a wide 
range of individuals with a  history of head trauma, including American football players, 
soccer and hockey players, boxers, wrestlers and soldiers who have received battlefield 
injuries. It has even been reported in athletes as young as 17, who only played sports in 
high school or college. Given the wide range of people that are diagnosed and the recent 
increase in reported cases, CTE is likely more prevalent than previously thought. To date, 
the only definitive means to diagnose CTE is through post-mortem autopsy. The 
neuropathological features of CTE are increasingly well-characterized, yet the clinical 
aspects of CTE require further elucidation. There is an urgent need for methods that can 
reliably diagnose CTE during life. To address this gap, new clinical research diagnostic 
criteria for CTE were proposed and studies to validate its utility are ongoing. 
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Chapter 5 
Cumulative Head Impact Exposure Predicts Later-Life Depression, Apathy, 
Executive Dysfunction, and Cognitive Impairment in Former High School And 
College Football Players 
 
Copyright © 2016, Mary Ann Liebert, Inc 
 
Introduction 
Repetitive head impacts (RHI) refer to the cumulative exposure to recurrent 
concussive and subconcussive events [1-6]. A concussive event is a direct or indirect 
impact to the head of sufficient intensity to produce overt clinical symptoms that 
typically resolve within days or weeks [5],  but can persist for months [7] or more than 
one year [8]. The mechanisms of concussion are believed to involve shearing and tensile 
forces to axons that occur during the impact induced acceleration, deceleration, and 
rotational forces of the brain [9]. A subconcussive event is similar in that it also involves 
a transfer of mechanical energy to the brain at enough force to injure axonal integrity, but 
does not result in clinical symptoms [1-4, 10, 11]. However, the intensity of impact 
necessary to trigger this potential neuronal damage is not known and whether there are 
levels of impact that are benign to neuronal functioning has also not been determined. 
The investigation of RHI has most commonly been in the setting of contact sports, 
such as American football. Over 4.5 million amateur athletes participate in tackle football 
each year [12, 13], and this sport has one of the highest rates of concussion [14, 15] 
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Surveys of high school and college athletes show that around 50% of football players 
suffer a concussion each year, and more than 30% sustain multiple concussions [14, 16, 
17]. Subconcussive events are likely even more frequent, as helmet-based accelerometer 
studies estimate that amateur football players average 600 subconcussive impacts per 
season in high school and over 1000 at the collegiate level [3]. The high prevalence of 
concussive and subconcussive events in amateur football players is concerning given 
their reported association with acute [18-20] and chronic [21-25] neurological 
consequences. Repetitive subconcussive blows (measured by helmet accelerometer 
sensors recording events that exceed 14.4g [10]) are associated with pre- to post-season 
cognitive decline [10, 26], functional brain alterations (e.g., reduced neurophysiological 
health) [10, 26, 27], and microstructural white matter brain changes [28] in high school 
football players.  
Although research on this topic still is limited, cumulative concussive as well as 
subconcussive impacts may be a key contributor to later-life neurological consequences, 
including the neurodegenerative disease, chronic traumatic encephalopathy (CTE) [29]. 
Importantly, 16% of pathologically confirmed cases of CTE have no reported history of 
concussion [30], highlighting the potential long-term risks of subconcussive injury. In 
addition, although CTE has been described predominantly in former professional contact 
sport athletes, a recent study of deceased amateur athletes and controls found that a 
history of contact sport involvement was the greatest risk factor for CTE neuropathology 
[31]. Various exposure metrics (e.g., age of first exposure to football [32-34], duration of 
football play [11, 35-37], concussion history [21-25]) have been linked to later-life 
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cognitive and neurobehavioral disturbances in former football players and other contact 
sport athletes. These different metrics may reflect different aspects of RHI exposure, each 
with slightly different effects on the brain [11, 35]. 
A direct relationship between RHI and long-term clinical outcomes has been 
difficult to formally test due to the lack of validated tools to quantify cumulative RHI 
exposure [38]. Quantifying RHI exposure is methodologically challenging given that it 
involves a self-reported assessment of multiple events that occur throughout one’s 
athletic career. Thus far, research on RHI and long-term outcomes has relied on single, 
indirect metrics based on a subject’s history of traumatic brain injury (TBI) that involves 
retrospective self-reports or proxy reports using a structured interview containing 
validated scales [39-41]. These scales include those recommended by the National 
Institute of Neurological Disorders and Stroke (NINDS) common data elements and the 
Center for Disease Control (CDC) [42]. Despite known limitations, numerous studies 
have demonstrated the usefulness of retrospective report in predicting long-term 
consequences following multiple concussions [21, 22, 43]. While short-term head impact 
exposure could be quantified prospectively with the placement of accelerometers in the 
helmets of athletes, this approach does not estimate cumulative exposure over one’s 
athletic career, which is speculated to be of primary importance for predicting later-life 
impairments and CTE [44, 45]. In response to this need,  Kerr et al. recently proposed the 
Head Impact Exposure Estimate (HIEE) [46], which estimates a football player’s total 
hours of contact exposure, excluding exposure prior to high school, using self-report 
interview. However, the HIEE has not been validated in a model with clinical outcomes.  
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In our study, we developed and validated a metric to estimate an athlete’s total 
cumulative exposure to RHI from football, referred to as the cumulative head impacts 
index (CHII). To derive the CHII we combined two sources of information: a) individual 
self-report measures of athletic exposure; and b) extrapolated objective measures based 
on position(s) played, obtained from published helmet-accelerometer studies. Our metric 
includes estimates for youth, high school and collegiate level exposure, and incorporates 
percentages for all positions played (i.e. primary, secondary, tertiary, etc.). The purpose 
of this study was to evaluate the relationship between the CHII and later-life cognitive, 
behavioral, and mood impairment. Additionally, we compared the predictive validity of 
the CHII against three other individual exposure metrics, namely total season/years 
played, age at first exposure, and overall concussion history [21-23, 25, 32, 33, 43, 47].  
We hypothesized that cumulative head impact exposure would have a measurable 
threshold, above which the risk of developing later life clinically-meaningful cognitive, 
mood, and behavioral impairment increases significantly. 
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Materials and Methods 
Study Design. This present sample was part of a larger ongoing study, the 
Longitudinal Examination to Gather Evidence of Neurodegenerative Disease (LEGEND) 
study, at the Boston University Alzheimer’s Disease and CTE Center. LEGEND is a 
longitudinal study to assess potential risk factors for short- and long-term consequences 
of RHI. Participation involves annual telephone-based cognitive assessments, web-based 
measures of mood, behavior, and cognition, and saliva sampling for APOE genotyping. 
The LEGEND research protocol was approved by the Institutional Review Board of 
Boston University Medical Campus and written consent was obtained from all LEGEND 
participants. Study participation was open to adults, age 18 or older, who were either 
active or former athletes, across all sports and levels of play. There is no active 
recruitment program for LEGEND. Rather, this is a convenience sample in which 
potential subjects learn of the study through descriptions on the investigators’ websites 
and through word-of-mouth. Therefore, the LEGEND sample should not be viewed as 
being representative of all athletes. Detailed descriptions of the LEGEND protocol have 
been previously published [25, 47, 48]. 
 
Participants. Of the 800 participants in the LEGEND dataset at the time of 
analysis, 93 former amateur football players met the following inclusion and exclusion 
criteria: 1) highest level of football played was at high school or college; 2) no 
concussion sustained in the year prior to their initial evaluation (to diminish potential 
effect of acute brain injuries on clinical outcome measures); and 3) no participation in 
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another contact sport (i.e., amateur wrestling, boxing, bull riding, diving, horse jumping, 
ice hockey, karate, lacrosse, martial arts, mixed martial arts, entertainment wrestling, 
rugby, and soccer). The final sample included 17 former high school football players and 
76 former collegiate football players. Demographic characteristics of the sample are in 
Table 1. 
 
Table 5.1. Demographics  
 
Total 
Sample 
N=93 
High 
School 
N=17 
College 
N=76  
 Mean (SD) Mean (SD) Mean (SD) *p-value 
Age (years) 47.3 (13.9) 43.6 (11.6) 47.7 (14.2) 0.2760 
Formal education (years) 16.9 (2.1) 15.3 (2.1) 17.2 (2.0) 0.0005 
Education (terminal degree N%)     
High School / GED 11(11.8) 6 (35.3) 5 (6.6) 0.0018 
Bachelor’s / Associates / 
etc 
50 (53.8) 7 (42.2) 43 (56.6) 
Master’s or Doctorate 32 (34.4) 4 (23.5) 28 (36.8) 
Working Full or Part Time 
N(%) 
63 (67.7)  10 (58.8) 53 (69.8) 0.673 
Marital Status Married N(%) 39 (41.9) 5 (62.5) 34 (63.0) 0.658 
Body Mass Index 31.5 (5.6) 31.5 (6.7) 31.5 (5.3) 0.994 
Handedness-Right N(%) 74  (79.6) 13 (76.5) 61 (80.3) 0.484 
Military history N(%) 14 (15.1)  5 (29.4) 9 (11.8) 0.0671 
*Wilcoxon two sample test. Numbers in parentheses are standard deviations except 
when otherwise indicated. 
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Health & Athletic History. Participants were administered a structured 
questionnaire that has been used previously [25, 32, 47], and was designed to collect 
retrospective information about the participant’s lifetime athletic experience, past medical 
history, and concussion history. Questions about athletic experience captured variables 
regarded by the literature as being potential predictors of brain trauma, such as: 1) sports 
played [11, 49], 2) age at first exposure to tackle football [32-34], 3) levels of play [50-
53] (youth, high school, college, professional), 4) number of seasons played at each level 
[27, 28, 54], 5) total years played [23, 35-37], 6) all positions [55-58] played for each 
sport (1st, 2nd, 3rd etc.) at each level, 7) percentage of game time played at each position 
[46, 58], and 8) age at retirement from the sport [36].  
The self-reported number of concussions was obtained, after participants were 
read a “modern” definition of concussion, based on the CDC statement on sports-related 
concussion [59] and the Third International Conference on Concussion in Sport held in 
Zurich [60]. The concussion history characteristics of the sample are provided in Table 2. 
Since the distribution of self-reported concussions is highly skewed, we used the log of 
concussions in all subsequent analyses to normalize the distribution. Participants were 
also asked to report their age at first exposure (AFE) to tackle football and the total 
number of seasons they played (i.e., duration of football play) (Table 2). For our analysis, 
participant’s AFE was converted into a dichotomous variable: AFE before age 12 and 
AFE at age 12 or above. Age 12 was selected as the cutoff based on our previous work on 
AFE as an exposure metric associated with later-life clinical and structural changes [32, 
33]. For duration of play, we used seasons rather than years because for some athletes a 
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year of football involved both a fall and spring season.  
 
Table 5.2. Exposure variables  
 Total Sample 
N=93 
High School 
N=17 
College 
N=76 
 
 Mean (SD) Mean (SD) Mean (SD) p-value 
aConcussion history 
Median (IQR) 20 (3) 10 (13) 20 (39) 0.0431* 
bCHII 5805.7 (3091.2) 
3237.6 
(1932.4) 
6384.4 
(3015.4) <.0001* 
Age at first exposure 
(years) 10.9 (2.7) 10.8 (2.7) 11.0 (2.7) 0.884 
Average years of youth 
football 3.3 (2.5) 3.4 (2.3) 3.3 (2.5) 0.931 
Seasons of football play 11.1 (4.2) 7.1 (3.1) 12.0 (3.1) <.0001 
Time since retirement 
(years) 26.3 (14.2) 26.4 (12.2) 26.3 (14.4) 0.971 
*Wilcoxon two sample test; aInterviewers read participants a current definition of concussion 
(methods described elsewhere [47]) and asked to estimate their concussion history based on 
that definition; bCumulative Head Impacts Index. Numbers in parentheses are standard 
deviations except when otherwise indicated. IQR = inter-quartile range. 
 
Cumulative Head Impact Exposure Index (CHII). The CHII was developed as an 
estimate of an athlete’s total cumulative exposure to RHI from football. To derive an 
individual’s CHII we combined data from two sources of information: a) individual self-
report measures of athletic exposure obtained from the LEGEND questionnaire at each 
level played (youth, high school, college), such as number of seasons played, positions 
played at each level (primary, secondary, and tertiary), and the proportion of the season’s 
total game time played at each position; and b) a measure of estimated head impacts 
received per season, based on data from published helmet accelerometer studies that 
report the frequency of head impacts per season by position and level of play (See below 
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and Table 3) [55-57 61, 62].  
 
Published Accelerometer Studies Used to Determine Frequency of Head Impacts by 
Position and Level of Play. To obtain estimates of the frequency of head impacts by 
position and level of play, we performed a systematic review of the literature (using 
Pubmed) on helmet accelerometer studies, using the following keywords/search terms: 
HITS system, 6DOF, accelerometers, helmet-sensor, football, youth, high school, and 
college. Studies that satisfied the following a priori inclusion criteria were selected: 
1. Head Impacts were measured during every practice and game for the entire 
season. 
2. Level of play (youth, high school, college) was identified.  
3. Head impact frequencies were reported for positions of play.  
4. Any impact event with a peak linear acceleration less than 10g was excluded from 
analysis. A minimum cutoff of 10g ensures the elimination of non-impact events 
(e.g., jumping) from the calculation of head impact frequency [37, 63-65 56, 66].  
Table 3 provides a summary of key data-points obtained from each accelerometer study 
that met our inclusion criteria. The participants in the studies summarized in Table 3 were 
active in both games and practices. Since most players at youth level play at multiple 
positions, we include a single number to reflect exposure for all seasons each player spent 
at youth level. There was a single high school study identified that grouped together 
certain positions, such as linesmen, regardless of  whether they played at offensive or 
defensive positions. Since many players at the high school level would interchangeably 
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play at both offense and defense, using a similar exposure metric for these positions is a 
realistic assumption [61]. Impact frequencies from these studies was pooled and 
weighted, whenever possible, to derive averages weighted by each study’s sample size. 
These weighted averages are estimates of the impact frequencies per position at the 
different levels of play (youth, high school, college).  
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Table 5.3. Summary of data collected from review of helmet-accelerometer studies  
Level Position Study 
Minimum 
acceleration  N 
Mean/
Media
n  
Weighted mean 
impacts per 
season 
College 
 
DL 
 
Crisco et al 
2010 [57] 14.4 g 29 1086 
871 Mihalik et al 2007 [55]  10.0 g 13 965 
Crisco et al 
2011 [62] 10.0 g 49 718 
LB 
 
Crisco et al 
2010 [57] 14.4 g 29 846 
685 Mihalik et al 2007 [55]  10.0 g 9 655 
Crisco et al 
2011 [62] 10.0 g 47 592 
DB 
 
Crisco et al 
2010 [57] 14.4 g 34 487 
417 Mihalik et al 2007 [55] 10.0 g 12 731 
Crisco et al 
2011 [62] 10.0 g 55 306 
OL 
 
Crisco et al 
2010 [57] 14.4 g 46 960 
728 Mihalik et al 2007 [55] 10.0 g 22 921 
Crisco et al 
2011 [62] 10.0 g 75 543 
OB/RB 
 
Crisco et al 
2010 [57] 14.4 g 23 459 
412 Mihalik et al 2007 [55] 10.0 g 12 589 
Crisco et al 
2011 [62] 10.0 g 37 326 
WR 
 
Crisco et al 
201057 14.4 g 16 305 
237 Mihalik et al 2007 [55] 10.0 g 5 501 
Crisco et al 
2011 [62] 10.0 g 30 157 
QB 
 
Crisco et al 
2010 [57] 14.4 g 8 305 206 Crisco et al 
2011 [62] 10.0 g 14 149 
High 
School 
 
QB Broglio et al 2011 [61] 15 g 4 467 467 
WR/DB Broglio et al 15 g 28 372 372 
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2011 [61] 
RB/LB Broglio et al 2011 [61] 15 g 27 619 619 
DL/OL Broglio et al 2011 [61]  15 g 41 868 868 
Youth All positions 
Daniel et al 
2012 [56]  10 g 7 107 107 
Player positions selected by our study participants were grouped, whenever necessary, in 
accordance with position groups as reported in the selected helmet-accelerometer studies and 
cross-referenced with position groups as characterized by relevant and authoritative 
publications [58,114]. DL = defensive linemen, LB = linebackers, DB = defensive backs, OL = 
offensive linemen, OB/RB = offensive backs or running backs, WR = wide receivers, QB = 
quarterbacks, WR/DB = wide receivers and defensive backs (cornerbacks and safeties), 
DL/OL= linemen. For more detailed information see references listed in table.  
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The CHII was calculated from the self-report variables and weighted impact 
frequencies using the equations outlined in Table 4. A hypothetical case is provided to 
illustrate the calculation of the CHII: Mr. A is a 42 year old male who reports having 
participated in football at the youth, high school and collegiate levels.  
A. In college, Mr. A reported that he played a total of 3 seasons. His primary position 
for his college team was linebacker (LB); he reported having no secondary or 
tertiary positions of play. He estimated having participated in 85% percent of 
game downs as a linebacker. Thus, his college CHII was: (85%) x (685 impacts 
per season for LB from Table 5) x (3 seasons) = 1,747. 
B. In high school, Mr. A reported that he played for all 4 seasons. His primary 
position for his high school team was also LB; he reported having a secondary 
position playing the offensive line (OL) as a guard. Of all the games in high 
school, he estimated having participated in 40% percent of game downs as a LB 
and 30% as OL. Thus, his high school CHII was: [(40%) x (619 impacts per 
season for LB) x (4 seasons)] + [(30%) x (868 impacts per season for OL) x (4 
seasons)] = 2,032. 
C. Lastly, Mr. A reported that he played 4 seasons of football prior to high school. 
He reported having played as an OL throughout his youth participation. He 
estimated that he participated in 90% game downs for all 4 seasons. Thus, his 
youth CHII was: (90%) x (107 impacts per season for any position) x (4 seasons) 
= 385. 
His overall CHII  =  (A + B + C)  =  (1,747 + 2,032 + 385)  =  4,164. 
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Table 5.4. Calculation of the Cumulative Head Impacts Index   
YOUTH 
% games played at  
1
st
 position 
X 
Position’s weighted average #  
impacts per season X 
 Total # of  
youth seasons 
= [A] 
+ 
% games played at  
2
nd
 position 
X 
Position’s weighted average #  
impacts per season X 
Total # of  
youth seasons 
+ 
% games played at  
3
nd
 position 
X 
Position’s weighted average #  
impacts per season X 
Total # of  
youth seasons 
+ 
HIGH  
SCHOOL 
% games played at  
1
st
 position 
X 
Position’s weighted average #  
impacts per season X 
Total # of  
youth seasons 
= [B] 
 
+ 
% games played at  
2
nd
 position 
X 
Position’s weighted average #  
impacts per season X 
Total # of  
youth seasons 
+ 
% games played at  
3
nd
 position 
X 
Position’s weighted average #  
impacts per season X 
Total # of  
youth seasons 
  + 
COLLEGE 
% games played at  
1
st
 position 
X 
Position’s weighted average #  
impacts per season X 
Total # of  
youth seasons 
= [C] 
+ 
% games played at  
2
nd
 position 
X 
Position’s weighted average #  
impacts per season X 
Total # of  
youth seasons 
+ 
% games played at  
3
nd
 position 
X 
Position’s weighted average #  
impacts per season X 
Total # of  
youth seasons 
Cumulative Head Impacts Index = [A] + [B] + [C] 
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Clinical Outcomes & Measures.  
The following set of instruments administered to LEGEND participants were 
selected for the current study: (1) Brief Test of Adult Cognition by Telephone (BTACT) 
[67]; (2) Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) 
[68]; (3) Center for Epidemiologic Studies - Depression Scale (CES-D) [69]; and (4) 
Apathy Evaluation Scale (AES) [70]. Each of these measures were chosen a priori based 
on their previous use in studies of TBI and concussion (BRIEF-A [25, 71, 72]; AES [73-
75]; CES-D [76-78]; BTACT [79]), and on the availability of validated cut-off scores 
suggesting clinically meaningful impairment [68, 73, 80-82]. 
Brief Test of Adult Cognition by Telephone (BTACT) [67, 79]. The BTACT is an 
objective measure of cognitive function administered by telephone. The benefits and 
validity of cognitive test batteries administered by telephone are well-documented [79, 
83]. The BTACT requires 20 minutes to complete and consists of 6 subtests that measure 
episodic verbal memory (Immediate and Delayed Rey Auditory-Verbal Learning Test), 
working memory (Digits Backward), verbal fluency (Animals Categorical Fluency), task-
switching (Red/Green Test), inductive reasoning (Number Series), and processing speed 
(Backward Counting) [67]. A global composite score was derived with the bi-factor 
approach, which has an overall improved validity over the single-factor approach and is 
better able to distinguish between persons with a lifetime history of head injury [79]. Age 
and gender corrected scores were scaled relative to a healthy normative sample. 
Objective cognitive impairment was defined as 1.5 standard deviations below the 
normative mean [82, 84]. 
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The Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) 
[68]. Participants completed an online version of the BRIEF-A questionnaire, a well-
validated 75-item measurement of executive function behavior in activities of daily 
living. Participants rate “how often each of the 75 following behaviors has been a 
problem?” in the past month on a three-point Likert scale (1 = never, 2 = sometimes, 3 = 
often); higher scores indicate a greater degree of dysfunction. We used the global 
measure of executive function (Global Executive Composite [GEC]), as well as two 
factor-based measures of cognitive regulation (Meta-cognition Index [MI]) and 
behavioral-emotional regulation (Behavioral Regulation Index [BRI]). Raw scores are 
converted into standardized age-adjusted T-scores (M=50, SD=10). T-scores ≥1.5 
standard deviations of the normative mean (T-scores ≥ 65) are considered clinically 
impaired [68]. 
The Center for Epidemiologic Studies - Depression Scale (CES-D) [69]. The 
CES-D is a 20-item self-report measure of depression symptoms that was developed and 
validated by the National Institute of Mental Health [69]. Participants rate their 
depression symptom severity in the past week on a four-point Likert scale that ranges 
from “none of the time” to “all of the time.” Higher scores indicate more severe 
depressive symptoms, with an established total CES-D cutoff score ≥ 16 reliably 
indicating clinically meaningful depression [80, 81].  
Apathy Evaluation Scale (AES) [70]. The AES is an 18-item self-report measure 
of apathy over the past four weeks. Participants rate their apathetic emotions, thoughts, 
and behaviors in the past 4 weeks on a four-point Likert scale that ranges from “not at all 
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characteristic” to “very characteristic.” Higher total AES scores indicate worse apathy, 
with an established cutoff total AES score ≥ 34 reliably indicating clinically meaningful 
apathy [73]. 
 
Statistical Modeling.  
Group Comparisons. The former high school and collegiate football player groups 
were compared using two sample t-tests for continuous normal variables, Wilcoxon two-
sample tests for non-normal continuous variables, and chi-square tests for categorical or 
dichotomous variables.  
Regression Modeling. To test our study hypothesis we modeled each dichotomous 
outcome measure (probability of impairment or not) with our predictor metric (CHII). 
This model is illustrated in Figure 1. We first identified a point (threshold-dose) at which 
the magnitude of the relationship (slope) changes from a zero magnitude (B1=0) to a non-
zero magnitude (B2>0). The change-point threshold shows the conversion of the 
relationship from a baseline risk of playing football to a dose-response relationship above 
which higher exposure to head impacts can lead to higher risk of impairment [85]. The 
change point was identified using a Bayesian hierarchical model estimated by Markov 
Chain Monte Carlo (MCMC) method with 30,000 simulations implemented in PROC 
MCMC in SAS 9.4 [85]. An important contribution in modeling head impact exposure to 
long-term outcomes is the incorporation of concussion history into the model. Since a 
head impact is a necessary condition for a concussion, we cannot estimate the effect of 
head impacts by controlling for concussions in a simple regression setup. This 
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relationship between predictors where a value of one variable is directly caused by 
another is often described as endogenous [86]. If endogeneity exists between variables 
within our model, the following two problems would occur: (1) a linear regression model 
that includes both the CHII and concussion history would give invalid inference, and (2) 
the estimates of the slopes from such a regression model would be biased. To address the 
inference and bias problems caused by endogeneity we used an “instrumental variable 
model” with log concussions as the instrument [87]. The instrumental variable model can 
be described as a two-stage regression. In the first-stage regression, we estimate the effect 
of the log of the number of concussions on the CHII, while in the second-stage regression 
we use the predicted values from the first stage to estimate the effect of the CHII on the 
probabilities of impairment for each of the outcomes. Both regressions included age and 
education as covariates. Next, we applied the instrumental variable model using a 
bivariate probit model. The estimated effect of cumulative head impacts derived from this 
instrumental variable model is equivalent to an effect estimated among the compliers 
from a study where exposure was prospectively randomized [88]. Thus, an instrumental 
variable model allows for causal inference from observational data with large 
measurement error.88, 89 Furthermore, the instrumental variable approach reduces the 
measurement error of the estimates of frequency of head impacts by position and level of 
play. Since the studies used to estimate these frequencies are independent from the 
LEGEND study, their measurement error is uncorrelated from the self-reported 
concussions in LEGEND. Therefore, in this instance, concussions become an ideal 
instrument to calibrate and reduce the measurement error of head impacts exposure. 
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Similar approaches in different setting have been used in econometric and clinical 
therapeutic studies [90,91]. 
 
Figure 5.1. Illustration depicting the relationship of CHII to risk of impairment 
 
Figure 5.1. Schematic of the dose-response model with a constant baseline risk of later-
life impairment (Baseline gradient of slope = 0) below the cumulative head impact 
threshold-dose and with increasing probability of impairment (Dose-Response gradient of 
slope > 0) above that threshold-dose.  
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Comparison to other exposure metrics. We also examined total seasons played 
and age of first exposure (AFE) as simple exposure metrics that have demonstrated a 
significant relationship with clinical outcomes in other studies [11, 32, 33, 35, 36]. Total 
season played and AFE were independently added to our bivariate probit model with age 
and education as covariates. Next, we modeled clinical outcomes with concussion history 
in a separate univariate probit model, with age and education included as covariates. 
 
Results 
Participant Demographics & Group Comparisons. Participant demographics 
(Table 1), exposure variables (Table 2), and outcome measures (Table 5) were compared 
across the two highest levels of  play, i.e., high school and college. The college-level 
group had significantly more years of education (t-test=3.58, p-value=0.0005), more 
seasons played (t-test=4.85, p-value<0.0001), a greater number of concussions 
(Wilcoxon=592.5, p-value=0.0431), and a higher CHII (t-test=2.47, p-value=0.0156. All 
other group comparisons were nonsignificant. Mean scores on the BTACT, an objective 
measure of cognitive function, indicated that the entire sample was, on average, 
cognitively normal (Table 5).  
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Table 5.5. Behavior, mood, and cognition outcome measures 
 
Total 
Sample 
N=93 
High 
School 
N=17 
College 
N=76  
 Mean (SD) Mean (SD) Mean (SD) 
p- 
value 
Behavioral Regulation Index of the BRIEF-
A 64.1 (15.9) 64.4 (16.0) 64.0 (16.0) 0.93 
Metacognition Index of the BRIEF-A  64.5 (16.9) 62.2 (14.8) 65.0 (17.4) 0.55 
Global Executive Composite of the BRIEF-
A 65.3 (16.9) 64.2 (15.0) 65.6 (17.3) 0.76 
Center for Epidemiologic Studies 
Depression Scale 21.7 (15.5) 21.7 (17.9) 21.7 (15.0) 0.99 
Apathy Evaluation Scale 35 (11.5) 34.2 (12.5) 35.2 (11.3) 0.75 
Brief Test of Adult Cognition by Telephone 0.04 (0.9) -0.11 (1.1)  0.08 (0.90) 0.44 
BRIEF-A = Behavior Rating Inventory of Executive Function – Adult Version. 
 
CHII Exposure & Risk of Impairment. The CHII was calculated for all 93 
participants, and the means for former high school and collegiate football players are 
listed in Table 2. The CHII change-points listed in Table 6 indicate the threshold number 
of impacts, above which a dose-response relationship is initiated between exposure 
(CHII) and the risk of impairment. Figure 2 shows the predicted probabilities of 
impairment for different doses of exposure. The baseline risk of impairment significantly 
increases linearly after a change-point as exposure increases in all outcomes. (See 
supplementary Table 1 for a tabular summary of the data depicted in Figure 2). 
Specifically, we find that the risk of impairment increases steadily every 1000 impacts, or 
about twice the sample’s average’s season number of impacts (545) above the baseline 
change-point. For all outcomes, the risk of developing clinically meaningful impairments 
in mood, behavior, and cognition increased considerably with two additional seasons 
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worth of head impacts. For example, we found that adding 10 seasons of impacts above 
the baseline threshold increased a subject’s risk of developing objective cognitive 
impairment by 25 fold.  
 
Table 5.6. Change point thresholds from baseline constant risk to dose-response relation 
between CHII and risk of impairment 
Outcome Measure Clinical Domain 
Threshold for 
Dose-Response 
(*Median CHII) 
95% CI 
Behavioral Regulation Index of the 
BRIEF-A Behavior 2216 1537-8120 
Metacognition Index of the BRIEF-A Metacognition 2393 1571-6682 
Global Executive Composite of the 
BRIEF-A Executive Function 1850 1523-2011 
Center for Epidemiologic Studies 
Depression Scale Depression 1801 1514-2010 
Apathy Evaluation Scale Apathy 2160 1536-5754 
Brief Test of Adult Cognition by 
Telephone Cognition 7251 1754-9788 
*The Median and 95% CI from 30,000 Markov Chain Monte Carlo simulations. Change-point 
thresholds represent the median number of impacts above which there is a predictive dose-
response relationship between head impacts and clinically meaningful measures of impairment. 
BRIEF-A = Behavior Rating Inventory of Executive Function – Adult Version.  
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Figure 5.2. (A-F) Predicted probabilities of impairment with 95% CI for different doses of 
cumulative exposure 
 
Figure 5.2. (A-F) Each dichotomous outcome measure (A-F; probability of impairment) was fit 
using a bivariate probit, instrumental variable model adjusted for both age and education as well 
as our predictor variable of interest (CHII).  Baseline Risk refers to the risk of impairment at the 
CHII dose range below the thresholds identified in Table 6. Above these thresholds, a significant 
linear dose-response relationship between CHII exposure and later-life clinical impairment was 
found for all outcomes. See supplemental Table 1 for tabular data.  
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Supplemental Table 5.1. Predicted probabilities of impairment with 95% CI for different 
doses of cumulative exposure 
Clinical Outcome *Baseline CHII   
Baseline 
+ 1000  
Baseline 
+ 2000  
Baseline 
+ 3000  
Baseline 
+ 4000  
Baseline 
+ 5000  
p-
value 
Behavior 
(BRI) 
CHII 
Dose 0-2216 
2216-
3216 
3216-
4216 
4216-
5216 
5216-
6216 
6216-
7216 
<.0001  
Risk 
of 
Impa
irme
nt 
0.11(0.11-
0.12) 
0.18(0.15
-0.21) 
0.26(0.19
-0.34) 
0.36(0.24
-0.50) 
0.47(0.29
-0.66) 
0.58 
(0.34-
0.79) 
Meta-
cognition 
(MI) 
CHII 
Dose 0-2393 
2393-
3393 
3393-
4393 
4393-
5393 
5393-
6393 
6393-
7393 
0.0005 
Risk 
of 
Impa
irme
nt 
0.12(0.12-
0.13) 
0.19(0.15
-0.24) 
0.27(0.18
-0.39) 
0.37(0.21
-0.56) 
0.48(0.25
-0.72) 
0.59(0.29
-0.84) 
Executive 
Function 
(GEC) 
CHII 
Dose 0-1850 
1850-
2850 
2850-
3850 
3850-
4850 
4850-
5850 
5850-
6850 
<.0001 
Risk 
of 
Impa
irme
nt 
0.10(0.09-
0.10) 
0.16(0.13
-0.19) 
0.23(0.16
-0.32) 
0.33(0.20
-0.48) 
0.44(0.25
-0.65) 
0.55(0.30
-0.79) 
Depressio
n (CES-
D) 
CHII 
Dose 0-1801 
1801-
2801 
2801-
3801 
3801-
4801 
4801-
5801 
5801-
6801 
<.0001 
Risk 
of 
Impa
irme
nt 
0.12(0.11-
0.13) 
0.18(0.15
-0.22) 
0.27(0.19
-0.36) 
0.37(0.24
-0.52) 
0.48(0.29
-0.68) 
0.59(0.34
-0.81) 
Apathy 
(AES) 
CHII 
Dose 0-2160 
2160-
3160 
3160-
4160 
4160-
5160 
5160-
6160 
6160-
7160 
0.0161 
Risk 
of 
Impa
irme
nt 
0.15(0.14-
0.16) 
0.22(0.16
-0.28) 
0.29(0.17
-0.44) 
0.38(0.19
-0.61) 
0.48(0.20
-0.77) 
0.57(0.21
-0.88) 
Cognition 
(BTACT) 
CHII 
Dose 0-7251 
7251-
8251 
8251-
9251 
9251-
10251 
10251-
11251 
11251-
12251 
<.0001 
Risk 
of 
Impa
irme
nt 
0.10(0.08
1-0.11) 
0.23(0.19
-0.28) 
0.43(0.33
-0.54) 
0.65(0.49
-0.79) 
0.83(0.66
-0.94) 
0.94(0.80
-0.99) 
Adjusted for age and education. *Baseline refers to the risk of impairment at the CHII 
dose range below the change-point thresholds listed in Table 6. At and below these 
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thresholds risk of impairment is at a constant baseline. Above the threshold, there is a 
dose-response relationship between increasing CHII exposure and the risk of clinical 
impairment. All outcome measures were transformed into dichotomous variables 
(impairment or not) using established cut-off points. These results identify the risk of 
developing clinically meaningful impairment in later-life from exposure to impacts from 
amateur football. 
 
 187 
 
Other Exposure Metrics & Risk of Impairment. We added alternate exposure metrics to 
our bivariate probit model to test whether other metrics might be better at predicting 
clinical outcomes and/or whether they might eliminate the predictive significance of the 
CHII. Total seasons of play and AFE did not add independently to our bivariate probit 
model, nor did they eliminate the significance of the CHII for predicting clinical 
outcomes. When added to the model with the CHII, participants with AFE<12 showed 
some increase in the risk for impairment but did not achieve significance on any outcome 
after adjusting for CHI:  GEC (β=0.41, p-value=0.2542), MI (β=0.36, p-value=0.3456), 
BRI (β =0.56, p-value=0.073), CES-D (β =0.49, p-value=0.1771), AES (β =0.33, p-
value=0.4170), BTACT (β =0.81, p-value=0.1427). Interestingly, when controlling for 
CHI, increasing the total number of seasons played reduced the risk for clinical 
impairment : BRI (β =-0.11, p-value=0.0183), MI (β =-0.09, p-value=0.0847), GEC (β =-
0.07, p-value=0.1586), CES-D (β =-0.09, p-value=0.1224), AES (β =-0.07, p-
value=0.2011), BTACT (β =-0.03, p-value=0.6390). The significant negative association 
between total seasons played and BRI is consistent with previous research demonstrating 
a neurobehavioral benefit from regular exercise [92-94]. The betas (β indicates the 
magnitude and direction of the relationship between the predictor, AFE or total seasons, 
and the risk for impairment in a model that also takes into account a quantitative estimate 
of CHI exposure. For example, positive betas indicate a positive association between 
exposure and impairment, such that increasing exposure was associated with an increased 
probability of impairment. 
Lastly, we explored the role concussion history had on predicting clinical 
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outcomes and compared its predictive power to that of the CHII. Because of the 
endogeneity problem previously described (i.e., that head impacts are a necessary factor 
for both the CHII and concussions) we could not simply include concussion history as a 
covariate in our CHII model. The spearman correlation between concussion history and 
the CHII was 0.22 (p-value=0.02). Therefore, we ran a univariate probit model with age 
and education as covariates, in order to evaluate the predictive power of concussions on 
the probability of impairment. The estimates were: BRI (β =0.50, p-value=0.0109), MI (β 
=0.41, p-value=0.0255), GEC (β =0.48, p-value=0.0138), CES-D (β =0.48, p-
value=0.0195), AES (β =0.30, p-value=0.0717), BTACT (β =0.43, p-value=0.1526). 
Compared to the CHII, concussion history was limited to predicting self-reported changes 
in behavioral regulation (BRI), cognition (MI), executive dysfunction (GEC), and 
depression (CES-D), but not apathy (AES), or objective cognitive dysfunction (BTACT). 
Even for the significant outcomes (BRI; MI; GEC; CES-D), concussion history was 
found to have less predictive power than the CHII. 
 
Discussion 
We developed a metric of cumulative exposure to RHI from football, the CHII, a 
measure that includes self-reported exposure and estimated quantitation of head impacts 
based on published helmet accelerometer studies. The CHII was used to examine the 
relationship between cumulative RHI exposure and later-life cognitive, mood, and 
behavioral impairment in a sample of former football players whose highest level of play 
was either high school or college. Subjects denied having played any other contact sport 
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at any time. The mean CHII of 5,806 total impacts for our sample is consistent with the 
range of cumulative impacts expected for former high school and college football players 
[3]. We found that the CHII strongly predicts later-life clinical outcomes, outperforming 
other individual metrics such as concussion history, age at first exposure to tackle 
football, and total duration of play, suggesting that it is a useful metric to estimate 
lifetime RHI exposure. 
We view this study as an initial examination of the CHII and our findings of the 
relationship between earlier RHI exposure and later life impairments should be 
considered preliminary due to several limitations described below. Moreover, this was 
not a study of CTE or neurodegeneration; our outcome measures focused on clinically-
meaningful levels of cognitive, mood, and behavior impairment and did not include any 
biomarkers of underlying disease or injury. This study does, however, underscore the 
importance of subconcussive trauma in the development of later life neurological 
impairment. The number of self-reported concussions predicted impairment in fewer 
outcomes than the CHII. Compared to the CHII, concussion history did not significantly 
predict apathy or objective cognitive dysfunction (BTACT). These findings are consistent 
with previous imaging studies of amateur athletes which demonstrated that changes in 
brain functional imaging occurred after a single season of cumulative asymptomatic 
impacts without concussion [10, 26, 27] and post-mortem studies that indicate 16% of 
former contact-sport athletes with pathologically verified CTE had no concussion history 
[30, 36]. These studies together with our current findings highlight the critical need to 
evaluate prospectively the potential risk and later-life consequences of exposure to 
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repetitive asymptomatic blows to the head (i.e., subconcussive impacts). 
This study is the first in the literature to demonstrate a threshold dose-response 
relationship between estimated cumulative head impact exposure from football and later-
life risk for cognitive and neurobehavioral impairment. We found that after a threshold, 
the risk for impairment increased with additional impacts. Similar findings of a threshold 
dose-response from RHI have been reported in studies of soccer and boxing [35, 95-97]. 
Specifically, our results show that the risk of developing behavioral dysregulation, 
executive dysfunction, depression, and apathy nearly doubled with 2800 additional 
impacts above the threshold. Our findings also show that increasing the CHI dose from 
7200 to 11200 increased the risk for objective cognitive impairment by a considerable 
nine fold.   
Interestingly, the dose-response threshold for cognitive function was much higher 
relative to other outcomes. Though speculative, it is possible that changes in mood and 
behavior reflect a different underlying mechanism or areas of structural impairment than 
cognitive changes, and that the cognitive changes reflect the evolution and progression of 
underlying CTE pathology [36, 98]. This is consistent with previous imaging studies in 
soccer players, wherein a lower threshold for detecting microstructural brain changes 
from soccer heading was identified compared to the threshold for memory impairment on 
neuropsychological evaluation [95]. Furthermore, in CTE, individuals with cognitive 
symptoms present later in the clinical course than behavioral impairments [98].   
Our findings indicate that below identified thresholds, accumulated impacts have no 
apparent effect on the risk for cognitive or neurobehavioral impairment. However, 
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individuals had a baseline constant risk below the threshold. This baseline risk does not 
suggest that safety below the threshold is assumed. Moreover, our study design does not 
allow us to determine a safe time to cease RHI exposure, i.e., quit football. Furthermore, 
the baseline risk and the threshold likely depend on several subject-specific factors such 
as possible genetic susceptibility, body mass index, socioeconomic status, cognitive 
reserve, etc [99]. Large, well-controlled, prospective, longitudinal research that 
distinguishes threshold effects and baseline risk in football is clearly needed to identify 
maximum exposure levels for each player’s safety. Such research would ultimately 
facilitate the development of safety guidelines that could minimize the risk of adverse 
effects on the brain in football. 
Considering the public health implications of our study, there is also a need to 
investigate any causal evidence between RHI exposure and clinical impairment. 
Establishing cause indicates the possibility of intervention. We utilized the Bradford-Hill 
criteria for evaluating causal inference in observational studies [100] and our findings are 
suggestive of a causal relationship between cumulative head impact exposure and later-
life clinical impairment. We analyzed eight Bradford-Hill criteria in our model: strength, 
dose-response, consistency, plausibility, coherence, experiment, reversibility, 
temporality, and specificity. Strength of association between our predictor, the CHII, was 
very strong on all six measures of clinical impairment and higher than any other exposure 
predictor. The dose-response criterion is of particular importance in disorders that exhibit 
a latent onset, and this was supported by the present study [101]. Regarding consistency 
of association, the dose-response relationship has also been shown in boxers [94, 102-
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103]. The plausibility of association is supported by human and animal studies that show 
cumulative subconcussive impacts and axonal injury and blood brain barrier damage [10, 
11, 28, 93, 104-107]. Since 1928, a relationship has been hypothesized between RHI and 
neurological disease supporting the notion of coherence of association [106]. Animal 
models have shown reduced numbers of impacts results in a reduced negative 
consequences to support experimentation of association and the reversibility of 
association [109-110]. Lastly, exposure must precede the outcome, which conforms to 
observations in all previous studies and demonstrates temporality of association.  
These findings do not suggest that every individual with a history of RHI -- even 
exposure above the reported thresholds -- will have later life cognitive, mood, or 
behavioral impairments or develop a neurodegenerative disease, such as CTE. Support of 
a causal relationship does not imply a universal relationship. For example, a causal 
relationship between smoking tobacco and subsequent lung cancer has long been 
accepted. However, not all smokers develop lung cancer; some develop other conditions 
and diseases causally linked to smoking (e.g., stroke, heart disease, emphysema), and still 
others remain healthy throughout their lives. We hope that the use of the CHII (and 
subsequent iterations of this exposure metric) will result in greater clarification and 
validation of the causal relationship between football-related RHI and later life clinical 
impairment.  
The current study has clear limitations. Although all the accelerometer studies 
used to measure RHI discarded linear accelerations below 10g, some of the studies used a 
slightly higher minimum cutoff to register a hit. However, small differences in cutoff 
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points are likely not meaningful given that the majority of recorded impacts had mean 
accelerations well above the minimum cutoff points (as supported by the data 
summarized in Table 3). For instance, the frequency of impacts per season reported by 
Mihalik et al., [55] was lower than the frequency reported by Crisco et al., [57] despite 
having used a lower cutoff (Mihalik 10g; Crisco 14.4g). Additional research using both 
helmet-based and head-based accelerometers is needed to develop standardized, 
consensus based cutoff points [66]. In addition, within the CHII, it is assumed that 
players are active in both games and practice, and does not take into account players who 
do not participate in games. Participants in our study were active players in games in high 
school and in college. For example, former college players in our study averaged 3.6 
years of play and 50% game involvement. Therefore, because of the possible difference 
in RHI exposure between reserve players (who participate in all practices but limited 
game involvement) and starters (who participate in all practices and have extensive game 
involvement), and because of the potential discrepancy in the frequency and severity of 
RHI exposure between practices and games, our findings may not accurately reflect 
differences in long-term consequences between starters and reserve players.  Moreover, 
our study evaluated only certain aspects of exposure (i.e., cumulative impacts) and did 
not use other possible biomechanical metrics, such as cumulative linear and rotational 
accelerations. The sample size of the present study was also small due to the strict 
inclusion and exclusion criteria. The present results will need replication in larger studies. 
Furthermore, despite our analytic approach, the study design is cross-sectional which 
limits the extent to causal inference. Our convenience sample may induce a self-selection 
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bias limiting the external validity of our findings. However, our instrumental variable 
analytic approach reduced the measurement error bias and potential confounding effects 
[111]. Specifically, this method allowed us to provide unbiased estimates of causal 
effects in our nonrandomized sample [88, 89] and is increasingly utilized in clinical 
studies [112-113] particularly when there are obstacles to performing a randomized 
controlled trial.  
Future studies will be necessary to validate the CHII and improve our 
understanding on the long-term clinical consequences of RHI exposure. Larger studies 
are needed to investigate the effect of CHI exposure by age and level. Studies utilizing 
objective fluid and neuroimaging biomarkers will allow for a better understanding of the 
underlying etiology associated with CHI exposure. Case-controlled postmortem studies 
will also be necessary to examine the association between the CHII and CTE (and other) 
neuropathology. There is also the need to examine additional potential risk factors that 
may modify the relationship between RHI exposure and later life cognitive and 
neurobehavioral impairment, including, but not limited to, genetics, diet, exercise, 
substance use (including performance enhancing drugs), and cardiovascular risk. Finally, 
there is a need for similar models of cumulative RHI exposure for other contact sports, 
once accelerometer or some other objective measure of head impacts is more widely 
available. 
 
 
 
 195 
 
Conclusion 
We developed the CHII, a tool to quantify retrospective cumulative exposure to 
RHI, including subconcussive impacts. Using the CHII, we showed that RHI exposure 
among amateur football players is associated with later-life cognitive and 
neurobehavioral consequences. Although our findings raise safety concerns for 
participation in amateur football, prior to changes in policy and rules, prospective 
longitudinal research in larger samples is needed to validate the CHII and replicate and 
extend our associated findings.  
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Discussion and Future Directions 
 
Much has been learned about concussion and CTE neuropathology in recent 
years. Yet, the scientific study of the long-term clinical effects of repetitive head impacts, 
including subconcussive hits, remains in its infancy. The five published chapters of this 
dissertation represent important first steps towards addressing the paucity of research on 
this topic. 
The goal of the first chapter was to quantify symptom frequencies and examine 
the disease-specific clinical presentation of CTE in neuropathologically confirmed cases 
without comorbid neurodegenerative pathology. Consistent with earlier reports in boxers, 
two relatively distinct clinical presentations emerged: one group whose initial features 
developed at a younger age and involved behavioral and/or mood disturbance, and 
another group whose initial presentation developed at an older age and involved cognitive 
impairment. A binomial test of the proportion of APOE genotypes in our sample 
compared to an age-matched normative sample found that there were proportionally more 
ε4 homozygotes in the cognitive subtype group. These findings suggest APOE status 
could raise the risk of developing the cognitive manifestation of CTE in some people, 
though more research is needed.   
In chapter two, we proposed clinical diagnostic criteria for the long-term effects 
of RHI and CTE. The criteria used a two-step approach to clinical diagnosis. In the first 
step, the presence of certain signs and symptoms were identified in order to establish an 
initial diagnosis of what we termed traumatic encephalopathy syndrome (TES). TES is 
the preferred designation at the first stage of diagnosis and is meant to be inclusive of the 
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full spectrum of CTE as well as other possible long-term consequences of repetitive head 
impacts. The selection of symptoms and signs to be used as diagnostic evidence of TES 
and CTE was essential to the development of our two-step diagnostic approach. In our 
criteria, a sign or symptom was designated as diagnostic if it occurred in a minimum of 
70% of the neuropathologically confirmed CTE cases without comorbid disease, as 
described in chapter 1. The specificity of our first stage of diagnosis is illustrated by 
comparing the diagnostic threshold employed in other studies, such as the set of criteria 
proposed by Victoroff in 2013, where any sign or symptom that occurred in seventy 
percent of the cases was considered. In the next step of the two-step approach, we 
assessed the likelihood that TES is related to underlying CTE pathology as either TES 
with probable- or possible-CTE. To be diagnosed with possible-CTE, TES must have 
already been established but with a “progressive” course in combination with one 
positive potential biomarker for CTE that reflects the known neuropathological 
characteristics.  
In chapter three we evaluated potential clinicopathological associations between 
tau, amyloid beta, age, APOE genotype, and clinical outcomes in heterogeneous cohort of 
deceased athletes with neuropathologically confirmed CTE (n=114, mean age at 
death=60). Generally, when amyloid β peptide (Aβ) deposition was comorbid with CTE 
tauopathy (52% of cases) there was a significant association with severe tauopathy and 
worse clinical outcomes. Also, we identified a clear clinical and pathological dichotomy 
between CTE cases with Aβ deposition compared to those without. Clinically, cases of 
CTE with Aβ had a significantly older age at symptom onset and an older age at death. 
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Furthermore, age adjusted logistic regression found the odds of developing dementia 
were 4 times higher in CTE cases with Aβ deposition (either neuritic or diffuse) and, the 
odds of developing parkinsonism were 9 times higher in CTE cases with diffuse Aβ 
deposition. The frequency of the cognitive subtype increased in CTE subjects with Aβ, 
but this difference was not significant. Similar to what was reported in Chapter one, there 
was a significantly greater proportion of ε4 allele homozygotes in our sample compared 
to the control population (Z = 1.94, p = 0.026). However, we extended these findings and 
hypothesized that ε4 allele would be elevated specifically in CTE subjects with Aβ, but 
not in those without. We found that there was no difference between the proportion of ε4 
alleles in CTE subjects without Aβ (14%) compared to an age matched population norm 
(15%), but that there was a significantly increased proportion in CTE subjects with 
diffuse (27%, Z = 2.92, p = 0.002) or neuritic (25%, Z = 2.01, p = 0.022) Aβ plaques. A 
direct association between the ε4 allele and diffuse Aβ plaques in CTE was also found (p 
= 0.035). Pathologically, neuritic plaques were significantly associated with increased 
CTE tauopathy stage (β= 2.43, p = 0.018) and co-morbid Lewy body disease (OR= 5.01, 
p = 0.009). Lastly, to examine the direct effect of Aβ on CTE tauopathy we employed 
binary logistic regression and found the odds of a case progressing to the most severe 
stage of CTE, stage IV tauopathy, was 4 times higher in subjects presenting with co-
morbid neuritic plaques compared to those without even when adjusting for age. These 
findings are limited by retrospective cross-section design, but have important 
implications for ongoing studies evaluating biomarkers for the in vivo diagnosis of CTE. 
Furthermore, these findings have important implications for diagnosing CTE before 
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death. Our results suggest possible-CTE cases may have a more severe prognosis and 
complicated biomarker when APOE, ε4, and amyloid beta protein deposition are 
comorbid with CTE tauopathy.  
The fourth chapter reviewed and examined the clinical concepts associated with 
short- and long-term effects of RHI, with a special emphasis on the potential risk-factors 
for CTE. Clinical diagnostic criteria were operationalized for analyses and for the first 
time were applied to two neuropathologically confirmed case-reports of CTE, one a 
professional football player, and the other, a professional boxer. As the types of impacts 
and predominant forces differ between sports, we hypothesized that the clinical and 
pathological phenotype of CTE would also differ based on the type of sport exposure. To 
test our hypothesis, we compared the frequency and severity of motor symptoms and 
cerebellar dentate pathology between age- and CTE stage-matched groups of professional 
boxers and football players. In line with our hypothesis, boxers had a significantly higher 
frequency of motor symptoms and a greater severity of tauopathy affecting the cerebellar 
dentate than football players. Our results underscored the importance of cumulative 
exposure to RHI as a risk factor in the development and progression of CTE clinically 
and pathologically.  
The fifth and final chapter represents an important first in examining a cause-
effect relationship between exposure to repetitive head impacts through youth, high 
school, and college football, and later life impairments in cognition, mood, and behavior. 
In the absence of a direct measure of head impacts, we developed a metric to quantify 
cumulative repetitive head impact exposure from amateur football that we termed the 
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cumulative head impact index (CHII). To overcome the obstacles to conducting a 
randomized controlled trial involving total exposure over the course of an athletes 
playing career, we utilized instrumental variable analysis with the CHII as our primary 
predictor. This method allowed us to examine causal relationships between cumulative 
exposure and the risk of depression, apathy, behavioral dysregulation, executive 
dysfunction, and cognitive impairment in former amateur football players. Specifically, 
statistical analyses, adjusted for age and education, found a strong dose-response 
relationship between estimated total head impact exposure and the risk of impairment. 
Moreover, we found a threshold number of hits, below which there was no dose-response 
relationship between cumulative head impacts and risk for later life problems, but above 
which the greater the number of hits resulted in a greater risk for later life cognitive, 
mood, and behavioral impairment. It is important to note that the CHII estimated all 
football related hits above 10g, including the hits that did not result in the symptoms of a 
concussion, termed subconcussive impacts. In fact, concussion history alone did not 
predict objective cognitive impairment, highlighting the important role subconcussive 
impacts have in predicting long-term consequences. Establishing cause is important 
because it indicates the possibility of intervention and prevention. The focus of this study 
was limited to football, and there is a need for similar models of cumulative head impact 
exposure for other contact sports, once an accelerometer or some other objective measure 
of head impacts is more widely available. Our study was also limited by its small sample 
size. While we did demonstrate a minimum threshold of head impacts, these findings 
cannot be interpreted as suggesting that there is a safe number of hits for an individual as 
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the results were based on group findings.  
 
Summary. Overall, the chapters of this dissertation addressed the need to 
characterize the clinical features and etiology of CTE (See Figure 1. Dissertation 
Synthesis). In the first two chapters, we described the clinical presentation of CTE and 
propose clinical diagnostic criteria. In the remaining chapters, we examined the potential 
risk factors and predictive exposure models for the clinical etiology of CTE during life. 
Additional research to refine and extend our findings using an iterative process (outlined 
in Figure 1) is ongoing. More specifically, studies are being planned, or are underway, 
that operationalize our clinical diagnostic criteria to refine our understanding of the 
clinical manifestations and diagnosis of CTE during life and utilize our exposure metric, 
the CHII, to determine if it can be used to predict a clinical diagnosis of TES and 
“probable” CTE.  
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Figure 1. Dissertation Synthesis. The clinical features of CTE are 
addressed in chapters one and two. The etiology of CTE clinically is 
examined in the remaining chapters.   
 
Limitations. Although the limitations of each study are discussed by chapter, it is 
important to note that overall, these studies were limited by cross-sectional design. Future 
research is needed to extend our findings and further develop our proposed clinical 
criteria and CHII exposure metric in studies with larger samples using longitudinal, 
prospective experimental designs. For example, studies should be conducted that apply 
the CHII metric in individuals with post-mortem diagnoses of CTE or in living persons 
with suspected probable-CTE, once criteria and biomarkers are further refined and 
validated. Moreover, the analyses in this dissertation are limited by self-referral and 
would be appropriately described as convenience samples. The post-mortem samples 
from the Boston University VA Brain Bank and the clinical sample of retired football 
players from the Boston University CTE Center LEGEND study are limited self-referral 
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bias.  To address this potential bias, future studies should use non-selected population 
based samples, for example the Framingham Heart Study. Moreover, our analyses 
included only males and future research studies should also include individuals of both 
sexes/genders.  
 
Key Unanswered Questions. As the study of the clinical manifestations and etiology 
of CTE continues, several important questions in the field remain unanswered. For 
example, how common is CTE in the population? To address this question, the accuracy 
and validity of proposed clinical criteria and biomarkers for the diagnosis of CTE during 
life must be established. Once an in vivo diagnosis is possible, epidemiological research 
will be able to determine the population incidence and prevalence of long-term 
impairments related to RHI exposure and underlying CTE neuropathology. Another 
important question that needs to be addressed, is whether or not the tauopathy in CTE 
causes clinical symptoms or progression over time. Longitudinal studies that include 
serial neuroimaging scans specific for the hyperphosphorylated tau neuropathology of 
CTE (for example, PET neuroimaging with T807 for p-tau) can determine the likelihood 
of symptom onset and progression in living athletes. Moreover, the diagnosis of CTE 
during life using clinical diagnostic criteria and biomarkers would be help to differentiate 
the possible long-term outcomes related to prolonged exposure to RHI, including 
persistent PCS, primary depression, frontotemporal dementia, or Alzheimer’s disease, 
from CTE. A final question, why do some people exposed to RHI develop CTE whereas 
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others do not? To answer this question, non-selected longitudinal research is needed to 
refine potential risk factors of CTE,  including susceptibility genes (for example, MAPT, 
GRN, and C9ORF72), and to identify risk modifying factors such as body mass index, 
exercise, diet, substance use, socioeconomic background, and cognitive reserve. Future 
research should include a model with the CHII metric, or a variation of the CHII, as a 
predictor variable and incorporate additional risk- and modifying-factors to quantify their 
effect on the risk of developing CTE neuropathologically or probable-CTE clinically. The 
hope is that the use of the proposed clinical diagnostic criteria and cumulative head 
impact index in future studies will result in greater clarification of the modifiable, if not 
preventable, factors for long-term impairments related to RHI exposure and CTE. 
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